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Abstract 
The growth of obligate intracellular bacteria of the genus Chlamydia strictly depends on 
nutrients and energy delivered from the host cell, usually an epithelial cell, to an intra-
cellular vacuole in which the bacteria are able to multiply. This interaction with the host 
cell largely is promoted by chlamydial effector proteins interfering with host cell pathways 
by cleaving or binding host cell proteins. Infection with the human pathogen Chlamydia 
trachomatis often leads to chronic infection, with the bacteria being assumed to be in a 
persistent growth state. Chlamydial persistence is characterised by atypical, metabolically 
active, but non-dividing bacteria and can be elicited by different factors such as nutrient 
depletion, antibiotic treatment or cytokines. One important means of the immune system to 
combat infection with this pathogen is the presentation of chlamydial antigens through 
major histocompatibility complex I (MHCI) molecules on the surface of infected cells, 
which in turn activates cytotoxic T cells to kill Chlamydia-infected cells. 
In the present study, the MHCI antigen presentation pathway was examined during active 
and persistent infection in order to find out whether or not C. trachomatis interferes with 
this pathway dependent on its growth state. When analysing the expression of different 
components of the MHCI pathway, it was found that active C. trachomatis infection of epi-
thelial cells leads to degradation of the endoplasmic reticulum-resident antigen transporter 
subunit TAP2, which is essential for peptide delivery from the cytosol into the ER for 
loading onto MHCI. This correlated with abnormal MHCI trafficking and reduced MHCI 
surface expression in these cells. During IFN-? induced persistent C. trachomatis infection 
of epithelial cells degradation of TAP2 could not be observed, and MHCI trafficking and 
surface expression were not compromised in these cells. As another model for Chlamydia-
host cell interaction fibroblasts were analysed as additional host cell type. C. trachomatis 
showed atypical growth and some characteristics of chlamydial persistence in these cells, 
in part, this was a result of the induction of indoleamine 2,3-dioxygenase expression due to 
an infection-induced endogenous IFN-? production. However, chlamydial gene and protein 
expression during persistence within fibroblasts was completely different from the IFN-? 
induced persistence model. Nevertheless, MHCI expression was also found to be func-
tional and even upregulated in fibroblasts during chlamydial infection. 
Furthermore, the Chlamydia-induced Golgi fragmentation, which was accompanied by 
degradation of the two Golgi proteins GM130 and Golgin-245 through the secreted 
chlamydial protease CPAF, was analysed as a second interference mechanism for the 
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MHCI trafficking through the cell. Strong CPAF expression was only found during active, 
but not persistent and fibroblast infection. This correlated with degradation of GM130, 
Golgin-245, TAP2 and the mRNA export factor NXF1, which was found as another newly 
discovered target for chlamydial cleavage activity, during active infection, whereas cleav-
age of these proteins was reduced both during persistent and fibroblast infection. 
Altogether, the results show that the ability of Chlamydia to interact with host cell path-
ways, such as the MHCI antigen presentation pathway, largely depends on host cell 
conditions that promote productive chlamydial growth and thus expression of CPAF and 
other chlamydial effector proteins. During chlamydial persistence an interference with 
MHCI antigen presentation was not detected, which suggests that elimination of persis-
tently infected cells through the host immune system principally should be possible in 
vivo. An interference with the MHCI presentation pathway during active C. trachomatis 
infection may reduce recognition through cytotoxic T cells and thus represent a mechanism 
to escape the immune response in order to complete chlamydial development. 
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Zusammenfassung 
Das Wachstum obligat intrazellulärer Bakterien der Gattung Chlamydia hängt strikt von 
Nährstoffen und Energie ab, die sie von der Wirtszelle – normalerweise einer Epithelzelle 
– erwerben. Dies geschieht durch Rekrutierung der Nährstoffe zu einer intrazellulären 
Vakuole, in der sich die Bakterien vermehren. Diese Interaktion mit der Wirtszelle wird im 
Wesentlichen durch chlamydiale Effektor-Proteine, die Wirtszell-Signalwege durch Spalt-
ung oder Bindung von Wirts-Proteinen beeinträchtigen, vermittelt. Die menschliche Infekt-
ion mit dem Erreger Chlamydia trachomatis führt häufig zu chronischer Infektion, bei der 
angenommen wird, dass die Bakterien in einem persistenten Zustand vorliegen. Die chla-
mydiale Persistenz ist durch atypische, Stoffwechsel-aktive Bakterien, die die Zellteilung 
eingestellt haben, gekennzeichnet und kann unter anderem durch Nährstoffmangel, 
Behandlung mit Antibiotika oder Zytokine ausgelöst werden. Ein wichtiger Teil des 
Immunsystems zur Bekämpfung der Infektion mit diesem Krankheitserreger ist die Präsen-
tation von Chlamydien-Antigenen durch Moleküle des Haupthistokompatibilitätskomplex I 
(MHCI) auf der Oberfläche infizierter Zellen. Dies führt zur Aktivierung zytotoxischer T-
Zellen, welche Chlamydien-infizierte Zellen daraufhin abtöten. 
In der vorliegenden Arbeit wurde der MHCI-Antigenpräsentations-Weg während aktiver 
und persistenter Infektion untersucht, um herauszufinden, ob C. trachomatis diesen 
zellulären Weg in Abhängigkeit seines Wachstumszustandes behindert. Die Analyse der 
Expression verschiedener Komponenten des MHCI-Weges zeigte, dass die aktive Infektion 
von Epithelzellen mit C. trachomatis zur Degradierung der TAP2-Untereinheit des 
Antigentransporters TAP führt. Dieser Transporter ist für die Lieferung von Peptiden in 
das Endoplasmatische Retikulum und somit für die Beladung von MHCI-Molekülen 
notwendig. Die TAP2-Degradierung korrelierte mit einem abnormalen MHCI-Transport 
und reduzierter MHCI-Oberflächenexpression in diesen Zellen. Während der IFN-? 
vermittelten persistenten C. trachomatis-Infektion von Epithelzellen wurde keine TAP2-
Degradierung gefunden, und der Transport und die Oberflächenexpression von MHCI 
waren in diesen Zellen nicht beeinträchtigt. Als weiteres Model für die Chlamydien-
Wirtszell-Interaktion wurde mittels Chlamydien-Infektion von Fibroblasten ein weiterer 
Wirtszell-Typ untersucht. Das Wachstum von C. trachomatis in diesen Zellen war 
atypisch, zeigte Merkmale der Persistenz und war zum Teil das Ergebnis einer Akti-
vierung der Indolamin-2,3-Dioxygenase-Expression aufgrund einer endogenen, durch In-
fektion verursachten IFN-?-Produktion. Allerdings unterschied sich das Expressionsmuster 
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chlamydialer Gene und Proteine während der Persistenz in Fibroblasten deutlich von dem 
während der IFN-? induzierten Persistenz. Dennoch war auch hier die MHCI-Oberflächen-
expression während der Infektion nicht beeinträchtigt sondern sogar hochreguliert. 
Des Weiteren wurde die Chlamydien-induzierte Golgi-Fragmentierung als zweiter Inter-
ferenz-Mechanismus für den intrazellulären MHCI-Weg untersucht. Dabei wurde eine 
Degradierung der Golgi-Proteine GM130 und Golgin-245 durch die sezernierte chlamy-
diale Protease CPAF beobachtet. Eine hohe CPAF-Expression kam nur während der 
aktiven, nicht aber persistenten und Fibroblasten-Infektion vor. Dies korrelierte mit der 
Degradierung von GM130, Golgin-245, TAP2 und einem weiteren, neu entdeckten Ziel-
Protein, welches von C. trachomatis gespalten wird, dem mRNA Exportfaktor NXF1, 
während der aktiven Infektion. Die Degradierung dieser Proteine war sowohl während der 
persistenten als auch der Fibroblasten-Infektion reduziert. 
Insgesamt zeigen die Ergebnisse, dass die Fähigkeit der Chlamydien mit zellulären Wegen 
wie dem MHCI-Antigenpräsentations-Weg zu interagieren stark von solchen Wirtszell-
Bedingungen abhängt, die das produktive Wachstum von Chlamydien und somit auch die 
Expression von CPAF und anderen chlamydialen Effektor-Proteinen begünstigen. Da 
während der Chlamydien-Persistenz keine Beeinträchtigung des MHCI-Weges beobachtet 
werden konnte, sollte die Entfernung von persistent infizierten Zellen durch das Immun-
system in vivo prinzipiell möglich sein. Die Interferenz mit dem MHCI-Weg während der 
aktiven Infektion hingegen könnte dazu führen, dass infizierte Zellen durch zytotoxische 
T-Zellen schlechter erkannt werden. Dies würde einen Mechanismus darstellen, um der 
Immunantwort zu entkommen und somit die Vervollständigung des Entwicklungszyklus 
der Chlamydien zu gewährleisten. 
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1 Introduction 
1.1 Chlamydia 
1.1.1 The family of Chlamydiaceae 
The class Chlamydiae with the single order Chlamydiales represents one branch of the bac-
teria domain that consists merely of obligate intracellular bacteria. They are well-adapted 
parasites of different eukaryotic host cells ranging from single-cellular amoebae to highly 
differentiated epithelial cells of the mammalian mucosa. All members have a biphasic 
developmental cycle with alternation between an infectious, extracellular form and an 
intracellular, replicating form. The family of Chlamydiaceae currently holds several 
species that are pathogens of different vertebrates. Of these Chlamydia trachomatis is a 
species that is highly adapted to humans, and it consists of several serovars causing 
different diseases. Serovars A – C are the agents of trachoma, a tropical disease that is 
characterised by an ocular infection often leading to scarring and blindness (reviewed in 
Burton & Mabey, 2009). Serovars D – K usually cause a sexually transmitted urogenital 
tract infection, which can be asymptomatic. However, in some cases infection with these 
serovars can lead to pelvic inflammatory disease, an ascending infection of the upper parts 
of the female genital tract, with severe sequelae like ectopic pregnancy and tubal infertility 
(reviewed in Carey & Beagley, 2010). Lymphogranuloma venereum (LGV) is a sexually 
transmitted disease elicited by serovars L1 – L3 that, in contrast to serovars D – K, are able 
to invade and multiply in the local lymph-nodes resulting in severe lymphadenopathy 
(reviewed in Stary & Stary, 2008). 
Further chlamydial species that are known to cause disease in humans are Chlamydia 
pneumoniae, Chlamydia psittaci and Chlamydia abortus. C. pneumoniae is a ubiquitous 
human pathogen and usually infects the upper and lower respiratory tract which can lead to 
pneumonia, bronchitis, sinusitis and pharyngitis. Previous studies further revealed an 
association of C. pneumoniae infection with chronic diseases like intrinsic asthma, chronic 
obstructive pulmonary disease, multiple sclerosis, atherosclerosis and Alzheimer's disease 
(reviewed in Blasi et al., 2009). The usual hosts of C. psittaci are birds. However, this 
pathogen is also able to infect humans and to cause psittacosis, a severe pneumonia 
(reviewed in Beeckman & Vanrompay, 2009). Similarly, human infection can occur with 
C. abortus, a pathogen usually found in ruminants. Cases have been reported where 
infection of pregnant women with C. abortus led to abortion of the foetus and to sepsis 
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(Pospischil et al., 2002; Walder et al., 2005). Infections with C. psittaci and C. abortus are 
typical zoonotic diseases (Rohde et al., 2010). 
1.1.2 The chlamydial developmental cycle 
Chlamydiae strictly depend on nutrients and energy of the host cells for their growth and 
multiplication. Therefore these parasites have developed a well adapted intracellular niche, 
the so-called chlamydial inclusion. The inclusion represents a modified, host membrane 
derived vacuole in which the chlamydial organisms grow and form new progeny. This 
represents a convenient way to be protected from host cell defence mechanisms but also to 
efficiently interact with the host cell for acquisition of nutrients and adenosine triphosphate 
(ATP). 
In mammals the epithelial cell of mucosal surfaces is the primary target cell for infection 
with members of the family Chlamydiaceae. That is why the infections normally occur in 
the lung, the eye and the genital tract. 
 
EB invasion
host cell
elementary body (EB)
reticulate body (RB)
EB attachment
differentiation
of EB to RB
replication and cell
division of RBs
differentiation of 
RBs to EBs
release of EBs
 
Fig. 1: The chlamydial developmental cycle.  
Depicted is the replicative infection cycle under optimal growth conditions such as occurring in cell culture. 
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The replicative developmental cycle of C. trachomatis during an active infection starts 
with the attachment of the extracellular, infectious form, the elementary body (EB; approx-
imately 0.3 μm in size), to the host cell membrane followed by an invasion through endo-
cytosis (Fig. 1). The EB converts to a reticulate body (RB), which is larger (approximately 
1.0 μm) and shows metabolic activity. This RB starts to multiply finally leading to a highly 
increased number of RBs inside the inclusion. The late phase of the developmental cycle is 
characterized by an asynchronous re-differentiation of the RBs to EBs. After approxi-
mately 48 h the newly formed progeny is released from the host cell and ready for new 
rounds of infection (reviewed in AbdelRahman & Belland, 2005). 
1.1.3 Interaction of Chlamydia with the host cell 
For optimal growth chlamydiae need to considerably manipulate the host cell in order to 
escape host defence mechanisms on the one hand and to acquire nutrients and energy from 
the host cytosol on the other hand. To this purpose chlamydiae secrete different effector 
proteins into the host cytosol. Results from several studies have shown that chlamydiae 
possess a type III secretion system (TTSS) and that secretion of many chlamydial proteins 
into the cytosol and inclusion membrane occurs through this secretion apparatus (Fields et 
al., 2003; Peters et al., 2007; Stephens et al., 1998). 
Active modulation of the host cell already starts during EB attachment as shown by C. 
trachomatis secretion of the translocated actin-recruiting phosphoprotein (TARP) by the 
TTSS into the host cytosol during this stage (Clifton et al., 2004). After recruitment of 
actin to the site of chlamydial entry through a process that depends on small GTPases of 
the Rho family (Balaná et al., 2005; Carabeo et al., 2004; Subtil et al., 2004), TARP 
directly binds and promotes polymerisation of actin (Jewett et al., 2006). This results in a 
cytoskeleton rearrangement that is necessary for internalisation of the EB (Carabeo et al., 
2002; Jewett et al., 2010). Further interactions with the cytoskeleton that occur later in the 
development involve recruitment of actin and intermediate filaments to the inclusion 
through a RhoA-dependent mechanism (Kumar & Valdivia, 2008). This likely serves to 
build a cytoskeleton scaffold around the inclusion in order to stabilise the intracellular 
pathogen vacuole (Kumar & Valdivia, 2008). C. trachomatis uses also actin polymeri-
sation for release of new progeny from the host cell through extrusion which leaves the 
host cell intact and, beside cell lysis, represents an alternative mechanism of host cell exit 
(Hybiske & Stephens, 2007). 
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To be protected from lysosomal degradation chlamydiae have evolved a mechanism to 
separate the inclusion from the normal endocytic trafficking pathway very early after host 
cell invasion. It has been shown that soon after entry the C. trachomatis EB moves to the 
perinuclear region by using dynein to traffic on microtubules to the Microtubule Organi-
sing Centre (MTOC) (Clausen et al., 1997; Grieshaber et al., 2003). By this the inclusion is 
located close to the Golgi apparatus and the chlamydiae now start to recruit host cell 
sphingolipids and cholesterol from the trans-Golgi compartment and from multivesicular 
bodies (MVBs) to the inclusion (reviewed in Scidmore, 2011). This is an efficient mecha-
nism to disguise the inclusion as an exocytic vesicle in order to escape lysosome fusion 
(reviewed in Rockey et al., 2002). The comprehensive interaction of chlamydiae with the 
vesicular trafficking pathway is accompanied by fragmentation of the Golgi apparatus 
(Heuer et al., 2009), which is the result of cleavage of the structural protein Golgin-84 
through the Chlamydial Protease/proteasome-like Activity Factor (CPAF) secreted from 
the chlamydial inclusion (Christian et al., 2011). This fragmentation is supposed to 
enhance the transport of lipid-containing Golgi vesicles to the inclusion. Beside sphingo-
lipids and cholesterol, glycerolipids are also acquired by Chlamydia and necessary for their 
growth, however their acquisition occurs independent of the Golgi exocytic pathway 
(Wylie et al., 1997). Further sources of lipids for chlamydiae represent lipid droplets, 
which are ER-derived lipid storage organelles and are even taken up into the chlamydial 
inclusion lumen (Cocchiaro et al., 2008; Kumar et al., 2006). 
A necessity for interaction with the host cell is the modification of the inclusion membrane 
with chlamydial proteins called Inc proteins (reviewed in Rockey et al., 2002). Most of 
them are expressed very early (2 h p.i.) during chlamydial growth and have diverse func-
tions in interaction with the host cell (Shaw et al., 2000 a). For example C. trachomatis 
IncG was found to bind the mammalian protein 14-3-3? that is involved in regulating many 
host signalling pathways (Scidmore & Hackstadt, 2001). Also, several Inc proteins possess 
similarities to eukaryotic SNARE proteins that play important roles in vesicle membrane 
fusion implicating a role in regulating vesicle trafficking (reviewed in Scidmore, 2011). 
Certain Rab proteins, which are crucial regulators of the vesicular trafficking pathway, are 
associated with the inclusion membrane, probably by directly or indirectly interacting with 
Inc proteins (reviewed in Scidmore, 2011). They are supposed to play an important role in 
directing vesicle trafficking to the inclusion. For example Rab6, Rab11 and Rab14 are 
necessary for sphingomyelin delivery to the C. trachomatis inclusion (Capmany & 
Damiani, 2010; Rejman Lipinski et al., 2009). Importantly, Rabs that are involved in early 
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endosome to late endosome trafficking and lysosome fusion, such as Rab 5, Rab 7 and Rab 
9, were not found to localise to the chlamydial inclusion (Rzomp et al., 2003). The 
exclusion of these Rab proteins may be crucial for preventing entry of the chlamydial 
inclusion into the endosomal pathway in order to escape lysosomal fusion and degradation. 
Infection of a cell with C. trachomatis has further implications for its growth. It is known 
that C. trachomatis inhibits cytokinesis without affecting mitosis thus leading to cells with 
more than one nucleus (Greene & Zhong, 2003). This could result from the cleavage of 
cell cycle proteins such as Cyclin B1 through a chlamydial protease secreted into the host 
cytosol (Balsara et al., 2006 a; Paschen et al., 2008). Chlamydiae also tightly associate 
with centrosomes which results in supernumerary centrosomes, abnormal spindle poles and 
defects in chromosome segregation (Grieshaber et al., 2006). 
It is well known that chlamydiae inhibit apoptosis and immune defence mechanisms in 
order to complete their development. Host cell death only seems to be induced late during 
chlamydial development, but the exact mechanisms still are unclear and do not seem to 
involve classical apoptotic and necrotic pathways (reviewed in Miyairi & Byrne, 2006 and 
in Sharma & Rudel, 2009; Yu et al., 2010). 
Chlamydiae are also able to interfere with several important host signalling pathways, for 
example C. trachomatis has been shown to interrupt NF-?B signalling, an important host 
defence and inflammatory pathway, through different mechanisms (Lad et al., 2007 a, Lad 
et al., 2007 b; Le Negrate et al., 2008). 
Thus, chlamydiae have evolved several means to efficiently manipulate the host cell with 
the primary aims of an intracellular pathogen to promote productive growth and suppress 
host cell defence mechanisms. 
1.1.4 The role of the chlamydial protease CPAF in Chlamydia host cell interaction 
A virulence factor that got into the focus of chlamydial research during the last years is 
CPAF, a serine protease that is secreted into the host cytosol during infection in order to 
degrade several host proteins (reviewed in Zhong, 2009). This protease is unique to 
chlamydiae and highly conserved among different chlamydial species (Huang et al., 2008; 
Zhong et al., 2001). Its name is derived from the observation that the activity of this prote-
ase could only be inhibited by the proteasome inhibitor lactacystin, but not by other typical 
protease or proteasome inhibitors (Zhong et al., 2000). CPAF is secreted in a type II secre-
tion dependent fashion into the inclusion lumen before translocation into the host cytosol 
(Chen et al., 2010 a). Interestingly, CPAF is produced and translocated as an inactive form 
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of 70 kDa size. Activation of CPAF occurs in the host cytosol by autocatalytic cleavage of 
an internal inhibitory segment that binds to the active site of CPAF. This produces an N-
terminal fragment of 29 kDa (CPAFn) and a C-terminal fragment of 35 kDa (CPAFc) that 
form an enzymatically active heterodimer (Chen et al., 2010 b; Huang et al., 2008). 
During the last decade several host proteins were discovered to be cleaved by CPAF. 
Among them are the transcription factors regulatory factor X 5 (RFX5) and upstream 
stimulatory factor 1 (USF-1) involved in regulating antigen presentation (Zhong et al., 
1999, Zhong et al., 2000), the cytoskeletal intermediate filament proteins vimentin, keratin 
8 and keratin 18 (Dong et al., 2004; Kumar & Valdivia, 2008), the lipid antigen presenting 
glycoprotein CD1d (Kawana et al., 2007), the hypoxia-inducible factor-1 (HIF-1) (Rupp et 
al., 2007), the Golgi protein Golgin-84 (Christian et al., 2011) and Nectin-1 which is 
involved in forming adherens and tight junctions between epithelial cells (Sun & 
Schoborg, 2009). The cleavage of these proteins probably has different functions for the 
growth of chlamydiae. For example the cleavage of host intermediate filament proteins is 
supposed to be necessary for rearrangements of the cytoskeleton surrounding and strength-
ening the chlamydial inclusion in order to allow for size increase during chlamydial growth 
(Kumar & Valdivia, 2008). 
A major role for CPAF has been observed in inhibiting apoptosis, as studies revealed 
degradation of the pro-apoptotic BH3-only proteins through this protease (Paschen et al., 
2008; Pirbhai et al., 2006) thus preventing cytochrome c release from mitochondria. A 
further role of CPAF in regulating cell death has been observed by degradation of Poly 
(ADP-ribose) polymerase-1 (PARP-1) and High-mobility group box 1 protein (HMGB-1) 
(Paschen et al., 2008; Yu et al., 2010). The degradation of HMGB-1 was accompanied by 
a lack of translocation of this protein from the nucleus into the cytosol, a mechanism that 
usually occurs during necrosis to promote inflammation (Yu et al., 2010). The role of 
CPAF in regulating host responses thus seems to be very comprehensive and likely is the 
result of broad substrate specificity (Huang et al., 2008). 
1.1.5 Chlamydial persistence 
Chronic chlamydial infections are often associated with severe sequelae like blindness or 
infertility. In vivo data from clinical studies and experimental animal infections suggest 
that during chronic infections chlamydiae persist in the host cells for a long time and estab-
lish a long-term association with the host (reviewed in Hogan et al., 2004). Since chronic 
chlamydial infections are difficult to diagnose and to treat and are related to severe 
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immunopathology, unravelling the characteristics and the eliciting factors of chlamydial 
persistence is a main topic of chlamydial research. Results from several in vitro studies 
suggest that chlamydial persistence is generally characterised by aberrant, non-cultivable, 
but viable, metabolically active bacteria that do not undergo cell division and re-
differentiation to EBs (reviewed in Hogan et al., 2004, Wyrick, 2010). It therefore can be 
considered as a rest in the developmental cycle. 
Chlamydial persistence in vitro can be elicited by several factors and is usually reversed to 
the active, replicative infection state after removal of the eliciting factor (reviewed in 
Hogan et al., 2004 and Wyrick, 2010). For example it can be induced by nutrient depri-
vation, antibiotic treatment, iron limitation or herpes simplex virus type-2 (HSV-2) co-
infection (Fig. 2). 
The so far best studied in vitro persistence model is the IFN-? mediated chlamydial persis-
tence. IFN-? is a cytokine that usually plays an important role in immune eradication of 
chlamydiae. However, treatment of Chlamydia-infected cells with doses of IFN-? that are 
not high enough to completely inhibit chlamydial growth can lead to persistent growth. It 
is the result of an elevated expression of the host defence enzyme indoleamine-2,3-
dioxygenase (IDO) that degrades the amino acid tryptophan. Because C. trachomatis does 
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immune response
?
HSV-2 co-infection other factors?
 
 
Fig. 2: Mechanisms of chlamydial persistence induction. 
AB: aberrant chlamydial bodies; TNF-?: tumor necrosis factor alpha; Trp: tryptophan; HSV-2: Herpes 
simplex virus 2. According to literature reviewed in Hogan et al., 2004 and Wyrick, 2010. 
 8 
not have a complete set of genes for tryptophan synthesis, intracellular depletion of this 
essential amino acid leads to starvation and thus persistence of the bacteria (Fig. 2; Beatty 
et al., 1994 a). However, due to the presence of complete tryptophan synthase subunit A 
and B (trpA and trpB) genes, genital strains of C. trachomatis are able to use indole in 
order to produce tryptophan on their own. This is contrary to ocular strains that only 
encode a truncated form of the tryptophan synthase subunit A. Hence, genital serovars 
could overcome the IFN-? inhibitory effect by utilising indole that is produced by other 
bacteria normally residing in the female genital tract (Caldwell et al., 2003; Fehlner-
Gardiner et al., 2002). The main characteristics of IFN-? induced chlamydial persistence 
are small inclusions containing few enlarged, aberrant RBs. They show reduced expression 
of the major outer membrane protein (MOMP), a main structural component of the chla-
mydial cell envelope and an antigen that induces a protective antibody response, while 
expression of the immuno-destructive heat shock protein 60 (HSP60) is maintained (Beatty 
et al., 1994 a, Beatty et al., 1994 b). In general, most of these characteristics are also found 
in other in vitro persistence models. Due to the variety of the so far known inducing factors 
chlamydial persistence probably represents a general stress response against hostile growth 
conditions (reviewed in Hogan et al., 2004). 
1.1.6 Immune response to C. trachomatis genital infection 
The infection of epithelial cells with C. trachomatis results in a pro-inflammatory response 
that is characterized by secretion of cytokines such as IL-8, CXC-chemokine ligand 1 
(CXCL1), granulocyte/monocyte colony-stimulating factor (GM-CSF), IL-6 and IL-1? 
(Rasmussen et al., 1997). These cytokines are able to recruit immune effector cells to the 
site of infection and participate in activation of several immune responses. 
Th1 type CD4+ T cells and cytotoxic CD8+ T cells, important members of the adapted 
immune response, both have very important roles in resolving a chlamydial infection 
(reviewed in Agrawal et al., 2009; Roan & Starnbach, 2008). By production of IFN-? they 
can efficiently restrict chlamydial growth. However, the severe pathology that is some-
times observed is considered to be a result of a strong inflammatory response that is also 
elicited by a high production of IFN-?. Furthermore, an inefficient clearance of chlamydial 
organisms from the site of infection is supposed to result in chronic infection associated 
with strong immunopathology which is likely to be induced by inflammation as a result of 
recurrent chlamydial propagation. 
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The humoral response also contributes to immunity against chlamydiae by producing anti-
bodies mainly recognizing chlamydial MOMP. Beside their function in direct antigen 
neutralisation, antibodies obviously play an important role in enhancing the Th1 immune 
response during chlamydial infection (reviewed in Agrawal et al., 2009) 
Because of the involvement of both CD4+ and CD8+ T cells and the restricted knowledge 
about the immune response mechanisms against human C. trachomatis genital infection, 
no vaccines have been successfully developed to date. The difficult task is to create a vac-
cine that efficiently protects from chlamydial infection without eliciting a harsh immune 
response that could lead to destructive immunopathology. 
1.1.7 Chlamydia-induced reactive arthritis 
Genital infection with C. trachomatis can elicit an inflammation of the joint known as 
reactive arthritis. Reactive arthritis occurs as sequela of a bacterial infection, usually 
caused by Chlamydia and enteric bacteria like Salmonella, Shigella, Campylobacter and 
Yersinia (reviewed in Carter & Hudson, 2010). It is not completely clear how the bacteria 
induce this disease, but it is known that bacterial antigens deposited in the joints probably 
evoke the inflammation. 
In Chlamydia-induced reactive arthritis (CiReA) viable chlamydial organisms are trans-
mitted to the joint through circulating monocytes and are able to persist in the synovium 
for a long time (reviewed in Gérard et al., 2010). Evidence for the persistent infection 
came from a study that found viable, atypical RBs residing in fibroblasts and macrophages 
in synovial samples from patients with CiReA (Nanagara et al., 1995). Further exami-
nations revealed the existence of RNA, especially short-lived rRNA transcripts, in such 
samples indicating that metabolically active and thus viable bacteria reside in the synovial 
tissue (Gérard et al., 1998 a; Rahman et al., 1992). Expression of the gene encoding 
MOMP could not be detected in these samples whereas the gene encoding HSP60 was 
readily expressed (Gérard et al., 1998 a). In vitro studies of chlamydial infection of mono-
cytes correlated with the in vivo data of chlamydial persistence. Chlamydial inclusions 
within monocytes contained large, aberrant, metabolically active RBs and did not produce 
EBs indicating the existence of typical persistent forms (Gérard et al., 1998 b; Koehler et 
al., 1997). Expression of MOMP also was strongly attenuated in these cells (Gérard et al., 
1998 b). Obviously, IFN-?-mediated tryptophan depletion through IDO seems not to be the 
mechanism that induces chlamydial persistence in monocytes (Koehler et al., 1997), and 
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the inducing factors are still unknown. Major components that may promote a strong 
inflammation in the joint likely are LPS and HSP60 (reviewed in Zeidler et al., 2004). 
In vitro studies on C. trachomatis infection of synovial fibroblasts also gave insights into 
the role of chlamydiae in eliciting reactive arthritis. It has been shown that these cells 
produce IFN-? after infection with C. trachomatis (Rödel et al., 1998 a), which upregulates 
MHCI antigen presentation in Chlamydia-infected synovial fibroblasts (Rödel et al., 2002), 
indicating an important role of these cells in promoting a Chlamydia-specific immune 
response in synovial tissue. 
Since antibiotics fail to eradicate the persistent chlamydial infection from the joints 
(Beutler et al., 1997; reviewed in Gérard et al., 2010) it is important to elucidate the 
mechanisms and factors that are involved in the immunopathology and the chlamydial per-
sistence during CiReA in order to find efficient ways of treatment. 
1.2 MHC class I antigen presentation during chlamydial infection 
1.2.1 The MHC class I antigen presentation pathway 
The presentation of non-self antigens through major histocompatibility complex (MHC) 
proteins on the surface of cells is an important part of the immune system to initiate elimi-
nation of pathogens and tumour cells. The MHC class I antigen presentation pathway pres-
ents antigenic peptides from intracellular sources such as viruses and misfolded proteins to 
CD8+ T cells that in turn are activated to kill the infected or tumour cell. In contrast, the 
MHC class II antigen presentation pathway usually presents antigens from exogenous 
sources to CD4+ T cells. Whereas MHCII antigen presentation is often restricted to 
professional antigen presenting cells like dendritic cells, macrophages or B cells, princi-
pally all cells are able to present antigens by MHCI antigen presentation. MHC class I 
molecules are glycosylated heterodimers that consist of a heavy chain which has a trans-
membrane domain and forms the peptide binding groove, and the small accessory protein 
?2 microglobulin (?2M). In humans the MHC heavy chains are called human leucocyte 
antigens (HLA), and there are three major HLA class I genes (HLA-A, -B and –C). 
The classical MHCI antigen presentation pathway is depicted in Fig. 3. Newly synthesized 
MHCI heavy chains are co-translationally translocated through the endoplasmic reticulum 
(ER) membrane followed by correct folding with the help of the ER-resident chaperones 
calnexin and binding immunoglobulin protein (BiP). Then the MHCI heavy chains 
associate with soluble beta-2 microglobulin (?2M) and enter the peptide loading complex 
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(PLC) where they are ready to be loaded with peptides. Peptides for MHCI presentation 
are generated from antigens in the cytosol through the activity of the proteasome and other 
proteases. These peptides then are transported into the ER through the transporter associ-
ated with antigen processing (TAP), which preferentially transports peptides of 8 – 16 
amino acids length. Further trimming of the peptides in the ER lumen occurs by the endo-
plasmic reticulum aminopeptidases 1 (ERAP1) and 2 (ERAP2). They generate peptides of 
8 – 10 amino acids length, which is the optimal length for loading on MHC class I mole-
cules. After peptide loading, the MHCI-peptide complexes are transported out of the ER 
into the Golgi, where further processing of MHCI occurs, and finally reach the cell surface 
(reviewed in Jensen, 2007, in Schölz & Tampé, 2009 and in Wearsch & Cresswell, 2008). 
Peptide loading of MHCI molecules is promoted and highly regulated by the PLC, which 
includes the chaperone calreticulin, the thiol oxidoreductase ERp57, the transmembrane 
protein tapasin and TAP. Tapasin, ERp57 and calreticulin act together in quality control of 
peptide loading of MHCI and retain unstable, suboptimally loaded MHCI molecules in the 
ER. Tapasin further functions in bridging TAP with the other PLC components. TAP 
belongs to the ATP-binding cassette (ABC) transporter family that uses ATP hydrolysis as 
energy source for transport of different substrates. It is a heterodimer consisting of the two 
subunits TAP1 and TAP2 each having a transmembrane domain and a nucleotide binding 
domain (NBD) (reviewed in Schölz & Tampé, 2009 and in Wearsch & Cresswell, 2008). 
 
 
Fig. 3: The MHC class I antigen presentation pathway.  
(Schölz & Tampé, 2009) 
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At sites of infection usually the production of type I and type II IFN occurs and contributes 
to the immune response to intracellular pathogens by upregulation of several defence path-
ways. This includes the improvement of the MHC class I antigen presentation by upregu-
lating the expression of components of the antigen presentation pathway such as MHC 
class I heavy chains, ?2M, TAP1 and TAP2. IFNs further activate the expression of special 
proteasome subunits, namely LMP2 (?1i), MECL1 (?2i) and LMP7 (?5i). Replacement of 
the constitutive catalytic proteasome subunits ?1, ?2 and ?5 by these IFN-inducible sub-
units results in the so-called immunoproteasome, which generates a different peptide reper-
toire for presentation to CD8+ T cells during infections in order to improve recognition and 
eradication of infected cells (reviewed in Sijts & Kloetzel, 2011). 
1.2.2 MHC class I presentation of chlamydial antigens to CD8+ T cells 
Because Chlamydia are obligate intracellular bacteria it is conceivable that MHCI antigen 
presentation of intracellularly processed pathogen-derived peptides to CD8+ T cells would 
be more efficient for detection and elimination of Chlamydia-infected cells than MHCII 
antigen presentation. Another reason for the importance of the MHCI pathway during 
eradication of chlamydiae is given by the fact that the main target cell for chlamydial 
infection is the epithelial cell which like most cells usually only presents peptides via 
MHCI but not via MHCII. Although many studies in mice indicate that CD4+ T cells play 
a dominant role in conferring protection against chlamydial infection (for example Magee 
et al., 1995 and Su & Caldwell, 1995), CD8+ T cell responses were found to essentially 
participate in resolving chlamydial infection in vivo in mice, and this occurred mainly by 
secreting TNF-? and IFN-?, cytokines that are known to restrict intracellular chlamydial 
growth (Igietseme et al., 1994; Ramsey & Rank, 1991; Starnbach et al., 1994; Starnbach et 
al., 1995). Further, murine CD8+ T cells primed to chlamydial antigens were capable to 
efficiently kill Chlamydia-infected non-haematopoietic cells in an in vitro cytotoxicity 
assay (Beatty & Stephens, 1994; Starnbach et al., 1995). Both chlamydial and host protein 
synthesis as well as the secretory pathway were necessary to induce cytotoxicity. Thus, 
intracellular processing of chlamydial antigens and presentation via MHC class I indeed 
seem to occur in Chlamydia-infected cells. Moreover, a recent study indicated an important 
role of CD8+ T cells in genital chlamydial infection as CD8+ T cells proliferated in lymph 
nodes, migrated into the genital mucosa and produced IFN-? in a murine model of genital 
C. trachomatis infection (Roan & Starnbach, 2006). Thus, control of chlamydial infection 
through MHCI presentation to CD8+ T cells seems to be especially important at primary 
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infection sites because this would lead to direct elimination of the infected epithelial cells 
and the restriction of chlamydial growth through cytokines. 
Downregulation of MHCI surface expression is a strategy applied by several viruses to 
escape CD8+ T cell recognition and to ensure that the infected cell stays intact until the 
production of new progeny is completed. For Chlamydia, which also strictly depend on the 
intracellular niche for growth and formation of new progeny, evasion of CD8+ T cell 
recognition could thus be an important means to complete their development in epithelial 
cells and to generally escape immune recognition. Indeed, downregulation of MHCI sur-
face expression has been observed in C. trachomatis infected epithelial cells by different 
authors (Hook et al., 2004; Ibana et al., 2011; Zhong et al., 2000). MHCI and ?2M 
expression were found to be reduced in these cells, and it was hypothesised that this down-
regulation was the result of CPAF-mediated degradation of RFX5, a transcription factor 
involved in MHCI and MHCII gene expression (Zhong et al., 2000). However, these 
findings contradict to other studies mentioned above that found efficient CD8+ T cell 
responses during chlamydial infection in vitro and in mice. Furthermore, infection of 
synovial fibroblasts with C. trachomatis resulted in endogenous IFN-? production that led 
to efficient upregulation of MHCI surface expression on these cells throughout the whole 
developmental cycle (Rödel et al., 2002). This suggests that chlamydial organisms do not 
interfere with MHCI antigen presentation in this cell type. Interestingly, CD4+ and CD8+ 
T cells proliferating in response to C. trachomatis EBs were found in the synovial fluid of 
patients with CiReA, and the response could be inhibited by antibodies to MHCI and 
MHCII (Sieper et al., 1991). Furthermore, chlamydial peptides were identified that were 
presented by HLA-B27 to CD8+ T cells from infected HLA-B27 transgenic mice, and a 
response to these epitopes was also detected with CD8+ T cells from patients with CiReA 
(Kuon et al., 2001). These studies point to an important role of CD8+ T cell recognition of 
MHCI presented chlamydial peptides in the immune response during CiReA. 
Less is known about MHCI antigen presentation during chlamydial persistence. It is not 
yet clear whether chlamydial persistence represents a state where evasion of immune 
recognition occurs. However, it was found that IFN-? and penicillin induced chlamydial 
persistence did not affect the lysis of infected cells by CD8+ T cells suggesting that 
chlamydiae do not interfere with MHCI surface expression during this growth arrest 
(Rasmussen et al., 1996). Further studies are needed to clarify the influence of different 
host cell conditions and chlamydial developmental stages on MHCI antigen presentation in 
order to get a more detailed picture of CD8+ T cell immunity to chlamydial infection. 
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1.3 The aim of the present study 
The aim of the present study is to clarify whether the MHCI antigen presentation pathway 
is functional or inhibited during productive and persistent C. trachomatis infection, and by 
which mechanism chlamydial interference with the MHCI antigen presentation pathway 
occurs. This will help to understand the cellular as well as the immune response to chlamy-
dial infection and chlamydial immune evasion mechanisms in greater detail, which is of 
vital importance for the development of efficient treatment and vaccination strategies. 
 
Three different infection models were studied and compared: (i) the normal productive 
chlamydial growth in epithelial cells (designated as active infection), (ii) the atypical, 
persistent growth of chlamydiae in epithelial cells (persistent infection) using the well-
established IFN-? induced persistence model and (iii) the atypical chlamydial growth in 
fibroblasts, which could represent an alternative host cell type for persistent infection 
during CiReA and in sublining tissue areas during pelvic inflammatory disease. 
 
The objectives of the present study were as follows: 
 
1. To analyse the atypical growth of C. trachomatis in fibroblasts in detail and to 
compare it with the other two infection models in order to define the role of 
fibroblasts as a potential host cell for chlamydial infection. This has been done by 
examination of inclusion morphology, formation of new progeny and chlamydial 
protein and gene expression analysis. Further, it has been investigated whether IDO 
is involved in mediating atypical growth of C. trachomatis in fibroblasts. 
 
2. To examine whether and how C. trachomatis interferes with the MHCI antigen 
presentation pathway in the different infection models. This has been done by 
measurement of MHCI expression on the surface of infected cells and by expres-
sion analysis of important intracellular components involved in MHCI antigen 
processing during infection. 
 
3. To analyse if the Chlamydia-induced fragmentation of the Golgi apparatus influ-
ences MHCI processing and trafficking to the cell surface and to define the role of 
the chlamydial protease CPAF in interference with the MHCI antigen presentation 
pathway.  
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2 Material and Methods 
2.1 Material 
2.1.1 Mammalian cells and bacterial strains 
BGM cells (from kidney of African Green 
Monkey) 
Friedrich Loeffler Institute of Molecular 
Pathogenesis, Jena, Germany 
Chlamydia trachomatis serovar D  
strain IC Cal 8 
Institute of Ophthalmology, London, UK 
HeLa cells CCL-2 (from human cervix) American Type Culture Collection, 
Manassas, Virginia, USA 
Normal human dermal fibroblasts (from 
juvenile foreskin) 
PromoCell, Heidelberg, Germany 
2.1.2 Material 
Media, buffers, chemicals, antibodies, nucleic acids and other materials used in the present 
work are listed in Appendix 6.1. 
2.2 Methods 
2.2.1 Cell culture 
HeLa cells and fibroblasts were grown in cell culture flasks with Opti-MEM/10% FCS at 
37°C and 5% CO2. Culture of BGM cells was done in DMEM/10% FCS. For subculture 
semi-confluent monolayers were washed with PBS and detached by trypsin/EDTA treat-
ment. Trypsin was inactivated by adding Opti-MEM/10% FCS and cells were collected by 
centrifugation at 250 x g for 5 min. After resuspension in Opti-MEM/10% FCS cells were 
seeded into new cell culture flasks. Long-time storage of suspended cells was done in 
liquid nitrogen at -180°C using medium with 10% FCS containing 14% DMSO as cryo-
preservative. 
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2.2.2 Propagation of C. trachomatis 
Propagation of chlamydial organisms was done in BGM cells. Cells grown in T-25 flasks 
were infected with 1 x 107 inclusion forming units (IFUs) per flask and incubated for 44 – 
48 h at 37°C and 5% CO2. The chlamydiae were harvested by scraping the cells with a cell 
scraper into 0.2 M sucrose/2% FCS/PBS. The cells were lysed by sonification to release 
chlamydial EBs from the cells. To remove cellular debris the suspension was centrifuged at 
4,000 x g for 3 min. The supernatant containing EBs was stored in aliquots at -80°C. The 
suspension was proofed for sterility by streaking a small amount on a Columbia blood agar 
plate, a chocolate agar plate and a Winkle agar plate and testing it for mycoplasma contam-
ination via PCR. The amount of infectious EBs in the suspension, expressed as IFUs/ml, 
was determined as described in chapter 2.2.4. 
2.2.3 Infection procedure 
Confluent cell monolayers were inoculated with chlamydial organisms at a multiplicity of 
infection (MOI) of 5, if not otherwise indicated, and centrifuged at 4,000 x g for 60 min at 
37°C. The inoculum was replaced by cell culture medium with 2% FCS. Cells were incu-
bated for the indicated times at 37°C and 5% CO2. For induction of chlamydial persistence 
in HeLa cells the cell monolayers were pre-treated with 100 U/ml IFN-? 48 h before infec-
tion. Immediately after centrifugation cells were further treated with 100 U/ml IFN-? in 
cell culture medium with 2% FCS. For experiments using treatment with IFN-β (100 
U/ml), IFN-? (100 U/ml), IFNAR antibody (1 μg/ml), chloramphenicol (100 μg/ml) and 
cycloheximide (2 μg/ml), respectively, the substances were added directly after infection to 
the culture medium. 
2.2.4 Determination of inclusion number, IFUs and burst size 
1 x 105 cells were seeded in shell vials containing coverslips, and on the next day they got 
infected with C. trachomatis at a MOI of 0.5. After fixation with methanol the chlamydial 
inclusions were stained with a FITC-conjugated mouse anti-MOMP antibody (MikroTrak 
Chlamydia trachomatis Culture Confirmation Test, Trinity Biotech Plc, Bray, Ireland) 
according to the manufacturer’s instructions. The number of inclusions was determined by 
counting inclusions on 10 microscopic fields by epifluorescence microscopy. To determine 
the production of infectious EBs (IFUs), chlamydiae were released from infected mono-
layers into 0.2 M sucrose/2% FCS/PBS through sonification. The suspension was stored at 
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-80°C. IFUs were determined by means of titrating different dilutions of the suspension on 
BGM cell monolayers grown on coverslips and subsequent infection through centrifuga-
tion. After fixation and staining at 24 h p.i. the inclusions were counted by epifluorescence 
microscopy. Each inclusion represented one IFU. Total number of IFUs was determined by 
including the microscope factor, the dilution factor and the volume of the titrated sample in 
the calculation. The burst size was determined by dividing the total number of IFUs by the 
total number of inclusions. The value represents the IFUs produced per inclusion. 
2.2.5 Preparation of cells for transmission electron microscopy 
Cell monolayers infected with C. trachomatis were fixed with 2% glutaraldehyde in 0.1 M 
sodiumcacodylate buffer for 5 min at RT. Cells were detached by scraping, and incubated 
for further 30 min with the fixative at RT. The samples were stored at 4°C. Electron 
microscopy was done by Elisabeth M. Liebler-Tenorio at the Friedrich Loeffler Institute of 
Molecular Pathogenesis (Jena, Germany) and according to Rödel et al. (2012).  
Briefly, 1-mm3 cubes were cut from the cells which had been embedded in 2% agarose 
before and fixed in 2% osmium tetroxide. Stained ultrathin sections were analysed with a 
transmission electron microscope (Tecnai 12, FEI, Eindhoven, The Netherlands). 
2.2.6 Confocal laser scanning microscopy of immunofluorescently stained cells 
For visualisation of the Golgi apparatus and intracellular distribution of MHCI confocal 
laser scanning microscopy was applied to cells stained with fluorescent dye-conjugated 
antibodies. Cells grown on coverslips were infected with C. trachomatis and incubated for 
the indicated time points. Then the cells were fixed with 2 % paraformaldehyde/PBS for 20 
min, washed three times with PBS and permeabilised with 0.1% Saponin/PBS for 10 min. 
Blocking occurred by incubation with blocking buffer (3% BSA/0.1% Saponin/PBS) for 
one hour. The cells were washed three times with 0.1% Saponin/PBS and incubated with 
rabbit anti-GM130 (Abcam, Cambridge, UK) at a dilution of 1:500 or mouse anti-Golgin-
245 (BD Biosciences, Heidelberg, Germany) at a dilution of 1:250 in blocking buffer over-
night at 4°C. After washing again three times with 0.1% Saponin/PBS, incubation with the 
fluorescence-conjugated secondary antibody (Alexa Fluor 633-conjugated goat anti-rabbit 
IgG or rabbit anti-mouse IgG, Invitrogen, Darmstadt, Germany) at a dilution of 1:1000 in 
blocking buffer was done for 1 hour in the dark at RT. Thereafter, a second staining step 
occurred for visualisation of chlamydial inclusions (demonstration of Golgi fragmentation) 
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or MHCI (co-localisation of MHCI with the Golgi). Chlamydial inclusions were stained 
with FITC-conjugated mouse anti-MOMP antibody at a dilution of 1:20 (MikroTrak 
Chlamydia trachomatis Culture Confirmation Test, Trinity Biotech Plc, Bray, Ireland). 
Staining of MHCI occurred with the mouse W6/32 antibody (a gift from Michael Knittler, 
Friedrich Loeffler Institute Tübingen, Germany) that binds the native form of the MHCI-
?2M heterodimer at a dilution of 1:50. The antibody was diluted in blocking buffer and 
incubated with the cells for one hour at RT. Finally, unbound antibody was removed by 
three times washing with 0.1% Saponin/PBS. For the visualisation of MHCI a second step 
of staining was performed through incubation with a fluorescence-conjugated secondary 
antibody (Alexa Fluor 488 rabbit anti-mouse IgG, Invitrogen, Darmstadt, Germany) 
diluted in blocking buffer at 1:1000 for 30 min at RT. The coverslips were mounted on a 
drop of mounting medium (ProLong Gold antifade reagent with DAPI, Invitrogen, 
Darmstadt, Germany) on a microscope slide. The mounting medium was cured by incuba-
tion overnight at RT. Images were generated with the confocal laser scanning microscope 
LSM 5 (Zeiss, Jena, Germany) using the ZEN software (Zeiss, Jena, Germany) and the 
following laser and filter options: 405 nm excitation wavelength (405-425 nm Laser Diode, 
25 mW) and a 420 – 480 nm bandpass filter for DAPI, 488 nm excitation wavelength 
(Argon Laser 488 nm, 25 mW) and a 505 – 530 nm bandpass filter for FITC or Alexa 
Fluor 488, 633 nm excitation wavelength (Helium-neon 633 nm laser, 5 mW) and a 650 
nm longpass filter for Alexa Fluor 633. 
Co-localisation values were computed by the ZEN software after choosing regions of 
interest. For examination of Golgi fragmentation cells were categorised in three groups: 
complete fragmentation, partial fragmentation and no fragmentation. The fragmented 
Golgi could be distinguished from the normal Golgi by the presence of stained dots 
irregularly distributed in the cytosol and the absence of a compact Golgi stack. Cells that 
contained a less compact Golgi stack and some distributed Golgi fragments were 
considered as having partial fragmentation of the Golgi. 
2.2.7 RNA isolation and reverse transcription 
RNA was isolated from the cells using the peqGOLD Total RNA Kit (Peqlab, Erlangen, 
Germany) according to the manufacturer’s instructions. The isolation included the diges-
tion of DNA with the peqGOLD DNase I Digest Kit (Peqlab, Erlangen, Germany). Meas-
urement of RNA concentration and purity was carried out with a NanoDrop spectro-
photometer using the OD260/OD280 nm absorption ratio. For reverse transcription of the 
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RNA into cDNA the Reverse Transcription System from Promega (Mannheim, Germany) 
was used. For a 20 μl reaction the following kit components were mixed: 4 μl MgCl2, 2 μl 
Reverse Transcription Buffer, 2 μl dNTP-Mix, 0.5 μl RNAsin (RNase inhibitor), 1 μl 
Oligo (dT) primers or 1 μl random primers and 0.5 μl AMV Reverse Transcriptase 
(containing 15 U). Finally, 10 μl H2O containing 1 μg RNA were added, and reverse 
transcription occurred at 42°C for 30 min. cDNA generated with Oligo (dT) primers was 
used for analysis of eukaryotic and cDNA made with random primers for analysis of 
chlamydial gene expression. 
2.2.8 Analysis of gene expression with real-time quantitative PCR 
PCR was performed using cDNA generated from RNA which has been isolated from 
mock- or Chlamydia-infected cells as described in chapter 2.2.7. Primer pairs were 
designed using the National Center for Biotechnology Information (NCBI) primer design 
tool (see Table 7 and Table 8 in Appendix 6.1.5 for primers used in the present study) and 
synthesised by Jena Bioscience, Jena, Germany. The primers were checked for correct 
binding and optimum annealing temperature with RT-PCR using GoTaq DNA Polymerase 
(Promega, Mannheim, Germany) and cDNA as template. The 25 μl RT-PCR reaction mix 
contained 5 μl GoTaq DNA Polymerase buffer, 0.5 μl of dNTP mix (10 mM), 1 μl forward 
primer (10 μM), 1 μl reverse primer (10 μM), 0.125 μl GoTaq Polymerase, 1 μl cDNA and 
17.4 μl H2O. The PCR reaction included a denaturation step at 94°C for 5 min, 30 cycles 
of 30 s denaturation at 94°C, 30 s annealing and 1 min elongation at 72°C, and finally 10 
min extension at 72°C. The PCR product was analysed by electrophoresis on a 1% agarose 
gel and staining with ethidium bromide. 
Real-time PCR was done with the SmartCycler II (Cepheid, Maurens-Scopont, France). 
The 20 μl PCR reaction mix contained 1x KAPA SYBR FAST qPCR Universal Mastermix 
(Peqlab, Erlangen, Germany), 1 μl of template and 0.2 μM of each primer. The PCR pro-
file used was the following: initial denaturation at 95°C for 60 s, 45 cycles of denaturation 
at 95°C for 30 s, primer annealing for 15 s (for the respective temperature see Table 7 and 
Table 8 in Appendix 6.1.5) and elongation at 72°C for 30 s. The relative quantitation of 
gene expression was done by calculating the ratio of the expression of the analysed gene 
relative to the expression of a reference gene (housekeeping gene). GAPDH was chosen as 
reference gene for human and 16SrRNA for chlamydial genes. The gene expression was 
calculated from the Cycle Threshold (CT) values of the PCR reactions. Primer efficiencies 
(E) were determined by performing real-time PCR reactions on different dilutions of one 
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cDNA sample made of RNA that was isolated from Chlamydia-infected HeLa cells. The 
resulting CT values were plotted against the respective cDNA concentrations giving a 
linear slope that was used for the calculation of E by using the formula E = 10-1/slope (Pfaffl, 
2001). 
For human gene expression the ratio was calculated using the following formula according 
to Pfaffl (2001): ratio = Etarget?CTtarget (control – treatment)/Ereference?CTreference (control – treatment). For 
chlamydial gene expression the relative transcription level was determined with a formula 
that includes the primer efficiencies of the respective genes modified from Kokab et al. 
(2010):  relative transcription level = E?CT (reference gene)/E?CT (target gene). Gene 
expression values are given as average of three independent experiments. 
2.2.9 ELISA for IFN-? quantitation 
Amounts of secreted IFN-? were measured in supernatants of mock- and Chlamydia-
infected cells with a Human Interferon-? ELISA Kit (Invitrogen, Darmstadt, Germany) 
according to the manufacturer’s instructions. 
2.2.10 siRNA transfection of fibroblasts 
Predesigned siRNAs for knockdown of IDO expression were purchased from Qiagen 
(Hilden, Germany; see Appendix 6.1.5) and used for transfection of fibroblasts at a final 
concentration of 25 nM according to the Fast-Forward protocol of the HiPerFect 
transfection reagent, which is composed of cationic and neutral lipids (Qiagen, Hilden, 
Germany). For six-well plates 2 x 105 cells per well were seeded in 2300 μl Opti-MEM 
with 10% FCS directly before transfection. 750 ng siRNA were diluted in 100 μl Opti-
MEM without serum. Then 18 μl HiPerFect was added, and the solution was mixed well. 
The transfection mixture was incubated at RT for 5-10 min and then added to the 2300 μl 
cell culture volume drop-wise while swirling the plate. For shell vials 8 x 104 cells were 
seeded in 500 μl Opti-MEM/10% FCS and transfected with a mixture of 100 μl Opti-MEM 
containing 187.5 ng siRNA and 4.5 μl HiPerFect. Transfection with AllStars Negative 
Control siRNA (Qiagen, Hilden, Germany) and HiPerFect reagent alone, respectively, 
using the same amounts as above, was performed as control. The transfected cells were 
incubated for 48 h at 37°C and 5% CO2 before infection with chlamydiae. The siRNA 
knockdown was monitored through confirming downregulation of IDO expression by real-
time PCR at 72 and 96 h after transfection (24 h and 48 h p.i.). 
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2.2.11 SDS-PAGE and immunoblotting 
The expression of host cell and chlamydial proteins was analysed by SDS-PAGE and 
immunoblotting. Infected or mock-infected cells grown in six-well plates were detached 
with a cell scraper into RIPA buffer (see Table 6 in Appendix 6.1.4) for cell lysis. The 
lysate was incubated for 45 min at 4°C and mixed thoroughly every 10 min. To remove 
cell debris the lysate was centrifuged at 20,000 x g for 10 min at 4°C. The supernatant con-
taining the proteins was stored at -20°C. 
Polyacrylamide gels were casted consisting of a lower resolving gel (with 5, 8, 10 or 12% 
acrylamide, depending on the size of proteins analysed) and an upper stacking gel with 
slots (see Table 6 in Appendix 6.1.4). For SDS-PAGE the protein lysate was mixed with 
the same volume of Laemmli sample buffer (Bio-Rad Laboratories, München, Germany) 
and boiled for 3 min. In cases where the transmembrane proteins TAP1 and TAP2 should 
be detected, the lysates were mixed with the same volume of 2x SDS-Urea sample buffer 
(see Table 6 in Appendix 6.1.4) and shaken for 15 min at RT. The samples and a pre-
stained protein standard (Bio-Rad Laboratories, München, Germany) were loaded onto 
single slots of a polyacrylamide gel covered with Tris/Glycine/SDS-electrophoresis buffer 
(Bio-Rad Laboratories, München, Germany). To separate the proteins the gel was run at 
150 volt until the bromophenol blue line approached the bottom line of the gel. 
For immunoblotting the proteins separated in the polyacrylamide gel were transferred on a 
nitrocellulose membrane (Bio-Rad Laboratories, München, Germany) using a semi-dry 
blot system (Bio-Rad Laboratories, München, Germany) and Bjerrum-Schafer-Nielsen-
transfer buffer (Bjerrum & Schafer-Nielsen, 1986; see Table 6 in Appendix 6.1.4) at 10 
volt for 90 – 120 min. The transfer of proteins was verified by incubation of the membrane 
with Ponceau S staining solution (see Table 6 in Appendix 6.1.4) that led to visualisation 
of all membrane-bound proteins. Ponceau S was removed by washing with PBS. The 
membrane was incubated in a blocking buffer containing 2% BSA in TBS-Tween for 2 h 
in order to allow binding of BSA to regions of the membrane where no protein had bound 
during the transfer. This step was necessary to prevent unspecific binding of antibody to 
these regions during the following incubation steps. 
Then the membrane was incubated with a primary antibody diluted in blocking buffer 
overnight at 4°C (see Table 10 in Appendix 6.1.6 for antibodies and the respective 
dilutions). The membrane was washed three times for 5 min in TBS-Tween. An alkaline 
phosphatase-conjugated secondary antibody (goat anti-mouse or goat anti-rabbit, Dianova, 
Hamburg, Germany) diluted in blocking buffer (1:1000) was added and incubated for 2 h 
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at RT. After a final wash three times for 10 min in TBS-Tween the binding of the 
secondary antibody was visualised by incubating the membrane in a solution of 5-Bromo-
4-chloro-3-indolyl phosphate (BCIP)/Nitro blue tetrazolium (NBT) (Sigma-Aldrich 
Chemie, München, Germany) which served as substrate for alkaline phosphatase. This 
enzyme reaction leads to a dark blue colour at antibody-bound protein bands. 
Generally, the same volumes of different protein lysates were loaded onto the gel. An anti-
body binding GAPDH (see Table 10 in Appendix 6.1.6) was used as loading control. The 
densitometry ratio of the MOMP and HSP60 protein bands was determined by using the 
ImageJ software (available from http://rsbweb.nih.gov/ij/). 
2.2.12 Flow cytometry 
Surface expression of MHCI on Chlamydia-infected cells was analysed by flow cytometry 
after double immunofluorescence staining of surface MHCI and chlamydial inclusions. 
Chlamydia- and mock-infected cell monolayers grown in six-well plates were detached 
with 400 μl Trypsin/EDTA per well. 100 μl FCS was added to inactivate trypsin. After 
addition of 1 ml PBS the suspension was centrifuged at 150 x g for 5 min at 4°C. The 
pellet was resuspended in 10% FCS/PBS containing the PE-conjugated mouse monoclonal 
antibody W6/32 binding to native MHCI molecules at a dilution of 1:50 (Santa Cruz 
Biotechnology, Heidelberg, Germany). After incubation for 30 min at 4°C in the dark the 
cells were washed once with 1 ml PBS/10% FCS. Then fixation occurred by incubation 
with 200 μl 2% paraformaldehyde for 10 min at RT. The cells were washed in 1 ml PBS 
and then permeabilised with 200 μl PBS/0.5% Saponin/0.5% BSA for 30 min at RT. 
Intracellular staining of chlamydiae was performed by incubation of the cells with 10 μl 
FITC-conjugated mouse anti-MOMP antibody (MikroTrak Chlamydia trachomatis Culture 
Confirmation Test, Trinity Biotech Plc, Bray, Ireland) in 200 μl PBS/0.5% Saponin/0.5% 
BSA. After incubation for 30 min at RT the cells were washed with PBS/0.5% 
Saponin/0.5% BSA and finally resuspended in PBS/0.5% BSA. Fluorescence intensity of 
20,000 cells was measured with a FACSCalibur flow cytometer and Cell Quest Software 
(both from BD Biosciences, Heidelberg, Germany). The cells that were incubated without 
antibodies and only with PE- or FITC-conjugated IgG, respectively, served as controls to 
exclude background fluorescence and unspecific antibody binding. 
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2.2.13 Cell-free cleavage assay 
In order to analyse whether chlamydial proteases that had been secreted into the cytosol are 
responsible for degradation of host cell proteins, a cell-free cleavage assay was performed 
according to Zhong et al. (2001) with little modifications. In this enzyme activity assay a 
purified protein or protein lysate is incubated with the cytosolic extract (CE) isolated from 
Chlamydia-infected cells in order to see if chlamydial proteases present in this CE cleave 
the protein substrate. The inclusion of protease inhibitors in the buffer used for CE 
preparation (see Table 6 in Appendix 6.1.4) ensures inhibition of most cellular proteases, 
but inhibition of the chlamydial protease CPAF does not occur through these inhibitors 
(Zhong et al., 2000; Zhong et al., 2001). 
Chlamydia-infected and mock-infected HeLa cells grown in six-well plates were detached 
at 48 h p.i. by treatment with 400 μl trypsin/EDTA per well. Trypsin was inactivated by 
addition of 100 μl FCS and the suspension was filled up with 1 ml PBS. The cells were 
pelleted by centrifugation at 250 x g for 5 min at 4°C and washed with ice-cold PBS. After 
a further centrifugation step the pellet was resuspended in 100 μl Cell extraction buffer 
(see Table 6 in Appendix 6.1.4) per well and incubated on ice for 15 min. Preparation of 
the CE was done applying dounce homogenisation with a conical tissue grinder with 20 
times of douncing. This gentle lysis ensures that cells get broken up without lysing the 
nuclei. The suspension was centrifuged at 1,000 x g for 10 min at 4°C and the supernatant 
representing the CE was transferred to a new tube. The pellet which contained the nuclei 
was kept for preparation of the nuclear extract (NE), in case cleavage of nuclear proteins 
should be analysed. Centrifugation of the CE at 20,000 x g for 15 min at 4°C was done to 
remove insoluble particles. The NE was prepared after washing the nuclei pellet two times 
in 1 ml Cell extraction buffer and centrifugation at 1,000 x g for 10 min at 4°C. The nuclei 
pellet was lysed in 50 μl Nuclear extraction buffer (see Table 6 in Appendix 6.1.4) per well 
and mixed thoroughly. After centrifugation at 20,000 x g for 15 min at 4°C the supernatant 
was kept for the assay as NE. Since the NE can be only used for detection of nuclear 
proteins, cell lysate from whole cells was used for the analysis of GM130, Golgin-245 and 
the TAP2 protein which are proteins located in the Golgi apparatus and the ER 
membranes, respectively. These cell lysates were made by scraping mock- and Chlamydia-
infected HeLa cells in 1% Triton-X 100/PBS containing the same protease inhibitors as the 
Cell extraction buffer. After incubation for 45 min at 4°C and mixing thoroughly every 10 
min the samples were centrifuged at 20,000 x g for 10 min and the supernatants were used 
for the assay. For the assay the CE was mixed with the NE or cell lysate, and the mixture 
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was incubated for two hours at 37°C. These conditions allow the protein substrate to be 
cleaved by protease activity. As control CE was incubated with Nuclear Extraction buffer 
or 1% Triton-X 100/PBS, respectively, and NE was incubated with Cell extraction buffer. 
To inhibit CPAF activity the CE from infected cells was pre-incubated with the 
proteasome inhibitor lactacystin (Clasto-Lactacystin ?-lactone, Sigma-Aldrich Chemie, 
München, Germany) for 20 min at 37°C before mixing with substrate and starting the 
assay. The assay was stopped by transferring the samples onto ice. The samples were 
analysed by SDS-PAGE and immunoblotting to detect the protein and its cleavage. 
2.2.14 Immunoprecipitation of CPAF 
To investigate whether CPAF was responsible for degradation of the examined host pro-
teins the protease was removed from the CE of Chlamydia-infected HeLa cells by means 
of immunoprecipitation followed by analysis of cleavage activity in a cell-free cleavage 
assay (see chapter 2.2.13). The appropriate amount of CE used for immunoprecipitation 
was determined in a cell-free cleavage assay where different volumes of CE were used to 
determine the minimum amount of CE necessary to cause full cleavage of the target 
protein. It was important to minimise the amount of CPAF in the CE to ensure that most of 
the CPAF is immunoprecipitated by the antiserum without the need to use huge amounts of 
antibody. The same amount of CE was used for the other samples in the cell-free cleavage 
assay. 200 μl of the CE from Chlamydia-infected cells were pre-cleared by incubation with 
1 μg mouse IgG and 20 μl Protein G PLUS-Agarose (both from Santa Cruz 
Biotechnology, Heidelberg, Germany) for 30 min at 4°C. The agarose beads were removed 
by centrifugation at 10,000 x g for 15 min at 4°C. 100 μl of the pre-cleared CE were mixed 
with 5 μl CPAF antiserum (a gift from the Institute for Medical Microbiology and 
Hygiene, University Hospital Ulm, Germany). Another 100 μl of the pre-cleared CE were 
incubated with 5 μl mouse IgG, and this sample served as irrelevant antibody control. 
After incubation overnight at 4°C with gentle agitation 35 μl protein G PLUS-Agarose was 
added and the samples again were incubated overnight at 4°C with gentle agitation. The 
immunoprecipitate was pelleted by centrifugation at 10,000 x g for 15 min at 4°C. The 
supernatant, that should contain no CPAF, was used for the cell-free cleavage assay. The 
immunoprecipitate pellet was washed four times in 1 ml RIPA-buffer (see Table 6 in 
Appendix 6.1.4), finally mixed with Laemmli sample buffer (Bio-Rad Laboratories, 
München, Germany) and heated for 3 min at 100°C to dissociate the proteins from the 
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agarose beads. After another centrifugation step at 10,000 x g for 15 min the supernatant 
was kept for analysis of the immunoprecipitated CPAF by SDS-PAGE. 
2.2.15 Endoglycosidase H treatment 
For the Endoglycosidase H (Endo H) cleavage of MHCI cell lysates were made by 
scraping cells into 1% Triton X-100/PBS containing protease inhibitors (0.1 mM PMSF, 
50 μg/ml aprotinin, 2 μg/ml leupeptin). After incubation for 45 min at 4°C with mixing 
every 10 min the lysates were centrifuged at 20,000 x g for 10 min at 4°C to remove 
cellular debris. For the assay 10 μl lysate were mixed with 20 μl Endo H reaction buffer 
(see Table 6 in Appendix 6.1.4) and incubated for 30 min at RT with shaking. Thereafter, 
100 U of Endo H (New England Biolabs, Frankfurt am Main, Germany) were added to 
each sample. The mixtures were incubated overnight at 37°C and finally analysed by SDS-
PAGE and immunoblotting. Samples without Endo H treatment were used as controls. 
2.2.16 Fluorescence in situ hybridisation (FISH) 
FISH was done according to Herold et al. (2001) with some modifications. Infected cell 
monolayers grown on coverslips were fixed with 2% paraformaldehyde for 20 min. After 
washing three times in PBS and permeabilisation with 0.5% Saponin/PBS for 10 min the 
coverslips were incubated with prehybridisation buffer (see Table 6 in Appendix 6.1.4) for 
15 min at 37°C. Cy3 labelled oligo(dT)50 (Jena Bioscience, Jena, Germany) was used as 
probe for hybridisation with poly(A)+ RNA. The cell monolayers were covered with 0.5 
pmol of Cy3 labelled oligo(dT)50 per μl hybridisation buffer (see Table 6 in Appendix 
6.1.4) and incubated in a closed humidity chamber for three hours at 37°C.  The following 
washing steps were applied (each two times for five minutes): 2x saline-sodium citrate 
(SSC) buffer (see Table 6 in Appendix 6.1.4) containing 20% formamide at 42°C, 2x SSC 
buffer at 42°C, 1x SSC buffer at RT and PBS at RT. Subsequently, immunofluorescence 
staining of chlamydiae was performed with a FITC-conjugated mouse anti-MOMP anti-
body (MikroTrak Chlamydia trachomatis Culture Confirmation Test, Trinity Biotech Plc, 
Bray, Ireland). Briefly, 10 μl of the antibody solution was diluted in 0.5% Saponin/PBS 
and incubated on the coverslips for one hour at RT. After washing three times with 0.5% 
Saponin/PBS the coverslips were mounted on microscopy slides with ProLong Gold 
antifade reagent containing DAPI (Invitrogen, Darmstadt, Germany) and examined with a 
confocal laser scanning microscope (LSM5, Zeiss, Jena, Germany) using the 543 nm 
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excitation wavelength (Helium-neon 543 nm laser, 1.2 mW) and the 560 nm longpass filter 
for Cy3, 488 nm excitation wavelength (Argon Laser 488 nm, 25 mW) and a 505 – 530 nm 
bandpass filter for FITC and 405 nm excitation wavelength (405-425 nm Laser Diode, 25 
mW) and a 420 – 480 nm bandpass filter for DAPI. 
2.2.17 Sample preparation for two dimensional (2D) gel electrophoresis 
Cells grown in T-25 flasks and infected with C. trachomatis at a MOI of 5 were scraped 
into 250 μl of 0.2 M sucrose/2% FCS/PBS per flask at 24 h p.i. The cell suspensions were 
collected on ice to inhibit proteases and to prevent a stress response that could result in a 
change of the chlamydial proteome. Chlamydial organisms were released from the cells by 
sonification. Then the suspension was stored at -80°C for later use. The preparation of RBs 
was done by density gradient ultracentrifugation of the cell suspensions according to 
Caldwell et al. (1981). The suspensions were centrifuged at 4,000 x g for 3 min at 4°C to 
remove cell debris. 24 ml of the supernatant (harvested from 96 T-25 flasks) was filled into 
a 34 ml quick-seal ultracentrifuge tube (Beckman Coulter, Krefeld, Germany) by means of 
a peristaltic pump. The density-gradient was generated with different concentrations of 
iodixanol (Visipaque 320, GE Healthcare, München, Germany). For the first round of 
ultracentrifugation the tube consisted of the following layers (from top to bottom): 24 ml 
cell suspension, 2 ml 8%, 3 ml 15% and 5 ml 30% of iodixanol solution. After centrifu-
gation at 40,000 x g for 50 min at 4°C the sediment containing the bacteria was homoge-
nised in 6 ml PBS. The next gradient filled in consisted of 1 ml 8%, 1 ml 15%, 1 ml 30%, 
12 ml 36%, 8 ml 40% and 5 ml 47% iodixanol. During the second ultracentrifugation at 
50,000 x g for 50 min at 4°C the RBs were collected as a ring in the 36% iodixanol zone 
and EBs resided between 40 and 47% iodixanol. The RB fraction was transferred to a new 
ultracentrifuge tube and the remaining iodixanol was removed by washing with PBS and 
centrifugation at 30,000 x g for 50 min at 4°C. The RB pellet was resuspended in 100 – 
200 μl of 50 mM Tris-HCl, pH 7.2 (with 2 mM DTT as protein stabilisator and 100 μg/ml 
PMSF, 2 μg/ml Leupeptin and 12 μg/ml Aprotinin as protease inhibitors) and sonified 
followed by incubation for 15 min on ice for lysis.  
The proteins were precipitated by TCA/acetone precipitation. Nine volumes of an ice-cold 
TCA solution (see Table 6 in Appendix 6.1.4) were added to the RB lysate and the sample 
was thoroughly mixed. After incubation overnight at -20°C and harsh mixing for 30 s the 
sample was centrifuged at 12,000 x g for 15 min at 4°C. The TCA solution was removed 
and the pellet washed twice in 1 ml of ice-cold washing solution (see Table 6 in Appendix 
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6.1.4). After complete removal of the acetone the pellet was allowed to air-dry for 5 min at 
RT, resuspended in lysis buffer for 2D gel electrophoresis (see Table 6 in Appendix 6.1.4) 
and incubated for 1 h at RT with mixing every 10 min to solubilise the proteins. After 
centrifugation at 20,000 x g for 20 min at 16°C the supernatant was transferred to a new 
tube. Protein concentration was determined according to Bradford et al. (1976) with the 
Bio-Rad Protein assay (Bio-Rad Laboratories, München, Germany) corresponding to the 
manufacturer’s instructions. The RB protein sample was stored at -80°C. 
2.2.18 2D gel electrophoresis of chlamydial RBs 
2D gel electrophoresis was carried out at the Leibniz Institute for Natural Product Research 
and Infection Biology in Jena, in cooperation with the department of Molecular and 
Applied Microbiology. The RB protein samples were separated by 2D gel electrophoresis 
according to Kniemeyer et al. (2005) and Grosse et al. (2008). The 2D gels were stained 
with the fluorescent dye SYPRO Ruby Protein Gel Stain (Sigma-Aldrich Chemie, 
München, Germany) and scanned with a Typhoon multicolour fluorescence and phosphor 
image scanner (GE Healthcare, Freiburg, Germany) to visualize the proteins. Analysis of 
the 2D gels and quantitation of the protein spots were done with the Delta 2D software 
(version 3.4, Decodon, Greifswald, Germany). After isolation of the proteins from the gels 
and their tryptic digestion the identification of the proteins occurred by mass spectrometry 
using the MALDI TOF/TOF mass spectrometer Ultraflex I (Bruker Daltonics, Bremen, 
Germany). This was followed by NCBI database search with the software MASCOT 2.1.0. 
(Matrix Science, London, UK) using a MASCOT score of p = 0.05 as significance level 
and the Protein Scape 1.3 software (Protagen, Dortmund, Germany). 
2.2.19 Statistics 
Average values and standard deviations were determined with Microsoft Excel. To deter-
mine if the values are significant from each other a student t-test assuming unequal vari-
ances was applied by using Microsoft Excel. P values < 0.05 were considered as statisti-
cally significant. 
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3 Results 
3.1 Characterisation of the persistent-like growth state of C. trachomatis 
in fibroblasts 
3.1.1 Comparison of the replication cycle of C. trachomatis between epithelial cells 
and fibroblasts 
Fibroblasts could represent another host cell type in vivo in which chlamydiae may repli-
cate after their spread from the infected epithelium to sublining tissue areas. Indeed, 
chlamydiae have been found inside of fibroblasts in synovial samples from patients with 
CiReA (Nanagara et al., 1995) and were shown to be able to grow in synovial fibroblasts 
after in vitro infection (Rödel et al., 1998 a, Rödel et al., 1998 b). However, little is known 
about the detailed growth behaviour of C. trachomatis in fibroblasts as well as the ability 
of these bacteria to persist inside of these cells. Thus, growth of this organism in this cell 
type was analysed in more detail and compared with the productive growth in epithelial 
cells which is the principal host cell type for productive infection of Chlamydia. 
HeLa cells, a cervix carcinoma cell line, were used as epithelial cell model and human 
diploid skin fibroblasts, which are primary cells, as fibroblast model for chlamydial infec-
tion. Dermal fibroblasts from foreskin were used, because they are easily available from 
healthy donors. Furthermore, they show similar growth behaviour like synovial fibroblasts 
(J. Rödel, personal communication). Fig. 4 shows that both HeLa cells and fibroblasts 
could be successfully infected with C. trachomatis as it can be seen by the development of 
inclusions. An obvious difference between the cell types was the size of inclusions, 
because inclusions within fibroblasts were much larger (~ 30 x 10 μm at 24 h p.i.) than 
inclusions within HeLa cells (~ 10 x 10 μm at 24 h p.i.; Fig. 4). Fibroblast inclusions could 
become very large, with sizes up to 100 μm length and 30 μm width, whereas HeLa cells 
only contained inclusions of up to 50 μm length and 20 μm width (Fig. 4). 
The replication efficiency of chlamydial organisms in both cell types was assessed by 
quantification of inclusions and intracellular production of new infectious EBs (expressed 
as IFUs) in shell vials at different time points after infection (Table 1). The amount of 
inclusion-containing HeLa cells was 4.7 x 104 representing 47% of all cells (1 x 105) in the 
culture. This correlates well with the MOI of 0.5 used for this experiment and indicates 
that HeLa cells are highly susceptible for C. trachomatis infection since almost every EB 
in the inoculum could infect and successfully develop an inclusion in HeLa cells. 
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Fig. 4: Immunofluorescent staining of C. trachomatis inclusions in HeLa cells and fibroblasts.  
Chlamydial inclusions in HeLa cells and fibroblasts infected with a MOI of 0.5 were stained with FITC-anti-
MOMP (green). Cells were counter-stained with Evans Blue (red). The pictures on the right are detailed 
pictures of the inclusions on the respective left pictures (marked with a rectangle). 
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In contrast, infection of fibroblasts with the same inoculum resulted in an inclusion number 
of only 2.4 x 103 which indicates that just 2.4% of all cells were infected. Because the 
inclusion number in fibroblasts was only 5% of that of HeLa cells (Table 1), it can be 
concluded that fibroblasts are much less susceptible for infection with C. trachomatis than 
HeLa cells. 
The difference was even more pronounced on the level of intracellular EBs (Table 1). The 
production of infectious progeny at 48 h p.i. was lower in fibroblasts than in HeLa cells by 
3 log ranges. Since both the inclusion number and the IFUs in HeLa cells and fibroblasts 
were different it was important to calculate the burst size (IFUs produced per inclusion) for 
direct comparison of the chlamydial replication efficiency (Table 1 and Fig. 5). In both cell 
types only few bacteria converted back from RBs to EBs already at 24 h p.i. In HeLa cells 
the burst size highly increased from 24 to 48 h p.i. to around 740 EBs per inclusion corre-
lating with the normal time period of 48 h that C. trachomatis needs to complete its intra-
cellular multiplication and re-differentiation to EBs. 
 
Table 1: Replication efficiency of C. trachomatis in epithelial cells and fibroblasts: inclusion numbers, 
IFUs and burst size. 
Cells were infected with C. trachomatis at a MOI of 0.5 and the number of inclusions was determined at 24 h 
p.i. The number of IFUs was determined at 24, 48 and 72 h p.i. The burst size represents the IFUs produced 
per inclusion. Values are given with standard deviations in brackets and show the mean of five independent 
experiments in duplicate. 
 time p.i. HeLa fibroblasts fibroblasts per-
centage of HeLa 
p value 
Inclusions 24 h 4.7 x 104  
(9.5 x 103) 
2.4 x 103  
(8.9 x 102) 
5.1% < 0.0000001 
IFUs 24 h 2.5 x 105  
(1.8 x 105) 
8.5 x 102  
(3.9 x 102) 
0.3% < 0.0001 
 
48 h 3.4 x 107  
(9.4 x 106) 
5.3 x 104  
(2.9 x 104) 
0.2% < 0.000001 
 
72 h 2.2 x 107  
(6.8 x 106) 
3.9 x 104  
(1.9 x 104) 
0.2% < 0.000005 
Burst size 24 h 5.9  
(5.4) 
0.4  
(0.2) 
6.5% < 0.05 
 
48 h 743.8  
(277.2) 
22.0  
(8.0) 
3.0% < 0.00005 
 
72 h 480.8  
(159.9) 
20.2  
(14.3) 
4.2% < 0.00001 
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Fig. 5: Burst size of C. trachomatis in epithelial cells and fibroblasts.  
See Table 1 for description and values. 
 
At 72 h p.i. the number of IFUs in HeLa cells decreased to 480 EBs per inclusion, suggest-
ing that EB release from the cells had occurred between 48 and 72 h p.i. In contrast, in 
fibroblasts a burst size of only 22 EBs per inclusion could be observed at 48 h p.i. 
representing only 3% of the amount in HeLa cells. The burst size of C. trachomatis in 
fibroblasts remained at this low level between 48 and 72 h p.i. indicating that there was no 
delay in the developmental cycle. 
Another approach to analyse the development and to evaluate the morphology of chlamy-
dial organisms in more detail is transmission electron microscopy. With this method EBs 
can be distinguished from RBs by their higher electron density and their smaller size 
(Matsumoto & Manire, 1970). At 48 h p.i. the inclusions in HeLa cells basically contained 
EBs (Fig. 6) correlating with the data in Fig. 5. In contrast, in fibroblasts much fewer EBs 
could be detected and inclusions were mainly filled with RBs. Interestingly, the morphol-
ogy and size of most of the RBs in fibroblasts was similar to that of RBs in HeLa cells 
indicating that they rather represent normal RBs than enlarged aberrant bodies (ABs) 
which are normally found during chlamydial persistence. However, a few ABs were also 
detectable in fibroblasts. Many of the normal-sized RBs in fibroblast inclusions contained 
a small electron dense point in their middle indicating a starting re-differentiation to EBs. 
This form is often found to be described as an intermediate body (IB). 
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Fig. 6: C. trachomatis inclusions 
visualised by transmission electron 
microscopy. 
Depicted in each picture is one cell con-
taining one chlamydial inclusion at 48 h 
p.i. The picture showing the fibroblast 
likely represents a cross section of an 
inclusion. The picture demonstrating the 
IFN-? mediated persistent infection of a 
HeLa cell was taken from the publica-
tion of Rödel et al., 2012. 
 
RB: reticulate body,  
EB: elementary body,  
IB: intermediate body,  
AB: aberrant body. 
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For comparison, the morphology of C. trachomatis during IFN-? mediated chlamydial per-
sistence in HeLa cells was also analysed. In this model, persistence was induced by incu-
bation of HeLa cells with 100 U/ml IFN-? 48 h before infection and ongoing post-infection 
treatment with IFN-?. The pre-treatment was necessary, because C. trachomatis serovar D 
is less susceptible to the IFN-? inhibitory effect than other C. trachomatis serovars, and 
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inhibition of IFU production only occurs when cells were pre-treated with IFN-? at a 
minimum concentration of 100 U/ml for 48 h before infection (Morrison, 2000; Yu, 2010). 
Inclusions that developed during IFN-? mediated persistence in HeLa cells were much 
smaller than those observed during active infection and contained only few, but very large 
ABs (Fig. 6). These results suggest that the growth of C. trachomatis in fibroblasts also 
differs from that during IFN-? mediated persistent infection in epithelial cells. 
3.1.2 IDO expression in C. trachomatis-infected fibroblasts 
In the IFN-? mediated chlamydial persistence model the tryptophan deficiency caused by 
IDO induces the persistent growth state of the chlamydial organisms (Beatty et al., 1994 
a). Expression of IDO can also be induced by type I IFN (Sanda et al., 2006), and synovial 
fibroblasts secrete IFN-? after infection with C. trachomatis which induces IDO expression 
in these cells (Rödel et al., 1998 a, Rödel et al., 1999). Thus, it was assumed that IDO 
could play a role in eliciting the atpyical growth state of C. trachomatis in fibroblasts. 
First, an ELISA was applied to quantify the amount of IFN-? in the supernatant of the cells 
to analyse if dermal fibroblasts also produce IFN-? upon infection with C. trachomatis. 
The results reveal that Chlamydia-infected dermal fibroblasts, but not HeLa cells, readily 
produce IFN-? after 48 h p.i. (Table 2). 
Similar to synovial fibroblasts (Rödel et al., 1998 a, Rödel et al., 1999), IDO expression 
was also highly upregulated after C. trachomatis infection of dermal fibroblasts (Fig. 7). 
To analyse, if the endogenously produced IFN-? accounts for this effect, an antibody bind-
ing to the type I IFN receptor (IFNAR) was used to block the type I IFN response. Incuba-
tion with this antibody abolished the upregulation of IDO expression in infected fibroblasts 
to a large extent (Fig. 7).  
 
Table 2: IFN-? production in HeLa cells and fibroblasts. 
Supernatants taken from infected and mock-infected cells (MOI 0.5) at the indicated time points were used 
for measuring the amount of secreted IFN-? with an ELISA Kit detecting human IFN-?. Values are the mean 
of three independent experiments with standard deviations in brackets. 
 HeLa fibroblasts 
C. trachomatis infection - + - + 
24 h p.i. - - - - 
48 h p.i. - - - 3.5 (3.1) U/ml 
72 h p.i. - - - 2.7 (2.0) U/ml 
 34 
0
200
400
600
800
CT CT + anti-IFNAR
ID
O
 
/ G
AP
D
H
 
ex
pr
es
sio
n
 
ra
tio
 
re
la
tiv
e 
to
 
m
o
ck
 
co
n
tr
o
l
*
 
 
Fig. 7: Influence of C. trachomatis infection on IDO gene expression in fibroblasts. 
Gene expression in C. trachomatis (CT) infected fibroblasts (MOI 0.5) at 48 h p.i. is depicted as x-fold regu-
lation compared to expression in uninfected cells. Depicted is the average value of three independent experi-
ments with standard deviation as error bar. An antibody binding the type I IFN receptor (anti-IFNAR) was 
added to the infected culture to neutralize type I IFN activity. *p < 0.01 compared to value for infected cells 
without treatment. 
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Fig. 8: Influence of C. trachomatis infection on IDO gene expression in HeLa cells. 
Gene expression at 48 h p.i. is depicted as x-fold expression change compared to untreated mock-infected 
cells (* p < 0.05 shows significant upregulation compared to mock-infected cells in the same infection 
model). The mean values of three independent experiments with standard deviation as error bars are shown. 
Cells were either not treated (active infection) or treated with 100 U/ml IFN-? (IFN-? active infection) and 
100 U/ml IFN-? (IFN-? active infection), respectively. To induce chlamydial persistence IFN-? treatment 
started already 48 h before infection (IFN-? persistent infection). 
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This result indicates that the infection-induced endogenously produced IFN-? strongly 
contributes to the induction of IDO expression after chlamydial infection of fibroblasts. 
For comparison, the effect of C. trachomatis infection on IDO expression was also exam-
ined in HeLa cells. No upregulation in IDO expression could be detected for HeLa cells 
actively infected with C. trachomatis (Fig. 8). Furthermore, the effect of IFN treatment on 
IDO expression in infected HeLa cells was analysed with two other infection models, in 
which IFN-? or IFN-? were added at 0 h p.i. In difference to the IFN-? induced persistence 
model that required 48 h pre-treatment with IFN-?, the addition of IFN-? and IFN-? after 
infection had no obvious effect on the morphology and growth of C. trachomatis serovar D 
in HeLa cells (data not shown). Thus, these two models are referred to as active infection 
with IFN-? and IFN-? treatment, respectively. In actively infected HeLa cells treated with 
IFN-? or IFN-? there was a significant upregulation of IDO expression compared to the 
respective IFN treated uninfected control. This effect was even more pronounced in the 
IFN-? mediated persistent infection model, and IFN-? generally was much more potent in 
eliciting IDO expression than IFN-?. Thus, IDO expression in HeLa cells could only be 
induced by exogenously added IFN, and the expression level was influenced by the IFN 
type and by infection with chlamydiae, which seems to induce factors that act synergisti-
cally with IFN in upregulating IDO expression. 
3.1.3 Role of IDO in growth inhibition of C. trachomatis in fibroblasts 
To examine whether IDO is involved in growth inhibition of C. trachomatis in fibroblasts, 
IDO expression was downregulated by siRNA knockdown in infected cells. Fig. 9 displays 
the efficiency of the knockdown through analysis of IDO gene expression in transfected 
relative to non-transfected cells. Transfection with IDO siRNA was very efficient with 
91% reduction in gene expression. However, transfection with the transfection reagent 
alone had also a slight effect on IDO expression by 25% reduction, and negative control 
siRNA even decreased expression to 49%. It is known that siRNAs are able to induce 
unspecific off-target effects by stimulation of innate immunity (reviewed in Samuel-
Abraham & Leonard, 2010). This could explain the observed effects of the transfection 
controls on IDO expression. These effects of transfection itself have to be considered when 
evaluating the results for IDO siRNA knockdown. 
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Fig. 9: Efficiency of IDO siRNA knockdown in C. trachomatis infected fibroblasts. 
IDO gene expression in Chlamydia-infected (MOI 0.5), transfected fibroblasts was analysed at 48 h p.i. 
Depicted is the percentage of gene expression relative to the infected, non-transfected control. The mean 
values of three independent experiments are shown with standard deviations as error bars. 
IDO siRNA transfection of fibroblasts led to a significant increase in chlamydial growth as 
can be seen by a nearly 2-fold increase in the inclusion number (increase from 6.6 x 103 
[control] to 10.3 x 104 [IDO siRNA] inclusions) and a 6.2-fold higher production of IFUs 
(increase from 2.7 x 104 [control] to 16 x 104 [IDO siRNA] IFUs) at 48 h p.i. (Fig. 10).  
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Fig. 10: Effect of IDO siRNA knockdown on C. trachomatis growth in fibroblasts. 
The inclusion numbers were calculated 24 h after infection (MOI 0.5) and IFUs were determined at 48 h p.i. 
Values are expressed as x-fold change of transfected cells relative to the non-transfected control cells. Values 
are shown as mean of three independent experiments in triplicate with standard deviations as error bars. *p < 
0.001 for IDO siRNA values compared to negative control siRNA values. 
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This resulted in a burst size almost 4 times higher than in non-transfected control cells. 
Although an influence on IDO gene expression had been observed in fibroblasts trans-
fected with transfection reagent alone or negative control siRNA, no significant change in 
chlamydial growth could be detected under these conditions. The results strongly suggest 
that IDO is involved in inducing the atypical development of C. trachomatis in fibroblasts. 
3.1.4 Expression of selected chlamydial genes in epithelial cells and fibroblasts 
infected with C. trachomatis 
To further characterize the atypical developmental cycle of C. trachomatis in fibroblasts a 
comparative proteome analysis of RBs isolated from infected fibroblasts and HeLa cells at 
24 h p.i. was used to find chlamydial proteins that are differentially expressed in both cell 
types (see Appendix 6.2 for results). On the 2D gel of RBs isolated from infected HeLa 
cells several chlamydial proteins could be identified by mass spectrometry. However, the 
detection of chlamydial proteins on the 2D gel of RBs from fibroblasts was hampered by 
co-purification of a huge amount of human proteins, probably due to the low percentage of 
inclusion-containing cells. Therefore the protein expression differences between the two 
samples could not be directly compared with each other with this method. Thus, to 
characterise the differences in the growth of C. trachomatis in fibroblasts and HeLa cells 
gene expression analysis of selected chlamydial genes at different stages of the develop-
mental cycle was performed as another approach. 
Most of the genes analysed were downregulated during IFN-? mediated persistent infection 
compared to active infection of HeLa cells at 48 h p.i. (Fig. 11).  These genes included 
ompA, which encodes the MOMP of the chlamydial cell envelope, dnaA, encoding a DNA 
replication protein, pgsA_2, encoding a key enzyme of the glycerophospholipid metabo-
lism, and omcB, which encodes the 60 kDa cysteine-rich outer membrane protein that is 
needed for generating the rigid EB cell wall (Hatch et al., 1986). Further, the expression of 
ct858 encoding CPAF was strongly reduced during IFN-? mediated persistence, which is 
consistent with the recently published results of our group (Rödel et al., 2012). Also, 
expression of two of the three genes encoding the chlamydial HSP60 (groEL, groEL_2 and 
groEL_3) was examined. The gene groEL_2 was included in the present work, because 
Gérard et al. (2004) found a significantly higher upregulation of groEL_2 expression 
relative to groEL in persistent infection in monocytes than in active infection of HEP-2 
cells. Both groEL and groEL_2 generally showed a lower expression level during IFN-? 
mediated persistence than during active infection of HeLa cells at later time points. 
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Fig. 11: Expression of C. trachomatis genes in the three different infection models. 
Cells were infected with a MOI of 0.5 for the indicated time points. Significant differences compared to 
actively infected HeLa cells are indicated with asterisks (*p < 0.05, **p < 0.005). The graphs show mean 
values of three independent experiments with standard deviations as error bars. 
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In contrast to the above described genes, a decrease in ftsW expression during IFN-? 
mediated persistence compared to active infection of HeLa cells could not be observed. 
The only gene for which expression was found to be highly upregulated (~ 100-fold at 24 h 
p.i.) in the IFN-? mediated persistence model relative to the active infection was the gene 
trpB, which encodes the tryptophan synthase subunit ?. 
Expression of the chlamydial tryptophan synthase subunits encoding genes usually is 
induced by tryptophan limitation, which is the case after IFN-? activation of IDO leading 
to degradation of most of the tryptophan in the host cell (Shaw et al., 2000 b). 
In contrast to the IFN-? mediated persistent infection of HeLa cells there was no general 
downregulation of chlamydial gene expression in infected fibroblasts compared to actively 
infected HeLa cells. Although expression of most of the genes examined was not much dif-
fering between these two infection models, some important differences were observed for 
ftsW, groEL_2 and pgsA_2. These genes showed a significantly higher expression at 48 h 
p.i. in infected fibroblasts relative to actively infected HeLa cells. Furthermore, expression 
of the CPAF encoding ct858 was higher in infected fibroblasts than during active infection 
of HeLa cells at 12 and 24 h p.i. trpB was the only gene that was characterised by an 
increased expression in both infected fibroblasts and the IFN-? mediated persistence model 
relative to actively infected HeLa cells. However, there only was a 2-fold upregulation of 
trpB expression at 48 h p.i. in fibroblasts, which is very low compared to the ~ 30-fold 
increased expression of this gene at the same time point in the IFN-? mediated persistent 
infection relative to the active infection of HeLa cells. In contrast to the IFN-? mediated 
persistence model, expression of the late gene omcB was upregulated in infected fibro-
blasts at 48 h p.i., similar to actively infected HeLa cells. This indicates that growth of 
chlamydial organisms in fibroblasts occurs in a similar way like active infection in HeLa 
cells until the late stage of the developmental cycle and is not interrupted at earlier stages 
like during IFN-? mediated persistence. 
Altogether, these results reveal that the expression of chlamydial genes is very different 
between infected fibroblasts and IFN-? mediated persistence in HeLa cells, especially for 
groEL_2, pgsA_2 and ct858, that showed an increased expression in infected fibroblasts 
and a decreased expression during IFN-? mediated persistence relative to active infection. 
The gene expression pattern of these two infection models correlates well with the dif-
ferent morphologies of the bacteria observed in the electron microscopic pictures (Fig. 6). 
It strongly suggests that the development of C. trachomatis is quite differently regulated 
between both cell types due to different host cell conditions. 
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3.1.5 Influence of IDO expression on chlamydial gene expression in fibroblasts 
infected with C. trachomatis 
The role of IDO in the atypical development of C. trachomatis in fibroblasts was also 
assessed on the chlamydial gene expression level. For this purpose IDO expression was 
reduced by siRNA knockdown in infected fibroblasts and expression of chlamydial genes 
was examined relative to expression in infected non-transfected cells at 48 h p.i. (Table 3). 
With the exception of dnaA the genes that were not significantly differentially expressed 
between infection in fibroblasts and active infection in HeLa cells also revealed no large 
expression change after IDO siRNA knockdown in fibroblasts (groEL, ompA, ct858, 
omcB, compare Table 3 with Fig. 11). This indicates that expression of these genes is not 
strongly influenced by IDO mediated tryptophan depletion in fibroblasts.  
 
 
Table 3: Influence of IDO siRNA knockdown on expression of chlamydial genes in fibroblasts. 
Gene expression was monitored in infected (MOI 0.5) fibroblasts at 48 h p.i. and displayed as x-fold expres-
sion ratio of transfected cells compared to non-transfected control cells. Values are shown as average of three 
independent experiments with standard deviations in brackets. For comparison, the x-fold expression ratios 
of chlamydial genes in infected fibroblasts compared to actively infected HeLa cells at 48 h p.i. are 
displayed, calculated from the values from the experiment displayed in Fig. 11. Values of genes, for which 
the IDO siRNA knockdown clearly abrogated the observed upregulation in fibroblasts compared to actively 
infected HeLa cells, are shown in bold. 
x-fold expression of C. trachomatis genes normalised to C. trachomatis 16SrRNA 
expression in transfected fibroblasts relative to fibroblasts without transfection 
 transfection 
reagent control 
negative 
control siRNA 
IDO siRNA fibroblasts vs. 
HeLa active 
(see Fig. 11) 
groEL 1.08 (0.36) 1.02 (0.03) 1.51 (0.27) 0.77 
ompA 1.02 (0.29) 1.27 (0.35) 1.47 (0.13) 0.95 
dnaA 1.44 (0.42) 1.17 (0.55) 0.65 (0.19) 1.06 
ct858 1.26 (0.55) 0.94 (0.22) 0.74 (0.03) 1.17 
omcB 0.97 (0.13) 0.93 (0.08) 1.08 (0.35) 1.23 
ftsW 1.41 (0.46) 1.16 (0.61) 0.46 (0.41) 2.12 
trpB 1.87 (0.27) 1.19 (0.96) 0.72 (0.20) 2.20 
pgsA_2 1.76 (0.60) 1.06 (0.63) 0.64 (0.41) 2.63 
groEL_2 1.53 (0.34) 1.11 (0.48) 0.48 (0.37) 2.76 
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However, for dnaA and genes that showed a significantly upregulated expression in fibro-
blasts relative to active infection in HeLa cells at 48 h p.i. (see Fig. 11) reduced expression 
was found after IDO siRNA knockdown (ftsW, trpB, pgsA_2, groEL_2, Table 3). This 
downregulation seemed to abrogate the normally observed differential expression between 
infected fibroblasts and actively infected HeLa cells (Table 3, values in bold). However, 
the transfection reagent alone and the negative control siRNA affected also the expression 
of these genes. Treatment of cells with transfection reagent alone led to their upregulated 
expression to a different extent, which was less when the cells were transfected with nega-
tive control siRNA. Although there was no statistical significance between the values for 
IDO siRNA transfection and the negative control siRNA values, probably due to the low 
amount of samples, the results are quite convincing because of the downregulation of gene 
expression after IDO siRNA transfection in spite of concomitant upregulated gene expres-
sion in the transfection reagent control. Thus, if one considers the IDO siRNA values rela-
tive to the transfection reagent control values the extent of downregulation would be even 
larger than the depicted values for IDO siRNA knockdown relative to untransfected cells. 
Hence, there obviously is a tendency to downregulation of those genes that had been 
upregulated in fibroblasts compared to active infection in HeLa cells when IDO expression 
is inhibited. These results additionally support the hypothesis that IDO is involved in medi-
ating an atypical growth of C. trachomatis in fibroblasts. 
3.1.6 Differences in the expression of the chlamydial protease CPAF between active 
and persistent infection in epithelial cells and in fibroblasts 
Since the present work focused on the C. trachomatis-host cell interaction, the expression 
of the important virulence factor CPAF, which is known to be involved in interference 
with different host cell functions, was analysed on the protein level in the three infection 
models and compared with the expression of chlamydial HSP60 and MOMP. 
As expected, the 29 kDa N-terminal fragment of the active form of CPAF (CPAFn), which 
usually is generated by autocleavage after secretion of the 70 kDa inactive form into the 
host cytosol (Huang et al., 2008), was expressed in readily detectable amounts at the late 
stage of actively infected HeLa cells (Fig. 12 A). The 70 kDa precursor form of CPAF 
could not be detected during active infection of HeLa cells. In contrast, during IFN-? 
mediated persistent infection in HeLa cells neither the 70 kDa nor the 29 kDa form of 
CPAF could be detected at all. This is consistent with the results on gene expression of the 
CPAF encoding gene ct858 that was found to be downregulated in persistently infected 
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Fig. 12: Protein expression of chlamydial CPAF, HSP60 and MOMP in the three infection models. 
A Depicted are immunoblots of whole cell lysates from C. trachomatis infected cells (MOI 0.5) generated at 
different time points of the chlamydial developmental cycle. CPAF (70 kDa): precursor form of CPAF. 
CPAFn (29 kDa): N-terminal fragment of proteolytically active CPAF.  
B MOMP/HSP60 ratio of the immunoblots shown in A as measured by densitometry. 
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relative to actively infected HeLa cells (Fig. 11). Because HSP60 was still expressed in 
relatively high amounts during IFN-? mediated persistent infection, it can be excluded that 
the lack of CPAF detection is due to the reduced amount of chlamydial organisms. Also a 
slight reduction in expression of MOMP relative to HSP60 could be found at 48 h p.i. for 
this model, as it is known from previous studies (Fig. 12 B, Beatty et al., 1993).  
In contrast, C. trachomatis-infected fibroblasts showed no decrease in the MOMP/HSP60 
ratio compared to actively infected HeLa cells, consistent with the gene expression results 
in Fig. 11. Although appearing as faint bands, CPAF protein was clearly expressed in 
infected fibroblasts, but at a much lower level than in actively infected HeLa cells. Both 
the 70 kDa and the 29 kDa forms were clearly visible at 48 h p.i., however the CPAF 
antiserum bound also unspecifically to a host cell protein at the size of 29 kDa (see lane of 
mock-infected fibroblasts in Fig. 12 A) thus interfering with a distinct detection of CPAFn 
in fibroblasts. Nevertheless, the increasing intensity of the band over the time of infection 
in correlation with the expression of the 70 kDa form suggests that CPAFn is expressed in 
infected fibroblasts. 
3.2 Influence of C. trachomatis infection on the MHC class I antigen 
presentation pathway 
3.2.1 Surface expression of MHC class I in C. trachomatis infected cells 
Altered MHCI surface expression can be the result of interference of intracellular 
pathogens with the antigen processing pathway (reviewed in Antoniou & Powis, 2008). 
Therefore, the first step in analysis whether C. trachomatis interferes also with this path-
way was investigation of MHCI surface expression on Chlamydia-infected cells using flow 
cytometry (Fig. 13 and Table 4). 
Because not every cell in a Chlamydia-infected sample contained an inclusion, differen-
tiation between infected (inclusion-positive) and uninfected (inclusion-negative) cells in 
the same sample occurred through immunofluorescent staining of chlamydial inclusions 
and gating into infected and uninfected populations after flow cytometric measurement. 
Only 10 – 20% of the cells in the Chlamydia-infected samples had a fluorescence intensity 
of inclusion staining that was above that of the cells of the mock-infected sample and could 
be considered as the infected cell population. This small rate of inclusion-containing cells 
is shown in Fig. 13 by the presence of the low peak (black) that represents the infected 
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population. The remaining cells of the Chlamydia-infected sample were considered as 
uninfected cell population. 
After 40 h p.i. of active infection of HeLa cells a slight reduction (19%) of surface MHCI 
was found in the inclusion-positive cell population compared to the inclusion-negative cell 
population. Treatment of HeLa cells with IFN-? and IFN-? generally increased MHCI 
surface expression. However, there was also a reduction of surface MHCI (23%) in the 
inclusion-positive population of the actively infected HeLa cells that were treated with 
IFN-?, although the level of surface expression was not reduced to that of the inclusion-
positive population without IFN-? treatment. This indicates that IFN-? efficiently 
increased MHCI expression not only in mock-infected but also in Chlamydia-infected 
HeLa cells. In both infection models the inclusion-negative population of the infected 
sample had a lower amount of surface-expressed MHCI than the mock-infected cell sample 
suggesting a paracrine effect due to soluble mediators. 
In the IFN-? induced persistence model MHCI expression was not significantly different 
between the inclusion-positive and the inclusion-negative cell population of the infected 
sample (Table 4). However, there was also a general reduction of surface MHCI in the 
Chlamydia-infected sample compared to the mock-infected sample, probably due to para-
crine effects. 
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Fig. 13: Influence of C. trachomatis infection on MHCI surface expression. 
Mock-infected (mock) and C. trachomatis-infected (CT) cells were prepared for flow cytometry at 40 h p.i. 
by PE-staining of surface MHCI and FITC-staining of chlamydial inclusions. Gating of the CT-infected 
sample was done to discriminate between infected and uninfected cell populations. Depicted are representa-
tive histograms. See Table 4 for median fluorescence intensity values of MHCI surface expression. 
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Table 4: Influence of C. trachomatis infection on MHCI surface expression. 
Results of flow cytometry analysis are shown as average values of the median of MHCI fluorescence inten-
sity of three experiments with standard deviations in brackets. a p < 0.05 vs. mock total, b p < 0.05 vs. CT 
total, c p < 0.05 vs. CT uninfected population. CT: C. trachomatis-infected cells. 
Average median fluorescence values 
HeLa active HeLa active  
+ IFN-? 
HeLa + IFN-? 
persistence 
fibroblasts Sample, cell 
population 
values % of 
mock 
values % of 
mock 
values % of 
mock 
values % of 
mock 
Mock,  
total 
627.5 
(26.1) 
100% 1384.1 
(48.9) 
100% 1330.7 
(135.1) 
100% 433.8 
(28.0) 
100% 
CT,  
total 
547.3 
(50.6) 
87% 1039.7 
(55.7)a 
75% 1019.6 
(172.1) 
76% 611.8 
(98.4) 
140% 
CT, 
uninfected 
population 
567.4 
(52.4) 
90% 1106.5 
(79.8)a 
80% 1035.3 
(184.6) 
77% 584.0 
(97.2) 
134% 
CT, 
infected 
population 
444.0 
(55.0)a 
71% 793.7 
(74.8)a,b,c 
57% 938.3 
(156.4) 
70% 824.4 
(84.3)a 
189% 
 
In contrast, the infection of fibroblasts resulted in an almost 2-fold upregulation of MHCI 
surface expression (Table 4). An increase in surface MHCI was also found in the 
inclusion-negative cell population of the Chlamydia-infected sample, but to a lower extent. 
Altogether these results point to a partial interference of chlamydial organisms with the 
MHCI pathway during active infection. However, the pathway seems to be functional 
during IFN-? mediated persistence and during infection of fibroblasts. 
3.2.2 Influence of C. trachomatis infection on expression of key proteins involved in 
MHCI antigen processing and presentation 
Some of the strategies that are used by pathogens to interfere with the MHCI antigen 
presentation pathway are inhibition of the expression or induction of the degradation of 
proteins involved in antigen processing (reviewed in Antoniou & Powis, 2008). It has been 
suggested that during C. trachomatis infection of epithelial cells CPAF may mediate 
downregulation of MHCI expression through degradation of the transcription factor RFX5 
(Zhong et al., 2000; Zhong et al., 2001). To see whether C. trachomatis also interferes 
with MHCI gene expression during IFN-? mediated persistence and infection of fibroblasts 
and whether other essential components of the MHCI antigen presentation pathway are 
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affected a quantitative gene expression analysis was done. Expression was examined for 
the MHCI encoding genes HLA-ABC (ABC referring to the three MHC class I major genes 
A, B and C), the TAP transporter encoding genes TAP1 and TAP2 and the genes LMP2, 
LMP7 and MECL1 which encode the three IFN-inducible immunoproteasome subunits. 
Table 5 shows the gene expression ratios of C. trachomatis-infected cells relative to mock-
infected cells for the different infection models. Surprisingly, in contrast to the study of 
Zhong et al. (2000) no significant downregulation of HLA-ABC expression could be found 
in any infection model indicating that there is no specific chlamydial interference with the 
expression of these genes. The only exception was LMP2, which was slightly but statisti-
cally significantly downregulated during active infection of HeLa cells. However, in all 
infection models the expression of TAP1 and TAP2 was upregulated after chlamydial 
infection, although to a lower extent during active infection. 
 
 
Table 5: Gene expression of components of the MHCI antigen presentation pathway in C. trachomatis 
infected cells. 
Values are given as x-fold expression change for Chlamydia-infected relative to mock-infected cells at 48 h 
p.i. Fibroblasts were additionally treated with an antibody neutralising type I IFN activity (anti-IFNAR). * p < 
0.05, ** p < 0.005 (relative to mock control, for fibroblasts + anti-IFNAR: relative to infected fibroblasts). 
Depicted are the mean values of three independent experiments with standard deviations in brackets. 
Significantly different values are marked in bold. 
x-fold gene expression normalised to GAPDH expression 
in infected cells relative to mock-infected cells 
 HeLa 
active 
HeLa 
active    
+ IFN-? 
HeLa 
active    
+ IFN-? 
HeLa  
IFN-? 
persistence 
fibroblasts fibroblasts 
+ anti-
IFNAR 
HLA-
ABC 
0.96 
(0.05) 
1.20 
(0.17) 
0.91 
(0.09) 
1.68* 
(0.55) 
5.02** 
(0.87) 
2.80** 
(0.64) 
TAP1 1.36 
(0.06) 
1.94* 
(0.27) 
1.39 
(0.46) 
2.82* 
(0.23) 
8.33* 
(1.75) 
5.29* 
(0.70) 
TAP2 1.42* 
(0.19) 
1.75** 
(0.24) 
1.33 
(0.25) 
2.48* 
(0.75) 
6.42* 
(2.27) 
4.69   
(2.34) 
LMP2 0.77* 
(0.06) 
1.25 
(0.10) 
0.85 
(0.41) 
1.77* 
(0.42) 
5.17* 
(0.20) 
3.46  
(0.73) 
LMP7 0.98 
(0.04) 
1.26 
(0.28) 
0.97 
(0.31) 
2.04* 
(0.55) 
2.87** 
(0.50) 
2.14  
(0.40) 
MECL1 1.26 
(0.13) 
1.48 
(0.53) 
1.18 
(0.38) 
1.82   
(0.19) 
1.74* 
(0.46) 
1.26  
(0.32) 
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In the IFN-? mediated persistence model the expression of almost all genes analysed was 
significantly upregulated, suggesting that IFN-? interacts synergistically with innate immu-
nity pathways that are induced by the infection thus increasing the expression of proteins 
involved in the MHCI pathway. 
The infection of fibroblasts resulted in a highly upregulated expression of the examined 
genes, especially for HLA-ABC, TAP1, TAP2 and LMP2. It was assumed that IFN-? secret-
ed after infection of fibroblasts with C. trachomatis is responsible for this upregulation. To 
test this hypothesis the type I IFN activity was neutralised by incubation of infected fibro-
blasts with an antibody binding to the type I IFN receptor (anti-IFNAR). The inhibition of 
type I IFN activity reduced the expression of the examined genes in infected fibroblasts 
(Table 5). However, the degree of reduction differed among the examined genes. 
Additionally, the impact of C. trachomatis infection on the expression of the corresponding 
protein products was examined (Fig. 14). As expected, expression of HLA-ABC, TAP1, 
TAP2 and the immunoproteasome subunits was increased after IFN treatment of HeLa 
cells. Interestingly, TAP2 was not detectable in actively infected HeLa cells both treated 
with and without IFN. This is in contrast to the TAP2 gene expression values that revealed 
an increased expression of this gene after active chlamydial infection of HeLa cells. These 
results suggest that the TAP2 protein could be degraded through C. trachomatis. Because 
TAP2 expression was readily detected during IFN-? mediated persistent infection of HeLa 
cells and after infection of fibroblasts, TAP2 degradation seems to occur only during active 
but not persistent infection of HeLa cells. Furthermore, there was a slight decrease in 
HLA-ABC expression during active infection of HeLa cells and a somewhat decreased 
amount of TAP1 protein after active infection of HeLa cells with IFN-? treatment. 
Consistent with the strong increase (> 5-fold) of HLA-ABC, TAP1, TAP2 and LMP2 
expression in infected fibroblasts (see Table 5), a higher amount of the corresponding 
proteins could also be detected in the immunoblot (Fig. 14). A similar effect of protein 
upregulation was seen after IFN-? treatment of uninfected fibroblasts. In those cases where 
gene expression ratios were only up to 3-fold increased (for instance during IFN-? medi-
ated persistent infection of HeLa cells, see Table 5) no distinct upregulation of the corre-
sponding proteins could be detected on the immunoblots, probably due to the less 
sensitivity of this method compared to real-time PCR analysis. 
Because downregulation of surface MHCI during active infection of HeLa cells has been 
suspected to be the result of RFX5 degradation by CPAF (Zhong et al., 2000, Zhong et al., 
2001), the expression of this transcription factor was also analysed under the different 
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infection conditions in the present study. As expected, RFX5 was readily expressed in 
uninfected HeLa cells, but the protein could not be detected during active infection of 
HeLa cells (Fig. 14). However, during IFN-? mediated persistent infection RFX5 expres-
sion still could be found, consistent with a previous study that showed inhibition of RFX5 
degradation during IFN-? mediated persistence of C. pneumoniae (Heuer et al., 2003). In 
contrast to this, no RFX5 protein at all could be detected in fibroblasts. This suggests that 
RFX5 is expressed just at low amounts in these cells thus impairing its detection. Because 
MHCI expression is upregulated in C. trachomatis-infected fibroblasts RFX5 seems not to 
be essential in infection mediated upregulation of MHCI expression in these cells. 
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Fig. 14: Expression of proteins involved in the MHC I antigen presentation pathway in C. trachomatis 
infected cells. 
The proteins were detected by immunoblotting after SDS-PAGE separation of whole cell lysates generated at 
48 h p.i. 
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3.2.3 TAP2 degradation during active infection with C. trachomatis 
To analyse if the diminished TAP2 expression in actively infected HeLa cells (see Fig. 14) 
was the result of intracellular replication of chlamydial organisms, infected cells were 
treated with chloramphenicol (Fig. 15). This led to complete inhibition of TAP2 down-
regulation. In contrast, treatment of infected cells with cycloheximide did not prevent the 
reduction in TAP2 expression. This suggests that proliferating chlamydial organisms but 
not newly synthesized host proteins are responsible for the observed effect. 
To see if the reduced TAP2 expression was the result of degradation through a chlamydial 
protease secreted in the host cytosol, a cell free cleavage assay was performed (Fig. 16). 
Cell lysate from mock-infected HeLa cells treated with IFN-? was used as substrate, be-
cause compared to non-treated cells it contained a higher amount TAP2 that was readily 
detectable on the immunoblot (see Fig. 14). After performance of the cell-free cleavage 
assay TAP2 could be only detected in the lysate of mock-infected cells incubated without 
CE and the mixture of lysate of mock-infected cells with the CE of mock-infected cells. 
However, it was neither detectable in the lysate generated from Chlamydia-infected cells 
nor in the CEs, as would be expected due to its membrane localisation to the ER. After 
incubation of the lysate from mock-infected cells with the CE from Chlamydia-infected 
cells the amount of TAP2 protein was highly reduced. This result indicates that a protease 
active in the host cytosol could be responsible for the degradation of TAP2. 
For analysis of the role of CPAF in this event, immunoprecipitation was used to remove 
the chlamydial protease from the CE of infected cells, and degradation was analysed in the 
cell-free cleavage assay. If CPAF was responsible for the observed TAP2 degradation, the 
incubation of this CE with the lysate from mock-infected cells would be expected to result 
in abrogation of TAP2 degradation.  
 
TAP2
GAPDH
C. trachomatis - -+ + +-
+ Cx + Chl
 
Fig. 15: Effect of inhibition of eukaryotic and prokaryotic translation on TAP2 expression in HeLa 
cells actively infected with C. trachomatis. 
Immunoblots of lysates from mock- and Chlamydia-infected HeLa cells either treated with no inhibitor, 2 
μg/ml cycloheximide (Cx) or 100 μg/ml chloramphenicol (Chl) for 48 h. 
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Fig. 16: Cell-free cleavage assay of TAP2. 
Immunoblot of cell-free cleavage assay samples containing either cytosolic extract (CE) and/or lysate genera-
ted from actively infected (CT) or uninfected (mock) HeLa cells at 48 h p.i. 
However, detection of the 75 kDa TAP2 in this sample was impaired by the presence of a 
huge amount of unknown protein that accumulated at the same size like TAP2 and 
prevented specific binding of the TAP2 antibody (data not shown). This large band was 
only seen after immunoprecipitation with the CPAF antiserum but not with IgG indicating 
that it origins from the CPAF antiserum. Because it was assumed that this protein could be 
serum albumin, attempts to remove this contaminating protein from the sample were made 
with DEAE sepharose. Yet, this resulted also in removal of TAP2 thus impairing detection 
(data not shown). 
However, treatment of the CE of Chlamydia-infected cells with lactacystin, that is known 
to inhibit CPAF activity (Zhong et al., 2001), could prevent TAP2 degradation in a cell-
free cleavage assay in a concentration dependent manner (Fig. 17). Because lactacystin 
was dissolved in DMSO before usage, treatment with DMSO alone was used as control to 
exclude that the effect was due to the solvent.  
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Fig. 17: Impact of inhibition of CPAF activity with lactacystin on the degradation of TAP2. 
Immunoblot of a cell free-cleavage assay that was performed by incubating the lysate of mock-infected HeLa 
cells with the CE of actively infected (CT) HeLa cells as source of cleavage activity. Cell lysate alone was 
used as control. Lactacystin inhibitor was added to the mixtures at the indicated concentrations. Because 
lactacystin was solved in DMSO, the solvent was added alone and served as control. *The respective 
lactacystin concentrations are indicated, and the same volume of DMSO was added instead of lactacystin. 
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Although DMSO partially inhibited degradation of TAP2 at an amount that was equal to 
the volume used for 200 μM lactacystin, the effect of DMSO in inhibiting cleavage was 
much less than that of lactacystin. 
These results suggest that C. trachomatis specifically degrades TAP2, probably through 
the activity of CPAF, which could serve as a mechanism to interfere with the MHCI anti-
gen presentation pathway. 
3.3 Role of Golgi fragmentation in the downregulated MHCI surface 
expression in actively C. trachomatis infected epithelial cells 
3.3.1 Fragmentation of the Golgi apparatus in C. trachomatis infected cells 
It has been shown that the infection with C. trachomatis leads to fragmentation of the 
Golgi apparatus (Heuer et al., 2009). It was hypothesized that this fragmentation may 
result in incorrect MHC class I processing thus contributing to the decreased surface 
MHCI expression observed in actively infected HeLa cells (Table 4). 
Golgi fragmentation was examined by immunofluorescent staining of the cis-Golgi protein 
GM130 and the trans-Golgi protein Golgin-245 in C. trachomatis infected cells (Fig. 18). 
Fragmentation of the Golgi apparatus did rarely occur in actively infected HeLa cells after 
24 h p.i. (Fig. 18 A). However, it was readily detected after 48 h in most of the inclusion-
containing HeLa cells for both the cis-Golgi and the trans-Golgi compartments. Golgi 
fragments seemed to localise near to or around the chlamydial inclusion, as has been 
already demonstrated by Heuer et al., 2009. 
During IFN-? mediated chlamydial persistence in HeLa cells a complete fragmentation of 
the cis-Golgi compartment at 48 h p.i. was detected only in few of the inclusion-positive 
cells (Fig. 18 B), most of them showed only a partial fragmentation by GM130 staining. In 
contrast, a complete fragmentation of the trans-Golgi in connection with an arrangement of 
Golgin-245 containing Golgi fragments around the chlamydial inclusion was found at 48 h 
p.i. in most inclusion-containing cells of this model. 
In fibroblasts a low percentage of the inclusion-positive cells exhibited complete fragmen-
tation of both the cis- and trans-Golgi compartment, whereas partial fragmentation was 
also observed in the majority of these cells (Fig. 18 C). 
These results suggest that fragmentation of the Golgi compartments occurs in all three 
models, although to a much lesser extent in fibroblasts and for the cis-Golgi in IFN-? 
mediated chlamydial persistence. 
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Fig. 18: Immunofluorescent staining of Golgi proteins in C. trachomatis infected cells. 
The Golgi apparatus (red) of mock-infected (48 h p.i.) and Chlamydia-infected (CT) cells (MOMP, green) 
was stained during active infection of HeLa cells (A), IFN-? induced persistent infection of HeLa cells (B) 
and infection of fibroblasts (C) with an antibody binding the cis-Golgi protein GM130 (upper panels) and  
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B HeLa, IFN-? persistent infection 
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with an antibody specific for the trans-Golgi protein Golgin-245 (lower panels), respectively. A magnified 
section showing the Golgi of infected cells at 48 h p.i. is shown on the right. Fragmented Golgi is marked 
with an arrow and partial fragmented Golgi is marked with an arrowhead. The percentage of inclusion-
negative (CT -) and inclusion-positive (CT +) cells (n = 20) showing either complete, partial or no 
fragmentation of the Golgi apparatus is depicted for each model and Golgi protein at 48 h p.i. in the graphs. 
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3.3.2 Degradation of GM130 and Golgin-245 during active C. trachomatis infection 
It was demonstrated recently that Golgin-84 cleavage by CPAF is responsible for Golgi 
fragmentation (Christian et al., 2011). Thus, it would be interesting to know whether 
GM130 and Golgin-245 are also degraded during chlamydial infection which could have 
severe effects on the Golgi processing of MHCI. Indeed, detection of these proteins by 
immunoblotting revealed a drastically reduced amount of both proteins after active 
infection of HeLa cells (Fig. 19). However, the expression of GM130 was also reduced in 
persistently infected HeLa cells and in infected fibroblasts compared to uninfected cells, 
although to a lower extent. In contrast, Golgin-245 expression was not affected by 
chlamydial infection in the IFN-? mediated persistence model. Interestingly, a 2-fold 
increase in Golgin-245 protein was observed in infected fibroblasts. 
To examine if chlamydial organisms were responsible for the reduced expression of 
GM130 and Golgin-245 observed in Fig. 19 during active infection chloramphenicol was 
added to infected HeLa cells in order to inhibit the growth of chlamydial organisms (Fig. 
20). This prevented the observed downregulation indicating that proliferating chlamydial 
organisms are needed. 
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Fig. 19: Expression of GM130 and Golgin-245 after infection with C. trachomatis. 
Immunoblots were made with cell lysates generated from Chlamydia- and mock-infected cells at 48 h p.i. 
Densitometry ratios are depicted for infected cells vs. uninfected cells normalised to GAPDH. 
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Fig. 20: Effect of inhibition of eukaryotic and prokaryotic translation on GM130 and Golgin-245 
expression in C. trachomatis infected cells. 
See Fig. 15 for description. Cx: cycloheximide, Chl: chloramphenicol. 
In contrast, treatment of infected cells with cycloheximide, an inhibitor of eukaryotic 
protein translation, did not prevent the downregulation of GM130 and Golgin-245. Thus, 
the results point to a Chlamydia-mediated degradation of both proteins that could be 
mediated by a protease secreted into the host cytosol. 
3.3.3 Role of CPAF in degradation of GM130 and Golgin-245 
Because it has been found recently that Golgin-84 is a target protein for CPAF cleavage 
(Christian et al., 2011), it was assumed that CPAF could also be responsible for the degra-
dation of GM130 and Golgin-245. A cell-free cleavage assay was applied in which whole 
cell lysates of mock-infected HeLa cells were used as a substrate containing both Golgi 
proteins. This substrate was incubated with CEs from mock- or actively Chlamydia-
infected HeLa cells which were used as source of the enzymatic activity. Both Golgi 
proteins were readily detected in the cell lysates of mock-infected cells (Fig. 21 A, lane 1). 
The proteins were not observed in the CEs (Fig. 21 A, lane 2 and 4) and in the lysates of 
Chlamydia-infected cells (Fig. 21 A, lane 3). The incubation of mock-cell lysate with the 
CE from infected cells resulted in degradation of GM130 and Golgin-245 (Fig. 21 A, lane 
6). In contrast, no disappearance of protein was seen when CE from mock-infected cells 
was used instead (Fig. 21 A, lane 5). This indicates that the protease responsible for 
degradation of the two Golgi proteins resides in the host cytoplasm. 
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Fig. 21: Role of CPAF in degradation of GM130 and Golgin-245 during active chlamydial infection. 
A Immunoblot showing the cell-free cleavage assay of samples containing cytosolic extract (CE) and/or 
lysate generated from actively infected (CT) or uninfected (mock) HeLa cells at 48 h p.i. sn IP CPAF: CPAF 
was removed from the CE prior to the assay by immunoprecipitation with CPAF antiserum. sn IP IgG: 
Immunoprecipitation control with unspecifically binding mouse IgG.  
B Immunoprecipitation of CPAF was verified by immunoblotting. The 29 kDa N-terminal fragment 
(CPAFn) and the 34 kDa C-terminal fragment (CPAFc) of CPAF were found in the immunoprecipitation 
pellet of the sample incubated with CPAF-antiserum but not in the pellet of the IgG control sample. The IgG 
heavy chains (50 kDa) and light chains (25 kDa) of the CPAF antiserum and control IgG antibody were 
readily detectable. sn: supernatant, IP: immunoprecipitation. 
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In order to examine the role of CPAF in this event the protease was removed from the CE 
of infected cells by immunoprecipitation with CPAF antiserum. The 29 kDa N-terminal 
fragment (CPAFn) and the 34 kDa C-terminal fragment (CPAFc) could be readily detected 
in the pellet of the CPAF immunoprecipitation sample (Fig. 21 B, lane 2), but not in the 
pellet of the sample with unspecific mouse IgG for immunoprecipitation (Fig. 21 B, lane 
4). CPAF was not found in the supernatant of the CPAF immunoprecipitation sample (Fig. 
21 B, lane 1). Unexpectedly, it was also not detectable in the supernatant of the control IgG 
immunoprecipitation sample (Fig. 21 B, lane 3). Because diluted CE was used in order to 
achieve a maximal removal of CPAF from the CE by immunoprecipitation, it therefore is 
likely that the concentration of CPAF protein in the CE was too low to be detected by 
immunoblotting. However, CPAF concentration was high enough to promote degradation 
of target proteins (Fig. 21 A, lane 6). The removal of CPAF from the CE of infected cells 
resulted in reduced degradation of GM130 and Golgin-245 when the immunoprecipitation 
supernatant was incubated with the mock-cell lysate (Fig. 21 A, lane 7). However, there 
was no total inhibition which could be explained by incomplete removal of CPAF from the 
CE during immunoprecipitation leading to remaining residual CPAF activity in the CE. 
This is also supported by the appearance of a second band of lower size when Golgin-245 
was detected indicating that the protein is partially cleaved at a side near to the C- or N- 
terminus. As a control, degradation was not reduced by immunoprecipitation with mouse 
IgG (Fig. 21 A, lane 8).  
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Fig. 22: Impact of inhibition of CPAF activity with lactacystin on cleavage of GM130 and Golgin-245.  
See Fig. 17 for description. 
 59 
Furthermore, the degradation of GM130 and Golgin-245 was inhibited when the CE from 
infected cells was treated with the CPAF inhibitor lactacystin (Fig. 22). The inhibitory 
effect increased with higher doses of the compound. DMSO alone only had a marginal 
inhibitory effect on the degradation. 
Altogether, both experiments strongly indicate that CPAF degrades GM130 and Golgin-
245 in the host cytosol of Chlamydia-infected cells. 
3.3.4 MHCI co-localisation with GM130 in C. trachomatis infected cells 
The fragmentation of the Golgi and degradation of Golgi proteins by chlamydiae is 
expected to have severe impacts on the function of the Golgi apparatus as a sorting and 
posttranslational modification compartment. To analyse the consequences of this pathogen-
host interaction for the MHCI processing immunofluorescent staining of GM130 and 
MHCI was used to see if MHCI molecules still localise to the Golgi compartment after 
infection with C. trachomatis. Furthermore, analysis of this co-localisation was important 
to see whether MHCI transport from ER to the Golgi was affected due to the degradation 
of TAP2 which may result in a defect of peptide-loading associated with a retention of 
MHCI molecules to the ER. 
In uninfected HeLa cells most of the intracellular MHCI localised to the Golgi (Fig. 23). 
The fragmentation of the Golgi to mini-stacks in actively infected HeLa cells and the low 
intensity of MHCI staining due to the low expression of MHCI in these cells made it 
difficult to detect co-localisation of MHCI with the Golgi. Nevertheless, a stronger staining 
intensity of MHCI seemed to occur in regions of the inclusion-containing cells where 
GM130 was stained indicating that MHCI can reach the Golgi compartment despite its 
fragmentation. The detection of co-localisation of MHCI with GM130 during IFN-? medi-
ated persistence was hampered because of the highly increased MHCI staining intensity 
due to enhanced MHCI expression elicited by IFN-? treatment. Here, MHCI was evenly 
distributed in the whole cell including the Golgi apparatus. In fibroblasts the localisation of 
MHCI to the Golgi was very well detectable. Although infected fibroblasts showed a 
higher overall MHCI staining intensity than uninfected fibroblasts most of the MHCI could 
be clearly detected in the Golgi compartment. 
To get a more precise picture, the co-localisation was quantified by defining regions of 
interests (ROIs) that were drawn around the Golgi compartment and calculating co-
localisation coefficients. The co-localisation coefficient M2 describes the percentage of the 
red pixel (GM130) co-localising with green pixel (MHCI). 
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Fig. 23: Co-localisation of MHCI with the Golgi apparatus during chlamydial infection. 
Immunofluorescent staining of the Golgi was done with an antibody binding to GM130 (red). Chlamydial 
organisms were stained by DAPI (blue) and inclusions are marked with a white asterisk. The same intensity 
adjustment was used for all samples in order to allow direct comparison of MHCI staining intensity between 
the three infection models. The third row of each panel shows a detailed picture of the Golgi region of an 
infected cell (marked with a square). White arrows indicate areas of co-localisation. The graph shows the 
average co-localisation coefficient M2 for ROIs from each 15 uninfected (mock) and 15 cells containing 
inclusions (CT). M2 represents the number of red pixel (Golgi) co-localising with green pixel (MHCI). 
The values were nearly the same between infected and uninfected cells in each model 
(graphs in Fig. 23). Actively infected HeLa cells only had ~70% of GM130-associated 
pixel co-localised with MHCI-associated pixel, whereas the other two models showed 
almost 100% co-localisation of these two proteins. This discrepancy can be explained by 
the different intensities of the MHCI staining, which was less in the actively infected HeLa 
cell model than in the other two models resulting in less pixel that could co-localise with 
the GM130-associated pixels. The results suggest that transport and localisation of MHCI 
to the Golgi is not influenced by chlamydial infection. 
 62 
3.3.5 Change in sensitivity of MHCI molecules to Endoglycosidase H cleavage after 
active infection with C. trachomatis 
Treatment of cell lysates with Endo H was used as another method to examine if MHCI 
molecules reached the Golgi compartment of infected cells and were processed to mature 
MHCI. Endo H cleaves asparagine-linked high-mannose type oligosaccharide chains from 
glycoproteins. This type of carbohydrate residue usually becomes attached to MHCI and 
other glycoproteins in the ER rendering the proteins sensitive to Endo H cleavage. After 
reaching the medial-Golgi these glycan residues get modified by ?-mannosidase II leading 
to resistance of the protein to Endo H cleavage. Endo H sensitive, immature MHCI mole-
cules are distinguished from Endo H resistant, mature MHCI by their lower molecular 
weight due do removal of the glycan residues (Freeze & Kranz, 2010). 
In uninfected HeLa cells both Endo H resistant and sensitive MHCI molecules were 
observed indicating a functional maturation of MHCI (Fig. 24). In contrast, only Endo H 
resistant but no Endo H sensitive MHCI molecules could be detected after active infection 
of HeLa cells. This suggests that active chlamydial infection leads to a reduction of MHCI 
molecules in the ER. Additionally, active infection of HeLa cells led to a strong decrease 
in the total MHCI protein amount. This reduction is more prominent than on the immuno-
blot in Fig. 14, and the differences could be explained by the usage of different lysis 
buffers for both experiments. For Endo H treatment only Triton-X 100 was used for lysis 
whereas RIPA buffer, containing additionally deoxycholic acid and SDS for better solu-
bilisation and denaturation of proteins, was used generally for sample preparation for 
immunoblotting (see chapter 2.2.11 and 2.2.15). Together with the observed lack of Endo 
H sensitive MHCI forms this result suggests that there is an interference with the MHCI 
processing pathway. The same Endo H cleavage pattern as seen during active infection was 
also detectable during active infection with additional IFN-? and IFN-? treatment, respec-
tively. However, a faint Endo H sensitive band appeared under IFN-? treatment of actively 
infected cells indicating some inhibitory effect of IFN-? on the chlamydial interference 
with MHCI processing. In persistently infected HeLa cells and in infected fibroblasts both 
Endo H sensitive and Endo H resistant MHCI molecules were present, with a similar 
amount of Endo H sensitive forms in both mock-infected and Chlamydia- infected cells in 
both models. This suggests that under these conditions the MHCI antigen processing 
pathway is functional and not manipulated by chlamydial organisms, which correlates well 
with the MHCI surface expression data (Table 4). 
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Fig. 24: Differences in sensitivity of MHCI molecules to cleavage with Endo H between the different 
infection models. 
Lysates from Chlamydia-infected and mock-infected cells were generated at 48 h p.i. and treated with or 
without Endo H. Endo H resistant (r) and sensitive (s) forms of MHCI were detected after immunoblotting 
with an antibody binding HLA-ABC. CT: C. trachomatis. 
3.4 C. trachomatis mediated degradation of the host cell mRNA export 
factor NXF1 
3.4.1 Influence of active C. trachomatis infection on NXF1 expression in HeLa cells 
During analysis of expression of proteins involved in antigen presentation an accidental 
discovery revealed that the host cell mRNA export factor NXF1 (nuclear RNA export 
factor 1) gets degraded in actively Chlamydia-infected HeLa cells. This discovery was the 
result of usage of a commercially available TAP1 antibody which was applied in order to 
analyse TAP1 expression in Chlamydia-infected cells. In fact, it turned out that this anti-
body represents an antibody clone specific for NXF1. 
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Fig. 25: NXF1 is degraded upon active C. trachomatis infection in HeLa cells. 
Immunoblots of HeLa cell lysates. 
A Mock- and Chlamydia-infected cells were either not treated or treated with cycloheximide (Cx, 2 μg/ml) 
and chloramphenicol (Chl, 100 μg/ml), respectively, and analysed at 48 h p.i. 
B Chlamydia-infected cells were incubated for different time points. 
C Different infectious doses (MOI) of C. trachomatis were used for infection, and cells were harvested at 48 
h p.i. 
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It was found that the expression of NXF1 was drastically reduced after active chlamydial 
infection of HeLa cells (Fig. 25 A). The 70 kDa band, which represents NXF1, disappeared 
after 48 h of infection and a prominent band of 47 kDa appeared instead suggesting that 
NXF1 got cleaved. Treatment with the eukaryotic protein translation inhibitor cyclohexi-
mide did not affect the degradation of NXF1 in infected cells. This excludes the possibility 
that host cell proteins newly synthesized after chlamydial infection account for the degra-
dation of NXF1. When Chlamydia-infected cells were treated with chloramphenicol the 
degradation of NXF1 was totally inhibited. These results suggest that a chlamydial pro-
tease is responsible for the cleavage of NXF1. 
The degradation of NXF1 started during the mid-cycle of chlamydial development as it can 
be seen by the appearance of a 61 kDa cleavage product at 16 hours p.i. (Fig. 25 B). The 
70 kDa band representing the NXF1 full-length protein disappeared over the time and 
could not be detected anymore at 26 hours p.i. The 61 kDa fragment was further cleaved to 
a 47 kDa fragment because only the 47 kDa band could be detected at 48 hours p.i. 
The degree of NXF1 degradation correlated with the infectious dose of C. trachomatis as it 
is shown in Figure Fig. 25 C. At 48 h p.i. the 61 kDa band could only be detected at lower 
doses. However, with higher infectious doses the amount of the 47 kDa cleavage product 
increased. The result suggests that the stronger proteolytical activity at higher infectious 
doses is due to an increased amount of inclusion-containing cells in which NXF1 got 
degraded. 
3.4.2 The role of CPAF in degradation of NXF1 
It was assumed that the degradation of NXF1 could be a result of the cleavage activity of a 
chlamydial protease secreted into the host cytosol during infection. To test this hypothesis 
a cell-free cleavage assay was applied in a similar approach as described in chapter 3.2.3 
and Fig. 16. However, instead of whole cell lysate only nuclear extract (NE) from mock-
infected HeLa cells was used as a substrate, because NXF1 is mainly located in the nucleus 
(Kang & Cullen, 1999). The NXF1 protein could not be detected at all in the CEs, and the 
NE of infected cells contained only the cleavage products of NXF1 (Fig. 26). When the NE 
of mock-infected cells was incubated with the CE of Chlamydia-infected cells the typical 
47 kDa cleavage band of NXF1 could be seen. As expected, incubation of the NE of mock- 
infected cells with the CE of mock-infected cells left the substrate uncleaved. 
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Fig. 26: Cleavage of NXF1 and other nuclear proteins in a cell-free cleavage assay. 
Immunoblots of cell-free cleavage assay samples containing either cytosolic extract (CE) and/or nuclear 
extract (NE) of uninfected (mock) or actively infected (CT) HeLa cells at 48 h p.i. Proteins detected were the 
nuclear proteins NXF1, RFX5, PARP-1 and the chlamydial proteins CPAF and MOMP. CPAFn: N-terminal 
fragment of CPAF. 
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There are other nuclear proteins, for example RFX5 and PARP-1, which are known to be 
degraded by C. trachomatis through the activity of CPAF (Paschen et al., 2008; Yu et al., 
2010; Zhong et al. 2001). As control, the cleavage of both proteins was analysed and could 
be detected in immunoblots of the cell-free cleavage assay in the NE of Chlamydia-
infected cells and after incubation of the NE from mock-infected cells with the CE from 
Chlamydia-infected cells (Fig. 26). 
During the preparation of the extracts of infected cells most of the chlamydial organisms 
are expected to be contained in the NE due to co-purification of whole chlamydial inclu-
sions with the nuclei after centrifugation of the CE that was prepared by limited douncing 
to keep the inclusions intact (Chen et al., 2009). This was analysed by detecting MOMP 
which revealed that most of the protein was present in the NE of infected cells (Fig. 26). A 
smaller fraction of MOMP was detected in the CE of infected cells suggesting a contami-
nation with chlamydial organisms due to too strong homogenisation which may lead to 
rupture of the inclusions and/or that MOMP is also located outside the inclusion as has 
been described previously (Giles et al., 2006; Giles & Wyrick, 2008). Beside its presence 
in the NE of infected cells the proteolytically active N-terminal fragment of the chlamydial 
protease CPAF (CPAFn) was also found in the CE of Chlamydia-infected cells correlating 
with the secretion of this protease into the host cytosol. Because the amount of CPAF rela-
tive to MOMP was much smaller in the NE than in the CE of infected cells, the presence of 
CPAF in the CE likely is the result of secretion of the protease into the host cytosol.  
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Fig. 27: Effect of inhibition of CPAF with lactacystin on NXF1 cleavage. 
See Fig. 17 for description. NE of mock-infected cells containing NXF1 was used as substrate. 
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CPAFn and GAPDH, which served as loading control, are expected to be present only in 
the CE but not in the NE due to their cytosolic localisation. However, both proteins could 
also be detected in the NE of both mock-infected and Chlamydia-infected cells. This likely 
is the result of a contamination of the NE with CE from the same lysate during the prepara-
tion of the NE. Furthermore, the homogenisation may have been not rigorous enough to 
lyse all cells in the preparation leading the presence of some whole cells in the NE. Never-
theless, this contamination of NE with CE has no influence on the results, since the NE 
only served as substrate for cleavage. Rather, it is important that the CE is not contami-
nated with NE to show the presence of CPAF and proteolytic activity in the cytosol. 
To examine if NXF1 is cleaved by CPAF, again CPAF was removed from the CE of 
infected cells by immunoprecipitation. However, it was not possible to detect NXF1 in the 
sample of NE mixed with the supernatant of CPAF immunoprecipitation due to inter-
ference of a contaminating 70 kDa serum protein band with antibody detection, the same 
phenomenon as described in chapter 3.2.3 (data not shown). When the CPAF inhibitor 
lactacystin was added to the CE of infected cells at a concentration of 200 μM, the cleav-
age of NXF1 in a cell-free cleavage assay was strongly reduced (Fig. 27). This suggests 
that CPAF is the protease that is responsible for the degradation of NXF1 in Chlamydia-
infected cells. 
3.4.3 Analysis of NXF1 degradation during IFN-? mediated chlamydial persistence 
and chlamydial infection of fibroblasts 
Because CPAF expression is downregulated during IFN-? mediated chlamydial persistence 
in HeLa cells (Fig. 11 and Fig. 12), it would be expected that under these conditions NXF1 
degradation would be reduced. As displayed in Fig. 28 cleavage of NXF1 was strongly 
reduced during IFN-? mediated persistent infection of HeLa cells whereas the protein got 
completely degraded during active infection. Further, it was examined whether NXF1 
degradation occurred in Chlamydia-infected fibroblasts. Although intact NXF1 could be 
still detected during infection, the amount was reduced and the 61 kDa cleavage product 
appeared (Fig. 28). This suggests that NXF1 is at least in part degraded during infection of 
fibroblasts. However, in contrast to actively infected HeLa cells no smaller cleavage 
products could be detected suggesting that less cleavage of NXF1 occurs due to a reduced 
CPAF activity during infection of fibroblasts. These results indicate that C. trachomatis 
mediated NXF1 degradation is strongly reduced during IFN-? mediated persistence and 
during infection of fibroblasts. 
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Fig. 28: Degradation of NXF1 during IFN-? mediated persistent infection and in infected fibroblasts. 
Immunoblots of lysates from cells incubated for the indicated time points after active and IFN-? mediated 
persistent C. trachomatis infection of HeLa cells as well as mock- and C. trachomatis-infection of fibro-
blasts. 
3.4.4 Examination of poly(A)+ RNA distribution in Chlamydia-infected cells 
It was assumed that the degradation of NXF1 in Chlamydia-infected cells would lead to an 
impaired transport of cellular mRNA out of the nucleus. Thus, to analyse whether 
poly(A)+ RNA accumulates in the nuclei of C. trachomatis-infected HeLa cells FISH was 
used as a method for detection of poly(A)+ RNA with fluorescence microscopy. Most of 
the nuclei of inclusion-containing cells exhibited a higher fluorescence intensity of 
poly(A)+ RNA than the nuclei of uninfected cells (Fig. 29). However, some parts of the 
cytoplasm in proximity to the nucleus showed also increased staining indicating a general 
upregulation of poly(A)+ RNA synthesis in Chlamydia-infected cells. Nevertheless, the 
results suggest that poly(A)+ RNA accumulates in the nuclei of Chlamydia-infected cells 
due to an impaired cellular mRNA export as a result of NXF1 degradation through the 
chlamydial protease CPAF.  
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Fig. 29: Influence of C. trachomatis infection on intracellular distribution of poly(A)+ RNA. 
Confocal laser scanning microscopy images of mock- and actively Chlamydia-infected HeLa cells at 48 h p.i. 
after immunofluorescent staining. Cell nuclei were stained with DAPI (blue) and chlamydial inclusions with 
an antibody detecting MOMP (green). Poly(A)+ RNA was detected by FISH using a Cy3-labeled oligo(dT)50 
probe (red). Nuclei (large arrows) and some areas of the cytoplasm (small arrows) of Chlamydia-infected 
cells showed increased poly(A)+ RNA fluorescence intensity. 
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4 Discussion 
In the present study the interaction of C. trachomatis with the host cell MHCI antigen 
presentation pathway was analysed and compared with regard to three different infection 
models (active infection of HeLa cells, IFN-? mediated persistence of HeLa cells, infection 
of fibroblasts) in order to elucidate whether and at which step C. trachomatis interferes 
with this pathway and how this is influenced by chlamydial persistence. 
In the first part of the present study the growth of C. trachomatis in fibroblasts was 
characterised to find out whether this cell type could generally function as a host cell for 
chlamydial growth. In fibroblasts C. trachomatis displayed a strongly reduced EB produc-
tion, when compared to active infection of HeLa cells, which suggests that the bacteria are 
able to persist in this cell type. However, chlamydial growth in fibroblasts differed also 
from IFN-? mediated persistent infection of HeLa cells in chlamydial morphology and 
gene expression. Because infection of fibroblasts led to IDO expression through endoge-
nous IFN-? production, the role of IDO in causing the atypical chlamydial growth was also 
assessed. siRNA mediated knockdown of IDO expression resulted in increased production 
of progeny indicating that IDO is involved in mediating atypical chlamydial growth in 
fibroblasts. 
The second part of the present work covered the interaction of C. trachomatis with the 
MHCI antigen presentation pathway. The expression of MHCI on the cell surface was only 
slightly downregulated during active infection of HeLa cells, indicating that there is some 
chlamydial interference but no total inhibition of this pathway. Analysing components of 
the MHCI pathway revealed that the antigen transporter subunit TAP2 was degraded 
during active infection, probably through the chlamydial protease CPAF. 
Further, the examination of the influence of Chlamydia-induced Golgi fragmentation on 
MHCI processing revealed that MHCI molecules are present in the fragmented Golgi of 
actively infected HeLa cells. However, tracking of MHCI molecules from the ER to the 
Golgi may be reduced after active infection due to interference at a step in the ER as 
indicated through the absence of Endo H sensitive MHCI molecules. Because TAP2 degra-
dation, altered MHCI processing and reduced MHCI surface expression only occurred 
during active but not persistent and fibroblast infection, it is suggested that TAP2 degra-
dation may be responsible for the surface MHCI downregulation during active infection. 
Additionally, it was found that the Golgi proteins GM130 and Golgin-245 are degraded by 
CPAF during active infection, and accidentally, the human mRNA export factor NXF1 was 
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also discovered as another target for chlamydial cleavage. Degradation of these proteins 
generally was strongly reduced during persistent and fibroblast infection. This correlated 
with decreased expression of proteolytically active CPAF in these infection models. The 
results show that the ability of chlamydiae to interfere with host cell pathways such as the 
MHCI pathway depends on the growth state of chlamydiae which is influenced by the host 
cell conditions such as the cell type or the presence of immunomodulatory factors. 
4.1 Persistent growth of C. trachomatis in fibroblasts 
The epithelial cell represents the typical chlamydial host cell type that promotes productive 
infection. Also other cell types are known in which Chlamydia are able to grow, such as 
macrophages, monocytes, fibroblasts and dendritic cells among others (Gervassi et al., 
2004 a; Manor & Sarov, 1986; Rödel et al., 1998 a). Direct evidence that fibroblasts and 
macrophages could promote chlamydial growth in vivo came from a study which showed 
that viable chlamydial organisms reside in these cell types in the joints of patients with 
chronic CiReA (Nanagara et al., 1995). This suggests that fibroblasts and macrophages 
could serve as a reservoir of chlamydiae during chronic chlamydial infection and thus 
could represent host cells for persistent infection. So far, the chlamydial growth and inclu-
sion formation has been well described for monocytes, macrophages and dendritic cells, 
revealing that chlamydiae are able to persist in these cell types (Koehler et al., 1997; 
Manor & Sarov, 1986; Rey-Ladino et al., 2007). Successful chlamydial in vitro infection 
of fibroblasts has been reported for synovial fibroblasts (Rödel et al., 1998 a), dermal 
fibroblasts (Baumert et al., 2009) and even gingival fibroblasts (Rizzo et al., 2008), 
suggesting that fibroblasts generally promote chlamydial growth independently of their 
organ origin. However, not much is known about the detailed growth behaviour of 
chlamydiae in fibroblasts. Thus, the first part of the present work was dedicated to the 
detailed characterisation of the C. trachomatis growth in fibroblasts. 
4.1.1 Chlamydial growth arrest in fibroblasts at the stage of RB-to-EB re-
differentiation 
The establishment of chlamydial persistence in vitro is known to be induced by different 
factors and host conditions (reviewed in Hogan et al., 2004). All of the known chlamydial 
persistence models have in common that new progeny is abrogated or strongly reduced, 
and in most of these models enlarged but viable chlamydial forms (ABs) are present in the 
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inclusions. Here, the IFN-? mediated chlamydial persistence model, in which chlamydial 
growth is restricted through IDO-mediated tryptophan depletion (Beatty et al., 1994 a), 
was used for comparison with chlamydial infection of fibroblasts, because it represents one 
of the most-well studied persistence models. 
Like in other persistence models a highly reduced production of EBs was found during 
infection of fibroblasts when compared with actively infected HeLa cells, which suggests 
that fibroblast infection could represent another model for chlamydial persistence. How-
ever, the comparison of chlamydial growth in fibroblasts with the IFN-? mediated chlamy-
dial persistence model revealed important differences. First, instead of being reduced in 
size chlamydial inclusions appeared much larger in fibroblasts than in the IFN-? mediated 
persistence model, and they exceeded even the size of inclusions during active infection of 
HeLa cells, probably because fibroblasts themselves are larger than HeLa cells. Second, 
inclusions within fibroblasts rarely contained enlarged ABs, instead apparently normal 
RBs and IBs were the pre-dominant bacterial forms and were present in much higher 
number than the few ABs in the IFN-? mediated persistence model. Third, the analysis of 
chlamydial gene expression in infected fibroblasts revealed no downregulation, when 
compared to actively infected HeLa cells, but even upregulation of the expression of some 
genes at the late stage of infection (48 h p.i.), whereas during IFN-? mediated persistent 
infection most genes were downregulated at this stage. Furthermore, an attenuated protein 
ratio of MOMP to HSP60, which is a hallmark of IFN-? mediated chlamydial persistence 
(Beatty et al., 1993), has not been found in infected fibroblasts. Thus, the atypical chlamy-
dial growth in fibroblasts seems to be very different from other known persistence models. 
However, the chlamydial growth in fibroblasts differed also considerably from that in 
active infection by the presence of a high number of RBs and IBs and a low production of 
EBs at 48 h p.i., indicating that the developmental cycle is not completed in fibroblasts at 
that time point. A possible explanation would be a delay in RB to EB differentiation. How-
ever, the amount of EBs produced in fibroblasts did not increase but rather remained at the 
same level at 96 and 120 h p.i. (data not shown), excluding this possibility. The presence of 
RBs and IBs at the late stage of the developmental cycle therefore rather indicates an arrest 
of chlamydial growth at the stage shortly before RB-to-EB differentiation, resulting in the 
inability to produce EBs and supporting the hypothesis of chlamydial persistence in fibro-
blasts. This persistence is different from the IFN-? mediated persistence model because it 
lacks aberrant chlamydial forms, a small inclusion size, a low number of chlamydial 
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organisms and a general downregulation of chlamydial gene expression, which all seems to 
be more typical for an arrest at an earlier stage of chlamydial growth. 
4.1.2 Different efficiencies of IFN to induce IDO expression between the three 
infection models 
Previous work of our group showed that C. trachomatis infection of synovial fibroblasts 
led to induction of interferon regulatory factor 1 (IRF-1) and the interferon-stimulated gene 
factor 3? (ISGF3?) expression, thus indicating an activation of intracellular defence path-
ways that contributed to the IFN-? expression observed after chlamydial infection of these 
cells (Rödel et al., 1998 a; Rödel et al., 1999). Furthermore, IDO expression was detected 
in infected synovial fibroblasts, and this was partially mediated by endogenously produced 
IFN-? (Rödel et al., 1999). In the present study it was shown that C. trachomatis infection 
of dermal fibroblasts leads also to IFN-? production, which in part contributed to an 
upregulation of IDO expression as revealed by a reduced expression after neutralisation of 
type I IFN activity. However, because this neutralisation did not lead to a decrease in IDO 
expression to the level of uninfected fibroblasts, other factors that are activated after chla-
mydial infection may contribute to and synergistically act with IFN-? in increasing IDO 
expression. Similarly, infection of HeLa cells led to activation of factors that together with 
IFN synergistically increased IDO expression. Such factors could be cytokines, such as IL-
1, which is produced by Chlamydia-infected cells (Rasmussen et al., 1997) and known to 
increase IDO expression in HeLa cells treated with IFN-? (Babcock & Carlin, 2000). 
Interestingly, the level of IDO expression was similar between infected fibroblasts and the 
IFN-? mediated persistently infected HeLa cells. When HeLa cells were treated with an 
amount of recombinant IFN-? that exceeded the amount of endogenous IFN-? produced by 
infected fibroblasts, IDO expression was still very low in comparison to infected fibro-
blasts. This could be due to differences in efficiencies between recombinant IFN-? and 
naturally produced IFN-? on the one hand and the usage of different cell types which could 
have differential susceptibilities to IFN-? on the other hand. For many cell lines strong 
IDO activity has only been reported to be induced by IFN-? but not or only marginally by 
type I IFN (Byrne et al., 1986; Ozaki et al., 1988; Takikawa et al., 1988). In the present 
work, a similar response to both IFN types could be detected for HeLa cells. However, the 
highly increased IDO expression in fibroblasts after chlamydial infection shows that the 
induction of IDO through low amounts of endogenously produced IFN-? seems to be very 
efficient in fibroblasts. 
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4.1.3 Role of IDO in chlamydial persistence in fibroblasts 
IFN-? is regarded as the main factor that induces expression of human IDO, an enzyme 
that converts L-tryptophan to N-formyl L-kynurenine, thus depleting the intracellular tryp-
tophan pool. IDO-mediated tryptophan depletion represents an effective innate immune 
mechanism to control infections with intracellular pathogens like Chlamydia, Toxoplasma 
gondii and different viruses (reviewed in King & Thomas, 2007). It is also well known to 
induce chlamydial persistence (reviewed in Hogan et al., 2004). 
Because synovial fibroblasts were shown to express IDO upon chlamydial infection (Rödel 
et al., 1999), IDO mediated tryptophan depletion might be responsible for the chlamydial 
growth arrest in fibroblasts. Indeed, the results of the present study show that IDO is 
involved in mediating chlamydial persistence in fibroblasts, as a 4-fold increase in burst 
size was found after IDO siRNA knockdown in infected fibroblasts, which correlates to 
around 80 EBs per inclusion. Also, the chlamydial gene expression after IDO siRNA 
knockdown in fibroblasts was altered to a state that was more similar to that in actively 
infected HeLa cells. However, the burst size in actively infected HeLa cells was still 9 to 
10 times higher than the burst size in infected fibroblasts after IDO siRNA transfection. 
Therefore, it can be assumed that the effect of IDO on the inhibition of chlamydial growth 
is much lower in fibroblasts than in the IFN-? mediated persistence model. This is 
supported by the expression of trpB which was found to be highly upregulated during IFN-
? mediated persistence, but only slightly increased in infected fibroblasts. trpB expression 
is a good indicator of the level of tryptophan depletion in infected cells and thus for IDO 
activity, because trpB transcription is repressed in the presence and activated in the 
absence of tryptophan (Wood et al., 2003). Interestingly, the upregulation of trpB expres-
sion started later in infected fibroblasts than in the IFN-? mediated persistence model. This 
further suggests that tryptophan starvation followed by inhibition of chlamydial growth 
occurs at a late stage of chlamydial growth and correlates with the hypothesis of an arrest 
of chlamydial growth in fibroblasts just before RB-to-EB differentiation. Furthermore, 
there may be a later onset of IDO expression in these cells, because chlamydial infection 
first leads to the production of IFN-? which in turn induces IDO expression. This results in 
a longer duration until the initiation of IDO synthesis, than would be the case when adding 
IFN to the cells directly after infection. In contrast, tryptophan depletion could occur at 
earlier time points and thus more efficiently in the IFN-? mediated persistence model due 
to pre-treatment with IFN-?. 
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Another possible reason for the discrepancies between the persistence in fibroblasts and the 
IFN-? mediated persistence in epithelial cells could be differences in the degree of IDO 
induction due to distinct efficiencies and concentrations of the IFN in each model. Indeed, 
it has been shown that the degree of the atypical morphology of the chlamydial forms 
depends on the concentration of IFN-? or the level of amino acid deprivation (Harper et al., 
2000; Jones et al., 2001). However, in the present study a similar level of IDO expression 
in both infection of fibroblasts and IFN-? mediated persistent infection of HeLa cells was 
found, indicating a similar efficiency of the endogenously produced IFN-? and the 
exogenously added IFN-? in IDO activation. Thus, a late onset of IDO expression could 
more likely be responsible for the lower effect of IDO on inhibition of chlamydial growth 
in fibroblasts compared to the IFN-? mediated persistence. However, treatment of HeLa 
cells with IFN-? after infection did not result in chlamydial persistence. Because of this 
and because of the results of the IDO siRNA knockdown it is suggested that IDO mediated 
tryptophan depletion is only one factor contributing to persistence induction in fibroblasts, 
and that additional factors are involved. 
It has been reported that IFN-? treatment of cells can also lead to intracellular iron deple-
tion (Byrd & Horwitz, 1993). IFN-? induced inhibition of C. trachomatis growth in HeLa 
cells could be reversed both by tryptophan and iron addition (Ishihara et al., 2005), 
suggesting that IFN exerts its inhibitory effect on Chlamydia by a combination of trypto-
phan and iron depletion. Another mechanism that is known to restrict growth of intra-
cellular pathogens is the IFN induction of inducible nitric oxide synthase (iNOS) that 
produces nitric oxide to eradicate pathogens (reviewed in Chakravortty & Hensel, 2003). 
However, in the present work iNOS expression has not been detected after chlamydial 
infection of fibroblasts (data not shown), and iNOS has been implicated in restriction of 
chlamydial growth basically in murine, but not in human cells (Roshick et al., 2006). 
Similar to fibroblasts C. trachomatis infection of monocytes results in chlamydial persis-
tence without addition of any exogenous factors (Schmitz et al., 1993). Treatment of 
infected monocytes with tryptophan or antibodies neutralising TNF-?, IFN-? or IFN-? did 
not abrogate the persistence (Koehler et al., 1997). However, IDO expression is upregu-
lated in Chlamydia-infected monocytes (Krausse-Opatz et al., 2007), and microarray data 
revealed an increased expression of IFN-? and other cytokines (Schrader et al., 2007). This 
suggests that although IDO is readily expressed upon chlamydial infection of monocytes, 
probably through endogenously produced cytokines, other factors are involved in the per-
sistence in monocytes. Due to the manifold cytokine expression and activation of diverse 
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intracellular pathways it is conceivable that several factors may contribute and synergisti-
cally act in inhibiting chlamydial growth in infection of monocytes as well as fibroblasts. 
4.1.4 Comparison of chlamydial gene expression in fibroblasts with other 
persistence models 
In most persistence models, such as the IFN-? mediated, amino acid depletion, iron 
deficiency, monocyte and the HSV-2 co-infection persistence model, the expression of 
MOMP was attenuated, suggesting that it is a general feature of chlamydial persistence 
(Belland et al., 2003; Deka et al., 2006; Gérard et al., 1998 b; Goellner et al., 2006; Jones 
et al., 2001; Timms et al., 2009). However, no MOMP downregulation has been observed 
in infected fibroblasts. Therefore, the phenomenon seems not to apply to all persistence 
models. Also in the penicillin persistence model no decrease of MOMP expression could 
be detected (Cevenini et al., 1988; Goellner et al., 2006; Nicholson & Stephens, 2002). 
Furthermore, the downregulation of the expression of the 60 kDa cysteine-rich outer 
membrane protein OmcB has been observed for the penicillin persistence and several other 
chlamydial persistence models (Beatty et al., 1993; Belland et al., 2003, Cevenini et al., 
1988; Goellner et al., 2006; Jones et al., 2001; Nicholson & Stephens, 2002). Decreased 
expression of late genes like omcB seems to point to a growth arrest during early stages of 
the chlamydial developmental cycle. However, similar to active infection in HeLa cells, 
omcB expression in Chlamydia-infected fibroblasts was highly upregulated at the late 
stage. This suggests a normal chlamydial development in fibroblasts until the late stage. 
Cysteine-rich proteins like OmcB are incorporated into the chlamydial cell wall at the late 
stage to form the rigid EBs (Hatch et al., 1986). Since EBs are rarely formed in fibroblasts, 
it is tempting to speculate that despite proper omcB transcription reduced protein synthesis 
of cysteine-rich proteins could occur by low availability of the amino acid cysteine. 
Indeed, cysteine seems to be essential for chlamydial RB-to-EB differentiation, as its 
depletion was reported to reduce the formation of new EBs (Allan et al., 1985). In contrast, 
cysteine seems not to be essential for the development of normal inclusions and RBs 
(Allan & Pearce, 1983). Thus, a low intracellular cysteine pool could be a potential induc-
ing factor for the observed atypical chlamydial development in fibroblasts. 
A general hallmark of chlamydial persistence seems to be the inhibition of chlamydial cell 
division, as was found by the attenuated expression of proteins involved in this process in 
several persistence models (Belland et al., 2003; Byrne et al., 2001; Gérard et al., 2001; 
Goellner et al., 2006; Klos et al., 2009). Surprisingly, expression of the gene encoding the 
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cell division protein FtsW was highly upregulated in fibroblasts, when compared to active 
infection at the late stage of the developmental cycle. Thus, in contrast to other persistence 
models bacterial multiplication appears not to be inhibited in fibroblasts, which is in 
correlation with the electron microscopy observations that revealed a high number of RBs 
in fibroblasts. The higher ftsW expression in infected fibroblasts compared to actively 
infected HeLa cells at 48 h p.i. suggests that the RBs within fibroblasts continue to 
undergo cell division instead of re-differentiating to EBs. Because fibroblasts are larger 
than HeLa cells the increased ftsW expression could further be explained by more space 
available inside the cell, which may result in higher cell division rates. 
Interestingly, instead of a downregulation an upregulation of ftsW expression was found in 
the IFN-? induced persistence model at 24 h p.i., which is in contrast to a previous study 
(Belland et al., 2003). Although the present work is very similar to this study in using the 
same cells and serovar, a higher concentration and longer pre-treatment of IFN-? as well as 
another cell culture medium with different nutrient composition was used in the present 
study. This shows that persistence induction is very sensitive to different culture condi-
tions. Furthermore, differences in conditions for gene expression analysis could account 
for the observed discrepancies. A similar difference in results as for ftsW expression was 
observed for the expression of pgsA_2, encoding a protein involved in phospholipid 
synthesis, which was found to be downregulated during IFN-? induced persistent infection, 
whereas its expression was upregulated in the study of Belland et al. (2003). However, in 
that study gene expression was only measured at 24 h p.i., but not at 48 h p.i. Like ftsW, 
the expression of pgsA_2 was highly upregulated in fibroblasts indicating that an enhanced 
metabolism and availability of nutrients could lead to increased cell division. Chlamydiae 
are known to acquire host lipids for incorporation into the bacterial cell and inclusion 
membrane (reviewed in Scidmore, 2011). The upregulation of pgsA_2 in infected fibro-
blasts could thus also be explained by the larger inclusion size, because an increasing 
inclusion membrane surface area would need more lipids to be acquired from the host cell 
and to be altered to bacterial phospholipids. 
One particularly interesting observation was the highly increased expression of groEL_2 
(also called ct604), encoding one of three HSP60 proteins, at the late stage of fibroblast 
infection. An upregulated expression of this gene was found in C. trachomatis infected 
monocytes, indicating that it plays an important role in persistent infection (Gérard et al., 
2004). This is supported by another study that showed a larger amount of this protein in 
iron deficiency mediated chlamydial persistence (LaRue et al., 2007). Importantly, 
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groEL_2 expression was also found to be upregulated in synovial samples from patients 
with CiReA (Gérard et al., 2004). The finding of increased groEL_2 expression in 
fibroblasts thus strengthens the hypothesis that this HSP60 form plays an important 
immunopathological role during in vivo persistence of chlamydiae, because HSP60 is 
supposed to contribute to the severe immunopathology observed during chlamydial 
infection. On the other hand, increased expression of this protein could simply represent a 
specific stress response to unfavourable growth conditions. 
4.1.5 Expression of the chlamydial protease CPAF in fibroblasts 
The chlamydial protease CPAF represents an important virulence factor during chlamydial 
infection. The present work revealed that CPAF was severely attenuated in the IFN-? 
mediated persistence model both at the transcriptional and the translational level, which 
has also been described recently (Rödel et al., 2012). Downregulation of CPAF expression 
had also been observed in C. psittaci persistence induced by IFN-? treatment or iron deple-
tion (Goellner et al., 2006). It has been reported that expression of genes encoding the type 
III secretion system is attenuated during IFN-? mediated chlamydial persistence (Slepenkin 
et al., 2003), indicating that translocation of chlamydial effector proteins could be severely 
reduced under these conditions. Although CPAF is translocated through the type II secre-
tion pathway (Chen et al., 2010 a), secretion of the protease into the cytoplasm was also 
found to be inhibited during IFN-? or iron deficiency mediated persistence (Heuer et al., 
2003). This correlated with an abrogation of RFX5 degradation (Heuer et al., 2003), a host 
transcription factor normally cleaved by CPAF during active infection (Zhong et al., 
2000). In the present study an inhibition of the degradation of RFX5 and other host 
proteins that are cleaved by CPAF was observed also during IFN-? mediated chlamydial 
persistence, which indicates that CPAF has no strong activity during persistent infection, 
thus reducing the ability of chlamydiae to manipulate the host cell. Interestingly, gene 
expression of CPAF was not diminished during infection of fibroblasts, and it even showed 
an increase at early stages when compared to active infection of HeLa cells. However, no 
or only reduced degradation of CPAF substrates has been observed in fibroblasts. Interest-
ingly, in contrast to actively infected HeLa cells the 70 kDa precursor protein of CPAF 
could be readily detected in infected fibroblasts. Because the precursor usually is processed 
as soon as it is translocated into the host cytosol, the result suggests an accumulation of the 
precursor protein in fibroblast inclusions due to a reduced translocation into the host cyto-
sol. This is supported by the lower amount of the active 29 kDa N-terminal CPAF form in 
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infected fibroblasts compared to HeLa cells. Another possibility could be that translocation 
readily occurs while autoprocessing of CPAF could be inhibited in the cytosol of fibro-
blasts due to suboptimal host cell conditions.  
4.2 Impact of chlamydial infection on MHC class I antigen presentation 
The presentation of intracellularly processed chlamydial antigens via MHCI to CD8+ T 
cells is important for the recognition and elimination of infected cells, especially of 
infected epithelial cells since they represent host cells for chlamydial multiplication and 
primary sites of chlamydial infection. However, Chlamydia have evolved mechanisms to 
escape immune defence in order to survive and finish their development inside the host 
cell. One such mechanism could be the downregulation of MHCI surface expression in 
order to escape recognition by CD8+ T cells. Indeed, the downregulation of surface MHCI 
has been found in C. trachomatis infected epithelial cells (Hook et al., 2004; Ibana et al., 
2011; Zhong et al., 2000). In the present study, a reduction of surface MHCI has also been 
detected in HeLa cells infected with C. trachomatis, however, compared to the above 
studies, there was only a slight decrease of surface MHCI expression in these cells. 
Downregulation of MHCI surface expression is a general mechanism applied by different 
viruses to escape CD8+ T cell mediated killing. This is achieved through endocytosis of 
MHCI from the cell surface, retention of MHCI in the ER or Golgi, proteasomal degrada-
tion of MHCI heavy chains and/or inhibition of TAP-mediated peptide transport (reviewed 
in Antoniou & Powis, 2008). Interestingly, TAP generally seems to be a very popular 
target for viral interference with MHCI antigen presentation as several viruses have been 
found to inhibit peptide transport through TAP (reviewed in Antoniou & Powis, 2008). 
Chlamydia also seem to possess the ability to inhibit TAP-mediated peptide transport, as 
chlamydial degradation of TAP2 has been found in the present work, which likely may 
lead to inhibition of peptide loading of MHCI and may be responsible for the observed 
surface MHCI downregulation during active infection of HeLa cells. 
Furthermore, because Chlamydia induce Golgi fragmentation (Heuer et al., 2009) it was 
assumed that this has also an influence on MHCI processing and transport to the cell 
surface. However, no clear evidence of an inhibition of MHCI trafficking due to Golgi 
fragmentation has been observed, because inhibition of MHCI transport already seems to 
occur at the ER in actively Chlamydia-infected HeLa cells due to TAP2 degradation. 
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4.2.1 Expression of the TAP transporter and immunoproteasome subunits in 
Chlamydia-infected cells 
Chlamydia are confined to an intracellular vacuole and do not get access to the ER and 
Golgi lumen as easy as viral proteins that are produced by the host protein translation 
machinery and often travel through the secretory route. Hence, an efficient way for 
Chlamydia to interfere with the MHCI pathway would likely be the attack of components 
of the MHCI pathway that are exposed to the host cytosol through chlamydial effector 
proteins secreted into the host cytosol. Thus, the TAP transporter and immunoproteasome 
subunits were analysed as potential targets by examination of their gene and protein 
expression. 
Some viruses, for example HIV-1 and CMV, are known to interfere with the assembly of 
the immunoproteasome (Gavioli et al., 2004, Miller et al., 2000), a proteasome which con-
tains different catalytic subunits that generate an altered peptide repertoire during infection 
and inflammation. Interestingly, the intracellular parasite Trypanosoma cruzi is also able to 
downregulate the IFN-? induction of immunoproteasome expression (Bergeron et al., 
2008). In contrast to these studies, it was found, that the expression of the immuno-
proteasome subunits LMP7 and MECL1 was not affected by Chlamydia. Only the gene 
expression of LMP2 was significantly downregulated after active chlamydial infection of 
HeLa cells. However, since this downregulation was less than 2-fold, and as no reduction 
in LMP2 protein expression could be detected in these cells, it is concluded that this 
slightly reduced LMP2 expression may have no functional relevance for the MHCI path-
way. This suggests that inflammation-induced formation of the immunoproteasome is not 
compromised by Chlamydia, thus leading to the proper generation of a different peptide 
repertoire which is known to increase the efficiency of MHCI presentation (reviewed in 
Sijts & Kloetzel, 2011). 
When analysing the expression of the TAP transporter subunits, TAP1 but no TAP2 
protein could be detected after active chlamydial infection of HeLa cells, although gene 
expression of TAP2 was not decreased. This disappearance of TAP2 protein was mediated 
by chlamydial degradation of TAP2, probably through the chlamydial protease CPAF. 
TAP2 expression was even slightly, but significantly, upregulated in actively infected 
HeLa cells without and with IFN-? treatment indicating a compensation for the decreased 
TAP2 protein by upregulating synthesis of new TAP2 as a possible feedback mechanism. 
Interestingly, a slight reduction of TAP1 protein has also been found in infected HeLa cells 
treated with IFN-?, and concomitantly TAP1 gene expression was significantly increased 
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in these cells. This phenomenon was not seen in IFN-? treated and non-treated actively 
infected cells, suggesting that TAP1 is not directly attacked by Chlamydia. It rather indi-
cates that TAP1 is less stable in cells treated with IFN-? than in cells treated with IFN-? or 
without treatment, which could be the case if TAP2 is degraded and cannot bind to and 
stabilise TAP1. Because most of the TAP1 in the IFN-treated cells is supposed to be newly 
generated due to the IFN treatment, instability of TAP1 may only affect newly synthesized 
TAP1 and thus might rather occur in IFN-treated cells. The differences between IFN-? and 
IFN-? could be explained by a general stabilising effect of IFN-? on the MHCI pathway 
components, because IFN-? was shown to increase the stability of MHCI by improving 
quality control and slowing maturation of MHCI in the ER (Fromm & Ehrlich, 2001). 
In contrast to active infection of HeLa cells, no TAP2 degradation has been found during 
persistent infection of HeLa cells and infection of fibroblasts. In both models, there was 
even an increased gene expression of HLA-ABC, TAP1, TAP2 and the immunoprotea-
some subunits after chlamydial infection. In fibroblasts this effect was partially mediated 
through type I IFN, as became apparent after neutralising the type I IFN response. How-
ever, because the effect of type I IFN neutralisation on gene expression was not the same 
for all genes analysed, other factors seem to be activated after chlamydial infection that 
could also increase the expression of certain MHCI related genes in fibroblasts to different 
levels. In addition, the potential of IFN-? to upregulate gene expression could differ 
between these genes. Factors that get activated after chlamydial infection and could act 
synergistically with IFN-? in upregulating gene expression of MHCI components could 
also be responsible for the increased gene expression observed during IFN-? persistent 
infection of HeLa cells. 
4.2.2 Role of RFX5 in MHCI antigen presentation in Chlamydia-infected cells 
Up to now, only one potential mechanism of chlamydial interference with MHCI surface 
expression has been documented, namely the degradation of RFX5 through CPAF (Zhong 
et al., 2000; Zhong et al. 2001). RFX5 is part of the regulatory factor complex (RFX) that 
is necessary for MHCII gene expression and also involved in transcription initiation of the 
MHCI genes (reviewed in van den Elsen et al., 1998). 
In contrast to the study of Zhong et al. (2000), no decreased expression of the MHCI 
encoding genes HLA-ABC has been observed in the present study, and there was only a 
slightly reduced amount of HLA-ABC protein product after active chlamydial infection of 
HeLa cells despite the degradation of RFX5 in these cells. Because of this, it was assumed 
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that RFX5 generally does not play any essential role in regulating MHCI gene expression 
upon chlamydial infection. Rather, redundant factors might exist that could bind to the 
MHCI promoter and activate MHCI transcription also in the absence of RFX5. The MHCI 
promoter contains different upstream elements that regulate gene expression, and different 
factors such as IRF-1, ISGF3 and NF-?B may bind to the promoter and could be sufficient 
to activate MHCI gene expression (Chang et al., 1992; Nielsch et al., 1991). Thus, it could 
be possible that increased expression of these factors during chlamydial infection could 
compensate for the RFX5 deficiency. This would also explain why an upregulation of 
MHCI expression was found during infection of fibroblasts despite a very low RFX5 
expression that was not detectable by immunoblotting. In C. trachomatis-infected fibro-
blasts IFN-? induction of ISGF3? has been shown to lead to increased MHCI expression 
(Rödel et al., 2002), in addition an elevated expression of IRF-1 was also found in these 
cells (Rödel et al., 1999). Since these factors are involved in binding to the MHCI pro-
moter, their increased expression in fibroblasts could be sufficient to enhance MHCI gene 
transcription despite low RFX5 expression. 
4.2.3 Differences in interference of C. trachomatis with MHC class I antigen 
presentation during active and persistent infection 
In contrast to actively infected HeLa cells, no interference with the MHCI presentation 
pathway was observed during IFN-? mediated persistence and fibroblast infection, as a 
downregulation of surface MHCI and a degradation of TAP2 was not detected under these 
conditions. Infected fibroblasts showed high upregulation of the MHCI pathway compo-
nents through endogenously produced IFN-? which explains the increased MHCI surface 
expression in these cells. This is consistent with the previous finding of MHCI upregu-
lation in synovial fibroblasts after C. trachomatis infection, which was shown to be medi-
ated by Chlamydia-induced endogenous IFN-? production (Rödel et al., 2002). 
Furthermore, the trafficking of MHCI from the ER to the Golgi was similar to mock-
infected cells during persistence and fibroblast infection as revealed by the presence of 
both Endo H sensitive and resistant forms. Thus, it seems that under host conditions where 
chlamydial growth is aberrant, such as in fibroblasts and IFN-? induced chlamydial 
persistence, MHCI antigen presentation is functional and not manipulated by chlamydial 
organisms. In part this could be explained by the strongly reduced CPAF expression and 
degradation of TAP2, respectively, which have been observed in persistently infected 
HeLa cells and in infected fibroblasts. Thus, during persistent chlamydial growth host cell 
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path-ways such as MHCI antigen presentation may be functional due to a reduced CPAF 
activity. These results are consistent with a previous study that showed efficient CD8+ T 
cell mediated lysis of C. trachomatis-infected cells in which persistence was induced by 
IFN-? and penicillin, respectively (Rasmussen et al., 1996). 
Apart from the differences in MHCI surface expression between actively and persistently 
Chlamydia-infected HeLa cells, there was a general MHCI downregulation that appeared 
also on inclusion-negative HeLa cells in both actively and persistently infected cell 
cultures. This is consistent with a previous study (Ibana et al., 2011) and probably the 
result of a soluble factor secreted by infected HeLa cells that influences the MHCI surface 
expression on uninfected neighbour cells. In contrast, this phenomenon could not be 
observed in the infected fibroblast culture, because fibroblasts increased their MHCI sur-
face expression upon infection due to secretion of IFN-?. Thus, MHCI surface expression 
could be influenced by different cytokines making it difficult to evaluate the real situation 
and the role of MHCI presentation in vivo. 
4.2.4 Correlation of CPAF expression with chlamydial interference with MHCI 
antigen presentation 
In the present study, a slight MHCI downregulation on the surface of actively infected 
HeLa cells was observed. As the results indicate that CPAF is responsible for degradation 
of TAP2, interference with MHCI expression might thus depend on the expression of 
CPAF. Therefore, MHCI expression and killing of infected cells by CD8+ T cells might be 
functional during chlamydial persistence, as described in the previous chapter. However, it 
might also be functional during the early chlamydial growth stage during active infection, 
since CPAF expression starts at later stages and degradation of substrates is not detected 
before 13 hours p.i. (Dong et al., 2004). This is consistent with the observation that effi-
cient activation of CD8+ T cells in response to the chlamydial class I accessible protein-1 
(Cap1), which is known to be recognised by Chlamydia-specific CD8+ T cells (Fling et al., 
2001), occurred between 8 and 24 h p.i. (Balsara et al., 2006 b) correlating with the time of 
cap1 expression. Other studies examining CD8+ T cell responses to Chlamydia-infected 
cells in vitro showed efficient CD8+ T cell mediated cytotoxic killing of cells that were 
actively or persistently infected for 24 h (Beatty & Stephens, 1994; Rasmussen et al., 
1996). Another study revealed a surface MHCI staining on C. trachomatis infected cells at 
18 h p.i. that was similar to that of mock-infected cells, and that same study found compa-
rable Endo H digestion results for infected and uninfected cells at 24 h p.i. (Scidmore et 
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al., 1996). However, all of these studies did not analyse CD8+ T cell cytotoxicity or MHCI 
expression in actively infected cells at later time points of C. trachomatis infection. As it is 
assumed that interference with MHCI antigen presentation correlates with CPAF activity, 
it would be expected that an inhibition of MHCI antigen presentation does not occur before 
24 h p.i., which would explain the functional MHCI expression and CD8+ T cell lysis of 
actively infected cells at 24 h p.i. However, the findings of the present study clearly 
suggest that MHCI antigen presentation is compromised during active infection, but still 
functional during IFN-? induced persistence at later time points (40 h p.i.). 
The hypothesis that interference with MHCI starts late during the developmental cycle is 
further supported by the finding that MHCI surface expression was only slightly reduced in 
actively infected HeLa cells. If blocking of MHCI trafficking would already occur at 
earlier stages of infection, a more drastic surface MHCI downregulation would be expected 
at 40 h p.i. This suggests that residual MHCI from early stages of infection, where normal 
MHCI trafficking is expected to occur, can still be detected at the cell surface. Cells that 
have severely reduced MHCI surface expression are usually recognised and eliminated by 
natural killer (NK) cells. Indeed, an induction of a NK cell response accompanied by IFN- 
? production was detected in response to Chlamydia-infected epithelial cells and started 
between 18 and 24 h p.i. (Hook et al., 2004), and this response depended on chlamydial 
but not on host protein synthesis. This further supports the hypothesis that interference 
with the MHCI antigen presentation pathway starts during later stages of chlamydial 
growth, when sufficient CPAF activity is available in the host cytosol.  
4.2.5 Degradation of TAP2 through C. trachomatis 
The degradation of TAP2 through a chlamydial protease, probably CPAF, is particularly 
interesting, since this is the first description of an attack of the TAP transporter through an 
intracellular pathogen residing in a host vacuole. TAP is an essential component of the 
MHCI antigen presentation pathway, because cell lines deficient for one or both subunits 
of the peptide transporter have a reduced level of surface MHCI expression and unstable 
MHCI molecules that are mostly retained in the ER (Cerundolo et al., 1990; Kelly et al., 
1992; Powis et al., 1991; Spies & DeMars, 1991; Townsend et al., 1989; van Kaer et al., 
1992). Hence, interference with the function of TAP is a good strategy to block MHCI 
traffic to the cell surface and thus is applied by several viruses. For example, the ICP47 
protein of HSV-1 is an efficient substrate inhibitor of TAP by binding to the peptide 
binding domain with high affinity (Ahn et al., 1996; Früh et al., 1995; Hill et al., 1995; 
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Tomazin et al. 1996). Likewise, Epstein-Barr virus (EBV) and human CMV are able to 
prevent ATP binding to TAP (Hewitt et al., 2001; Hislop et al., 2007; Kyritsis et al., 
2001). Degradation of the TAP transporter has also been described in virus-infected cells, 
for example upon murine ?-herpesvirus-68 infection (Boname et al., 2004; Boname et al., 
2005), however, this occurs through directing the TAP proteins to the host proteasome. 
It would be interesting to know at which sites of the TAP2 protein cleavage occurs in 
Chlamydia-infected cells. TAP is a typical ABC transporter made of the two subunits 
TAP1 and TAP2 that each contains a large transmembrane domain for anchoring in the ER 
membrane and an NBD at the C-terminus that is located in the cytosol (reviewed in 
Lankat-Buttgereit & Tampé, 2002). Because of the inaccessibility of the membrane-located 
transmembrane domain it is unlikely that CPAF cleaves in this region. However, parts of 
the protein that are exposed to the cytosol, such as the NBD, would be potential cleavage 
sites, as CPAF activity normally is detected in the host cytosol (Zhong et al., 2001). 
Although TAP1 and TAP2 possess similar NBDs, some parts, especially the core NBDs 
and the C-terminal tails, have reduced homology (Bouabe & Knittler, 2003), making it 
possible that CPAF cleaves in such regions which would explain the specific cleavage only 
of TAP2, but not of TAP1. Interestingly, the monoclonal antibodies that were used in the 
present work both recognise the C-terminal region of TAP1 and TAP2, respectively (van 
Endert et al., 1994). If the C-terminal region of TAP2, which the antibody binds to, would 
be cleaved off by CPAF, it would be likely to interfere with detection of TAP2 by either 
destroying the antibody epitope or by generating fragments that are too small to be 
detected by immunoblotting. Indeed, no cleavage fragment in the cell-free cleavage assay 
could be observed, which thus makes it likely that CPAF attacks the NBD of TAP2. 
Cleavage of the NBD of TAP2 would be expected to be sufficient to inactivate the function 
of the peptide transporter, since ATP binding is absolutely necessary for peptide transport 
(Androlewicz et al., 1993) and both NBDs of the TAP transporter are necessary for the 
transporter function (Alberts et al., 2001; Daumke & Knittler, 2001). It has been shown 
that the C-terminal tail of the NBD of TAP2 is essential for ATP binding and the peptide 
transport function (Bouabe & Knittler, 2003; Ehses et al., 2005). Thus, removal of the C-
terminal tail from TAP2 would be sufficient to inhibit ATP-binding to TAP2 and peptide 
transport into the ER in Chlamydia-infected cells. 
Through Endo H digestion of total MHCI in actively infected HeLa cells only Golgi-
resident Endo H-resistant, but no ER-resident Endo H-sensitive forms, could be detected. 
This is surprising, because in TAP-deficient cells most of the MHCI remained Endo H-
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sensitive due to their retention in the ER as empty (peptide-receptive) molecules (Garstka 
et al., 2007; Grandea et al., 2000). The lack of ER-resident MHCI in actively infected 
HeLa cells could be explained by either downregulated synthesis of new MHCI heavy 
chains and/or rapid degradation of the ER-resident MHCI molecules. Indeed, a slight 
decrease in the protein amount was found in these cells, although this was less visible in 
the normal immunoblot and more obvious in the Endo H experiment. This decrease in 
MHCI heavy chain protein cannot be explained by decreased transcription, as there was no 
significant downregulation of HLA-ABC gene expression. Furthermore, during active 
infection with IFN-? treatment no protein downregulation could be found and a few Endo 
H-sensitive bands occurred, which could either be due to an inhibitory effect on 
Chlamydia, thus reducing interference with MHCI antigen presentation, or, which is more  
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Fig. 30: Hypothetical model of C. trachomatis interference with the MHC class I antigen presentation 
pathway. 
The possible influence of TAP2 degradation on the TAP-mediated peptide transport and MHCI stability and 
the potential effect of Golgi protein degradation on MHCI surface trafficking are outlined. 
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likely, due to a strongly increased synthesis of TAP2 and other components which would 
allow peptide-loading of a few MHCI molecules as a result of incomplete chlamydial 
degradation of TAP2. 
Furthermore, IFN-? is known to stabilise MHCI molecules by improving peptide loading 
quality control (Fromm & Ehrlich, 2001). Thus, degradation of empty MHCI would be 
the most plausible explanation for the observed effect during active infection. Indeed, 
increased ER-associated proteasomal degradation (ERAD) of misfolded or unstable MHCI 
heavy chains was observed in cells that lack normal assembly of MHCI molecules such as 
in ?2M or TAP deficient cells (Hughes et al., 1997). Moreover, the enzymes involved in 
ERAD of MHCI heavy chains have been identified recently (Burr et al., 2011). Thus, it is 
hypothesised that newly synthesized MHCI chains are rapidly degraded in Chlamydia-
infected cells due to a defect in TAP-mediated peptide delivery from the cytosol as a 
consequence of TAP2 degradation. A hypothetical model visualising the mechanisms that 
C. trachomatis may apply to interfere with the MHCI antigen presentation pathway is 
displayed in Fig. 30. 
4.2.6 Role of Golgi fragmentation and Golgi protein degradation in inhibition of 
intracellular MHCI trafficking in actively Chlamydia-infected cells 
It has been reported that in cells infected with African Swine Fever Virus the Golgi got 
fragmented, which resulted in reduced MHCI surface expression (Netherton et al., 2006). 
Because it is known that Chlamydia are also able to induce fragmentation of the Golgi 
apparatus through CPAF-mediated degradation of Golgin-84 (Christian et al., 2011; Heuer 
et al., 2009), it was assumed that this could also have a negative impact on processing and 
transport of MHCI molecules through the Golgi to the cell surface and thus might con-
tribute to the reduced MHCI surface expression during active chlamydial infection. 
Similar to the study of Heuer et al. (2009) a complete fragmentation of the Golgi during 
active C. trachomatis infection of HeLa cells was also found in the present study by 
immunofluorescence staining of GM130 and Golgin-245. Additionally, it was shown that 
the cis-Golgi protein GM130 and the trans-Golgi protein Golgin-245 got degraded through 
CPAF during active infection of HeLa cells. Thus, beside Golgin-84 two other golgins are 
substrates of CPAF cleavage. This suggests that all golgins may be cleaved by CPAF 
which would assure that not only the cis-Golgi, but all sub-compartments of the Golgi 
could undergo fragmentation during chlamydial infection, provided that degradation of the 
golgins is leading to Golgi fragmentation in a similar way like cleavage of Golgin-84. This 
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hypothesis is supported by the finding that depletion of Golgin-245 and other trans-Golgi 
network (TGN) golgins resulted in fragmentation of the TGN (Derby et al., 2007; Yoshino 
et al., 2003). 
Although there was a complete Golgi fragmentation during active chlamydial infection, the 
immunofluorescence staining of GM130 and MHCI revealed no reduced localisation of 
MHCI to the Golgi in inclusion-containing cells compared to non-infected cells. Further-
more, examination of the Endo H cleavage pattern of MHCI during active chlamydial 
infection of HeLa cells showed that MHCI that is resistant to Endo H cleavage and thus 
localised to post-ER compartments is still present in these cells, although to a reduced 
amount. These results indicate that MHCI is not excluded from the Golgi compartment 
despite Golgi fragmentation. Since no Endo H sensitive MHCI was found upon active 
chlamydial infection, which indicates that MHCI is not present in the ER, it would be 
expected that no MHCI could be delivered from the ER to the Golgi. Thus, the Golgi-
resident MHCI in these cells could represent MHCI that has reached the Golgi during 
earlier stages of infection at which chlamydial interference with the MHCI antigen presen-
tation pathway had not yet occured. This is supported by the finding of a reduced amount 
of Endo H resistant MHCI in actively infected cells when compared to uninfected cells, 
indicating a decrease in the Golgi-resident MHCI amount due to the lack of delivery of 
MHCI from the ER. Cells infected with certain viruses were shown to accumulate MHCI 
in the Golgi due to interruption of transport of MHCI from the Golgi to the cell surface or 
endocytosis of surface MHCI (Abendroth et al., 2001; Greenberg et al., 1998). However, 
an increased amount of MHCI in the Golgi of actively Chlamydia-infected HeLa cells 
could not be observed indicating that there is no accumulation of MHCI in this compart-
ment. This further supports the hypothesis that no MHCI is delivered from the ER to the 
Golgi at later stages of infection. As explained in the previous chapter this lack of ER-
resident MHCI could be due to interruption of the MHCI antigen presentation pathway 
already at the stage of ER, likely through degradation of newly synthesised MHCI as a 
consequence of Chlamydia-mediated TAP2 cleavage. 
Due to this lack of delivery of MHCI to the Golgi it is difficult to evaluate the impact of 
Chlamydia-induced Golgi fragmentation on the MHCI trafficking. However, Golgi frag-
mentation may serve as a second, additional mechanism to inhibit MHCI trafficking to the 
cell surface (Fig. 30). The finding of Golgin-245 degradation in actively Chlamydia-
infected HeLa cells is particularly interesting, because the TGN-resident Golgin-245 seems 
to be necessary for the vesicle transport to the plasma membrane (Yoshino et al., 2003). 
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Moreover, a role for Golgin-245 in regulating the MHCI transport from the Golgi to the 
plasma membrane has been suggested (Brémond et al., 2009). 
Additionally, fragmentation of the trans-Golgi could have a negative effect on recycling of 
MHCI molecules from the cell surface. Indeed, it has been found that MHCI recycling 
from the plasma membrane requires the Rab GTPases Rab22a and Rab11 (Weigert et al., 
2004), and it is known that Rab11 is recruited to the chlamydial inclusion (Rzomp et al., 
2003). Thus, Chlamydia could also interfere with MHCI recycling from the cell surface by 
recruitment of Rab11 which would not be available anymore for the MHCI recycling. 
Alternative ways of peptide-loading could also be inhibited in Chlamydia-infected cells as 
a result of trans-Golgi fragmentation. For example, proprotein convertase 7 (PC7), that 
resides in the TGN and usually is involved in post-translational modification, is able to 
generate peptides that can be loaded on unstable MHCI molecules and by this partially 
rescues the surface expression in cells with defective PLC quality control (Leonhardt et al., 
2010). In Chlamydia-infected cells the function of PC7 as a second quality control could 
be compromised due to the fragmentation of the TGN as a result of degradation of Golgi 
proteins such as Golgin-245. This is supported by the observation that depletion of Golgin-
245 from the TGN resulted in dispersal of the TGN, with concomitant reduction of protein 
cleavage by the proprotein convertase furin (Yoshino et al., 2003). 
4.2.7 Golgi fragmentation and Golgi protein degradation during chlamydial 
persistence and fibroblast infection 
In contrast to the results of actively infected HeLa cells, during IFN-? induced persistence 
and in infected fibroblasts the Golgi was only partially fragmented in the majority of 
inclusion-containing cells. The only exception was the trans-Golgi compartment which 
was completely fragmented in the majority of persistently infected HeLa cells, similar to 
active infection. Although Golgi fragmentation occurred during these persistent conditions, 
MHCI trafficking was not compromised as there was no reduced MHCI surface expression 
after infection, MHCI still localised to the Golgi of inclusion-containing cells, and the 
Endo H cleavage pattern of MHCI was not different between mock-infected and infected 
cells. Thus, the results suggest that partial Golgi fragmentation does not seem to have any 
effect on the traffic of MHCI in these cells. In fact, the functional MHCI trafficking could 
be explained by the absence of degradation of Golgin-245 in persistently infected HeLa 
cells and infected fibroblasts, because Golgin-245 is necessary for the trans-Golgi trans-
port function (Yoshino et al., 2003) and involved in MHCI transport to the cell surface 
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(Brémond et al., 2009). In contrast to this, GM130, which is not essential for ER to Golgi 
transport, but instead is important for correct glycosylation of proteins in the cis-Golgi 
(Nakamura, 2010), still was degraded during persistent and fibroblasts infection, although 
to a lesser extent than during active infection leading to only 50% reduction in the protein 
level. Thus, it could be possible that MHCI trafficking is functional, while MHCI 
processing may be incomplete in persistently infected cells. This is supported by the 
finding that Golgi fragmentation by Chlamydia does not interfere with the delivery of 
glycoproteins to the cell surface, but does affect the processing of glycoproteins in the 
Golgi as indicated by an increased amount of premature glycoproteins containing an N-
acetyl-D-glucosamine chain on the cell surface (Heuer et al., 2009). 
Interestingly, the expression of Golgin-245 was upregulated after chlamydial infection of 
fibroblasts. It could be possible that this upregulation is a result of the increased transport 
enquiry for MHCI to ensure rapid elevation of MHCI surface expression. Indeed, Golgin-
245 vesicles were shown to increase transport of TNF-? to the cell surface in macrophages 
after stimulation with LPS (Lieu et al., 2008). Thus, a logical consequence would be to 
coordinate the increased synthesis of surface located proteins with an upregulation of the 
respective Golgi proteins involved in their transport to the cell surface. 
4.2.8 Other mechanisms of C. trachomatis to escape immune recognition by T cells 
It has been described recently that C. trachomatis infected macrophages induce apoptosis 
of T cells, and this was in part mediated by TNF-? secretion (Jendro et al., 2000; Jendro et 
al., 2004). T cell apoptosis represents another mechanism of how Chlamydia-infected cells 
could escape killing by CD8+ T cells. This could lead to decreased numbers of CD8+ T 
cells which may reduce the rate of lysis of infected non-haematopoietic cells. On the other 
hand, TNF-? was shown to strongly enhance MHCI surface expression on Chlamydia-
infected fibroblasts (Rödel et al., 2002), which could increase the probability to be detected 
by CD8+ T cells. 
CD8+ T cells are known to induce killing of infected cells through induction of apoptosis. 
However, chlamydiae inhibit apoptosis through different mechanisms (reviewed in Sharma 
& Rudel, 2009), and CPAF is known to be involved in this inhibition through degradation 
of the pro-apoptotic BH3-only proteins (Pirbhai et al., 2006). It has been shown that 
granzyme B, Fas and TNF-? mediated apoptosis, which are applied by CD8+T cells in 
order to kill target cells, are inhibited in Chlamydia-infected cells (Fan et al., 1998). 
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Hence, chlamydial inhibition of apoptosis may represent a very important and potent 
mechanism for preventing CD8+ T cell mediated killing of the infected host cell. 
C. trachomatis has not only developed mechanisms to escape the recognition by CD8+ T 
cells. The pathogen was shown also to degrade upstream stimulatory factor 1 (USF-1), a 
transcription factor necessary for MHCII gene expression, through CPAF (Zhong et al., 
1999; Zhong et al., 2001). This is expected to suppress MHCII surface expression, which 
would result in less recognition of Chlamydia-infected cells by CD4+ cells. Indeed, Zhong 
et al. (1999) observed a specific inhibition of IFN-?-inducible MHCII surface expression 
in Chlamydia-infected epithelial cells. 
Beside the MHCI and MHCII antigen presentation pathways, there is a third pathway of 
antigen presentation, which is specific for the presentation of self or foreign lipids to 
immune cells and involves the glycoprotein class CD1 as antigen presenting molecules. 
Similar to MHCI molecules, CD1 molecules consist of a membrane-binding anchor and an 
antigen binding domain and are associated with ?2M. They bind amphiphilic lipids, such as 
glycolipids, and expose the hydrophilic moiety of the lipids at the cell surface for recog-
nition by T cell receptors. There are two groups of CD1 molecules: group 1 CD1 (CD1a, 
CD1b, CD1c) molecules which present lipids to CD1 specific T cells and group 2 CD1 
molecules (CD1d) which present lipids to natural killer T (NKT) cells (reviewed in 
Schiefner & Wilson, 2009). Interestingly, in Chlamydia-infected epithelial cells CD1d was 
found to be a target of CPAF resulting in reduced CD1d surface expression (Kawana et al., 
2007). Thus, CPAF seems to interfere with different antigen presentation pathways under-
lining its importance as a virulence factor. It has been shown recently that invariant NKT 
cells may play an important role in protective immunity to CiReA by enhancing the CD4+ 
and CD8+ T cell response (Bharhani et al., 2009). This was demonstrated with CD1d 
knockout mice that had a more severe disease than wild type mice, as well as by a lessened 
severity of the disease through the activation of a NKT cell response. Because CPAF 
expression and associated degradation of different host proteins was found to be strongly 
reduced during infection of fibroblasts, it would be interesting to know if CPAF-mediated 
cleavage of CD1d is also inhibited in fibroblasts, because this would result in a functional 
CD1d surface expression similar to the functional MHCI surface expression. This could 
further underline the importance of infected fibroblasts as antigen-presenting cells during 
CiReA. 
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4.2.9 Chlamydial proteins that may elicit a CD8+ T cell response and their different 
expression during active and persistent infection 
Since Chlamydia are separated and protected from the host cytosol through residing in a 
modified host cell derived vacuole, the question arises how the host proteasome machinery 
gets access to chlamydial proteins. Certain chlamydial antigens, such as LPS, MOMP, 
Cap1 and IncA were detected outside the chlamydial inclusion (Brown et al., 2002; Giles 
et al., 2006) and thus could serve as potential antigens for MHCI presentation. 
An efficient CD8+ T cell response has already been shown to be elicited by MOMP and 
Cap1 derived peptides, respectively (Fling et al., 2001; Kim et al., 2000). Furthermore, 
OmcB was shown to be a candidate for MHCI presentation (Gervassi et al., 2004 b). Since 
expression of MOMP and the OmcB encoding gene was downregulated during IFN-? 
induced chlamydial persistence, but not in Chlamydia-infected fibroblasts, one might 
speculate that a protective CD8+ T cell response regarding these proteins could occur to 
fibroblasts, but not to persistently infected epithelial cells. In general, since expression of 
many chlamydial genes is reduced during IFN-? induced persistence several proteins might 
not gain access to the host cytosol under these conditions. It would be interesting to know 
if there are any chlamydial proteins that are processed for MHCI presentation during IFN-? 
induced persistence, and which that may be. 
Interestingly, the chlamydial HSP60 proteins GroEL_2 and GroEL_3, but not GroEL_1 
were detected in vesicles everting from the inclusion (Giles et al., 2006). Because an 
increased gene expression of GroEL_2 was found during the infection of fibroblasts in the 
present study, and GroEL_2 expression was also upregulated during infection of mono-
cytes (Gérard et al., 2004), it will be a future task to examine whether this protein is also 
processed to peptides that get presented on the cell surface via MHCI and whether by this 
it may play a special role in promoting severe immunopathology during chronic 
chlamydial infection, such as during CiReA. 
4.2.10 Role of CPAF mediated golgin degradation in Chlamydia-host cell interaction 
It has been reported recently that Golgin-84 is degraded through CPAF (Christian et al., 
2011). In the present study it was discovered that another two golgins, GM130 and Golgin-
245, are also cleaved through CPAF. Golgins are Golgi proteins with large coiled-coil 
domains reaching into the cytoplasm (reviewed in Goud & Gleeson, 2010), and because of 
this cytoplasmic exposure CPAF probably gets access easily to these proteins. Indeed, 
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Heuer et al. (2009) observed that the cleavage occurred in the N-terminal coiled-coil 
domain, thus this domain could be a general target for CPAF cleavage. 
In contrast to the results of the present study, Heuer et al. (2009) suggested that GM130 is 
not degraded by Chlamydia, because the immunoblot ratio of GM130 to tubulin was not 
changed during infection. However, the expression of both GM130 and tubulin decreased 
during the infection time course, and it cannot be excluded that tubulin expression was also 
affected by chlamydial infection. This could explain the different interpretation of the 
GM130 expression results by Heuer et al. (2009) in contrast to the findings of the present 
work where GAPDH was used as loading control. 
Golgi fragmentation is necessary for chlamydial growth as has been shown by a strongly 
reduced progeny formation when fragmentation was inhibited (Heuer et al., 2009). Since 
Chlamydia acquires sphingomyelin and cholesterol from the Golgi (Carabeo et al., 2003; 
Hackstadt et al., 1996), fragmentation of Golgi might facilitate this process. CPAF medi-
ated cleavage of Golgin-84 was shown to be responsible for the fragmentation of the Golgi 
apparatus (Christian et al., 2011; Heuer et al., 2009). Since knockdown of GM130 did not 
result in cis-Golgi fragmentation (Heuer et al., 2009), it is proposed that the degradation of 
golgins may also have other functions. Chlamydia are known to recruit Rab proteins to the 
inclusion in order to interact with vesicle trafficking (Rzomp et al., 2003). This probably 
serves as a mechanism to acquire vesicles containing proteins and lipids from the host cell. 
Golgins are well known to bind Rab proteins and probably serve as docking sites for 
vesicle trafficking (reviewed in Goud & Gleeson, 2010). Hence, chlamydial degradation of 
golgins may prevent binding of Rab proteins to the Golgi, thus facilitating their recruitment 
to the inclusion membrane. One Rab protein that is found to be localised at the inclusion is 
Rab1 (Rzomp et al., 2003), and Rab1 is known to bind to GM130 and to Golgin-84 
(reviewed in Ramirez & Lowe, 2009). Moreover, Rab1 is the only Rab protein required for 
the anterograde cargo transport from the ER through the Golgi (reviewed in Barr, 2009). 
Thus, degradation of GM130 and Golgin-84 could prevent binding of Rab1 to the Golgi, 
which may direct Rab1 vesicles everting from the ER to Rab binding inclusion membrane 
proteins. This is supported by the recent discovery of a C. pneumoniae inclusion 
membrane protein, which shares sequence similarity with Rab effector proteins such as 
Golgin-84 and GM130, and which was also shown to interact with Rab1, Rab10 and 
Rab11 (Cortes et al., 2007). 
The Golgi apparatus and the centrosome, the main MTOC of the cell, are in close proxim-
ity to each other, because the centrosome regulates the morphology of the Golgi through 
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generation of microtubules reaching through the cell. This association might be important 
for the directional protein transport in polarised cells and for the migration of cells 
(reviewed in Sütterlin & Colanzi, 2010). Rapidly after the invasion of host cells Chlamydia 
travel to the peri-Golgi region on microtubules in a dynein-dependent manner (Clausen et 
al., 1997; Grieshaber et al., 2003). By this, Chlamydia might be able also to interact with 
the centrosome. Indeed, C. trachomatis was shown to influence centrosome assembly lead-
ing to supernumerary centrosomes, to a defect in mitotic spindle formation and to abnor-
mal chromosome segregation, which suggests a possible role in cancer development 
(Grieshaber et al., 2006). Although the morphology of the centrosomes in Chlamydia-
infected cells appeared normal, they contained premature centrioles, and an abnormal 
centrosome number was detected from 30 h p.i. on (Johnson et al., 2009). This interaction 
of Chlamydia with the centrosome was not necessary for chlamydial growth, and the 
generation of such supernumerary centrosomes depended on the host cell centrosome 
duplication machinery (Johnson et al., 2009). It has been reported that GM130 is involved 
in regulating the centrosome function and assembly during interphase, because the deple-
tion of GM130 resulted in aberrant supernumerary centrosomes, a defect in microtubule 
nucleation and inhibition of cell division, which led to cell death through arrest in mitosis 
(Kodani & Sütterlin, 2008). Thus, GM130 degradation through CPAF could be an impor-
tant process involved in the abnormal centrosome amplification in Chlamydia-infected 
cells. Furthermore, GM130 has been shown to be required for microtubule nucleation at 
the Golgi apparatus (Rivero et al., 2009), an event that is necessary for maintaining Golgi 
morphology, cell polarisation and migration (Efimov et al., 2007; Miller et al., 2009). 
Hence, Chlamydia-mediated GM130 degradation could be an important event for abro-
gating polarised protein secretion and cell migration in order to reduce cytokine secretion 
and expression of surface-exposed molecules on polarised cells which could affect immune 
recognition. Recently, other gram-negative pathogens, such as enteropathogenic E. coli 
(EPEC), enterohaemorrhagic E. coli (EHEC) and Shigella flexneri have also been found to 
induce Golgi fragmentation and reduce protein secretion, probably by secretion of the 
TTSS protein EspG into the host cytosol, which interacted with GM130 and induced 
destabilisation of microtubules (Clements et al., 2011; Tomson et al., 2005). Therefore, 
interfering with the GM130 function might generally be an efficient strategy of some 
bacterial pathogens to manipulate multiple host cell functions for which this Golgi protein 
is necessary. 
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4.3 C. trachomatis mediated degradation of the host cell mRNA export 
factor NXF1 
An intriguing, accidental discovery of the present study has been the Chlamydia-induced 
cleavage of NXF1, which probably also involves CPAF. NXF1 belongs to the NXF protein 
family that is conserved among eukaryotic organisms (reviewed in Stutz & Izaurralde, 
2003). It forms a heterodimer together with the small protein p15, and this heterodimer 
functions as a transport receptor for the export of most of the poly(A)+ RNA from the 
nucleus to the cytoplasm (Wiegand et al., 2002). Transcription, processing and nuclear 
export of mRNA are tightly associated and controlled in the nucleus through many differ-
ent proteins. After its transcription the nascent mRNA is associated with many proteins of 
distinct functions resulting in the formation of a so-called messenger ribonucleoprotein 
(mRNP) complex. This mRNP complex is exported into the cytoplasm mainly through the 
mRNA export receptor NXF1/p15, which binds to it through recognition of other bound 
proteins and recruits the mRNP to the nuclear pore complex (NPC). The NXF1/p15 associ-
ates with certain proteins of the NPC, the nucleoporins, which results in translocation of 
the mRNP through the nuclear pore into the cytoplasm through an ATP-dependent mecha-
nism involving several other proteins located at the cytoplasmic face of the NPC. After the 
translocation through the nuclear pore, NXF1/p15 is released from the mRNP and trans-
ported back into the nucleus (reviewed in Carmody & Wente, 2009). 
In Drosophila melanogaster cells depletion of NXF1 led to strong accumulation of 
poly(A)+ RNA in the nucleus with concomitant inhibition of protein synthesis (Herold et 
al., 2001; Wiegand et al., 2002). FISH of poly(A)+ RNA in mammalian cells normally 
reveals equal distribution of mRNA in the cytoplasm and speckled nuclear mRNA signals. 
However, when mRNA export is impaired the nuclear speckles show increased staining 
intensity (Tokunaga & Tani, 2008). Using the same approach of FISH an enhanced 
fluorescence intensity of poly(A)+ RNA in the nuclei of Chlamydia-infected HeLa cells 
has also been observed in the present study, which suggests a nuclear accumulation of 
poly(A)+ RNA as a result of the degradation of NXF1. Interestingly, a stronger 
fluorescence signal in the cytoplasmic area near the nucleus of infected cells was also 
detected, which could represent cellular mRNA located at the ER for translation. An 
increased cytoplasmic poly(A)+ RNA amount would point to an upregulated mRNA 
synthesis in the nucleus. However, if the nuclear export of bulk mRNA is blocked as a 
result of NXF1 degradation, then the question would be how this mRNA enters the 
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cytoplasm. It remains to be elucidated if this increased cytoplasmic mRNA amount is a 
result of transport through a redundant mRNA export pathway or if it is remaining mRNA 
from an earlier infection stage, at which NXF1 was not yet degraded and host cell tran-
scription was still enhanced. This is supported by the fact that mammalian mRNA is very 
stable (Tokunaga & Tani, 2008). 
Several viruses are known that use nuclear export pathways to export their RNA from the 
nucleus to the cytosol, which is necessary for their propagation (reviewed in Fontoura et 
al., 2005). This is mediated by certain viral proteins that interact with components of the 
export pathway. On the other hand, this manipulation can also influence the export of 
cellular mRNAs, thus leading to an inhibition of the antiviral response (reviewed in 
Fontoura et al., 2005). Examples for viruses that use the NXF1 export pathway are type D 
retroviruses (Grüter et al., 1998), HSV-1 (Koffa et al., 2001), EBV (Juillard et al., 2009) 
and adenovirus (Yatherajam et al., 2011). So far, this is the first description of an intra-
cellular bacterial pathogen to interact with this pathway. The interesting question arising is 
that of why C. trachomatis does interfere with the NXF1 mRNA export pathway. The most 
likely explanation could be a general inhibition of cellular defence pathways through 
inhibition of protein synthesis as a consequence of compromised mRNA delivery to the 
cytosol. Since the NXF1 degradation was observed at a late stage of infection, normal host 
cell protein synthesis should not be compromised at early time points. At late time points 
Chlamydia would be expected to have a higher need for nutrients from the host cell, 
because of the increasing number of bacterial organisms. Thus, as suggested by Zhong 
(2009), degradation of several host proteins, including NXF1, through CPAF could deliver 
additional essential amino acids to the inclusion. This is a hypothesis that would generally 
explain the broad substrate specificity of CPAF. Inhibition of poly(A)+ RNA export would 
additionally have the advantage of availability of higher amounts of ATP for Chlamydia 
due to the inhibition of the host protein translation machinery, which usually requires huge 
amounts of energy. Thus, Chlamydia could benefit from interference with the cellular 
mRNA export from the nucleus in several ways. 
4.4 Summary and outlook 
In the present study the MHCI antigen presentation pathway has been studied during active 
and persistent chlamydial infection as well as during fibroblast infection, which also seems 
to represent another type of persistent infection characterised by a different chlamydial 
growth and gene expression profile than the IFN-? mediated chlamydial persistence. It 
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could be shown that C. trachomatis interferes with MHCI antigen presentation only during 
active, but not during persistent infection of HeLa cells and during fibroblast infection. The 
important antigen transporter component TAP2 was degraded by C. trachomatis only 
during active HeLa cell infection, which may be responsible for the reduced MHCI expres-
sion observed on the surface of these cells. Also, the Golgi fragmentation and CPAF-
mediated cleavage of the two Golgi proteins GM130 and Golgin-245 during active 
infection, which was strongly reduced during persistent and fibroblast infection, might 
contribute to inhibit trafficking of MHCI from the ER to the cell surface as a second step 
of chlamydial interference with the MHCI antigen presentation pathway. 
The present study further underlines the importance of the chlamydial protease CPAF as a 
multi-functional virulence factor that is involved in the degradation of different host 
proteins leading to disruption of several host cell pathways. It has been found that CPAF is 
involved in the cleavage of the Golgi proteins GM130 and Golgin-245, and is likely to play 
a role in the degradation of TAP2 and the mRNA export factor NXF1. The importance of 
CPAF for chlamydial development and pathogenesis is pronounced by the finding of a 
strong reduction of its expression and enzyme activity during chlamydial persistence, 
which reduces the ability of Chlamydia to interfere with host cell functions such as for 
example MHCI antigen presentation. 
Future studies will reveal how host cell functions are affected by the CPAF-mediated 
degradation of the proteins analysed in the present study. The functionality of the peptide 
transporter TAP should be examined as well as the intracellular processing and trafficking 
of MHCI in the ER and Golgi. Likewise, the identification of peptides presented by MHCI 
on the host cell surface during chlamydial persistence and fibroblast infection could give 
more insight if the processing of chlamydial proteins efficiently occurs under these condi-
tions. Cytotoxic effects of Chlamydia-specific CD8+ T cells on actively and persistently 
infected epithelial cells should be measured at later time points of infection (after 24 h p.i.) 
in order to see whether CD8+ T cell activation in response to Chlamydia-infected cells is 
reduced at late infection stages as a result of diminished expression of surface MHCI. 
Furthermore, as the present results of GM130 degradation point to an interference of 
Chlamydia with the centrosome function, the role of this event in centrosome multipli-
cation, assembly and chromosome segregation should be investigated. An interesting new 
field of Chlamydia-host cell interaction has been opened by the discovery of degradation 
of NXF1. Interference of Chlamydia with the cellular mRNA export as well as with the 
host cell transcription and translation machinery should be examined in detail to find out 
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why Chlamydia interfere with this pathway and what the consequences are for the host cell 
function. 
The ability of Chlamydia to grow well in fibroblasts, but with compromised conversion to 
EBs, represents another kind of chlamydial persistence which is distinct from the persis-
tence models known so far. Further work needs to be done to identify other factors beside 
IDO that are involved in the induction of chlamydial persistence in fibroblasts. Analyses of 
the role of fibroblasts in chlamydial infection, especially during CiReA, as well as the role 
of specifically expressed chlamydial proteins will add to our knowledge about the 
importance of this host cell type for chlamydial pathogenesis and persistent infection in 
vivo. 
The results of the present study will help to understand chlamydial persistence, Chlamydia-
host cell interaction and MHCI antigen presentation during chlamydial infection. This is 
important to find new therapeutical targets and to develop an efficient vaccine strategy in 
order to combat chronic chlamydial infections. 
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6 Appendix 
6.1 Material 
6.1.1 Chemicals 
Acetic acid VWR, Dresden, Germany 
Acetone VWR, Dresden, Germany 
40% Acrylamide/Bis Solution, 37.5:1 Bio-Rad Laboratories, München, Germany 
Agarose, LE, Analytical Grade Promega, Mannheim, Germany 
Ammonium persulfate (APS) Sigma-Aldrich Chemie, München, Germany 
Bromophenol blue Amresco, Solon, Ohio, USA 
Chloramphenicol Roth, Karlsruhe, Germany 
3-[(3-Cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS) 
GE Healthcare Europe, München, Germany 
Cycloheximide Serva Electrophoresis, Heidelberg, Germany 
DAPI Invitrogen, Darmstadt, Germany 
Diethylaminoethyl (DEAE) sepharose Pharmacia Fine Chemicals/Amersham 
Biosciences, Uppsala, Sweden 
Deoxycholic acid Sigma-Aldrich Chemie, München, Germany 
Dextran sulphate sodium salt from Leuconostoc 
spp. 
Sigma-Aldrich Chemie, München, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich Chemie, München, Germany 
Disodium phosphate dihydrate Roth, Karlsruhe, Germany 
Dithiothreitol (DTT) Roth, Karlsruhe, Germany 
Ethanol VWR, Dresden, Germany 
Ethidium bromide Roth, Karlsruhe, Germany 
Formamide Roth, Karlsruhe, Germany 
8% Glutaraldehyde solution grade I Sigma-Aldrich Chemie, München, Germany 
Glycerol Roth, Karlsruhe, Germany 
Glycine Bio-Rad Laboratories, München, Germany 
HiPerFect Transfection Reagent Qiagen, Hilden, Germany 
4-(2-Hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) 
Serva Electrophoresis, Heidelberg, Germany 
Clasto-Lactacystin ?-lactone Sigma-Aldrich Chemie, München, Germany 
Leupeptin Serva Electrophoresis, Heidelberg, Germany 
Magnesium chloride (MgCl2) Merck, Darmstadt, Germany 
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?-mercaptoethanol Ferak Berlin, Berlin, Germany 
Methanol VWR, Dresden, Germany 
Paraformaldehyde Sigma-Aldrich Chemie, München, Germany 
Pharmalyte, broad range pH 3-10, 25 ml GE Healthcare Europe, München, Germany 
Phenylmethylsulfonyl fluoride (PMSF) Serva Electrophoresis, Heidelberg, Germany 
Ponceau S Amresco, Solon, Ohio, USA 
Potassium chloride (KCl) Merck, Darmstadt, Germany 
Potassium dihydrogen phosphate Merck, Darmstadt, Germany 
ProLong Gold antifade reagent with DAPI Invitrogen, Darmstadt, Germany 
Saponin Sigma-Aldrich Chemie, München, Germany 
Sigma FAST BCIP/NBT Sigma-Aldrich Chemie, München, Germany 
Sodiumcacodylate Trihydrate Sigma-Aldrich Chemie, München, Germany 
Sodium chloride (NaCl) Sigma-Aldrich Chemie, München, Germany 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich Chemie, München, Germany 
Sodium-ethylenediaminetetraacetic acid  
(Na-EDTA) 
Amresco, Solon, Ohio, USA 
Sodium-ethylene glycol tetraacetic acid  
(Na-EGTA) 
Roth, Karlsruhe, Germany 
Sodium hydroxide (NaOH) Roth, Karlsruhe, Germany 
Sucrose Roth, Karlsruhe, Germany 
Tetramethylethylendiamin (TEMED) Bio-Rad Laboratories, München, Germany 
Thiourea Sigma-Aldrich Chemie, München, Germany 
Trichloroacetic acid (TCA) Merck, Darmstadt, Germany 
Tris(hydroxymethyl)methylamine (Tris) Amresco, Solon, Ohio, USA 
Tris/Hydrochloride (Tris/HCl) Promega, Mannheim, Germany 
Trisodium citrate dihydrate Roth, Karlsruhe, Germany 
Triton X-100 Serva Electrophoresis, Heidelberg, Germany 
Urea GE Healthcare Europe, München, Germany 
6.1.2 Kits 
Bio-Rad Protein Assay Bio-Rad Laboratories, München, Germany 
Human Interferon-? ELISA Kit Fujirebio inc., Invitrogen, Darmstadt, Germany 
KAPA SYBR FAST qPCR Universal Mastermix Peqlab, Erlangen, Germany 
peqGOLD Total RNA Kit Peqlab, Erlangen, Germany 
peqGOLD DNase I Digest Kit Peqlab, Erlangen, Germany 
Reverse Transcription System Promega, Mannheim, Germany 
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6.1.3 Proteins, enzymes and standards 
AmpliSizeTM Molecular Ruler, 50-2,000 bp Bio-Rad Laboratories, München, Germany 
Aprotinin, from bovine lung Sigma-Aldrich Chemie, München, Germany 
BSA Sigma-Aldrich Chemie, München, Germany 
Endoglycosidase H New England Biolabs, Frankfurt am Main, 
Germany 
FCS ReliaTech, Wolfenbüttel, Germany 
GoTaq DNA Polymerase Promega, Mannheim, Germany 
Prestained SDS-PAGE Standards, broad range Bio-Rad Laboratories, München, Germany 
Protein G PLUS-Agarose Santa Cruz Biotechnology, Heidelberg, 
Germany 
Recombinant human IFN-β PromoCell, Germany 
Recombinant human IFN-? ReliaTech, Wolfenbüttel, Germany 
6.1.4 Buffers and media 
Dulbecco’s Modified Eagle Medium (DMEM) 
liquid medium with stable glutamine, with 3.7 
g/l NaHCO3, with 4.5 g/l D-glucose 
Biochrom AG, Berlin, Germany 
Laemmli sample buffer Bio-Rad Laboratories, München, Germany 
Opti-MEM® I Reduced Serum Medium with 
GlutaMAXTM
 
I 
Invitrogen, Darmstadt, Germany 
Resolving Gel Buffer (1.5 M Tris-HCl, pH 8.8) Bio-Rad Laboratories, München, Germany 
Stacking Gel Buffer (0.5 M Tris-HCl, pH 6.8) Bio-Rad Laboratories, München, Germany 
SYPRO Ruby Protein Gel Stain Sigma-Aldrich Chemie, München, Germany 
50x Tris-acetate-EDTA (TAE) Electrophoresis 
Buffer 
Fermentas, St. Leon-Rot, Germany 
TBS, with Tween 20, pH 8.0 Sigma-Aldrich Chemie, München, Germany 
10x Tris/glycine/SDS Bio-Rad Laboratories, München, Germany 
1.5 M Tris-HCl pH 8.8 Bio-Rad Laboratories, München, Germany 
1.5 M Tris-HCl pH 6.8 Bio-Rad Laboratories, München, Germany 
Trypsin/EDTA solution (0.05%/0.02%) Biochrom AG, Berlin, Germany 
Visipaque 320 GE Healthcare Europe, München, Germany 
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Table 6: Composition of buffers and solutions 
buffer composition 
Cell extraction buffer 20 mM HEPES-NaOH (pH 7.5) 
10 mM KCl 
1,5 mM MgCl2 
1 mM Na-EDTA 
1 mM Na-EGTA 
1 mM DTT (add immediately before use) 
Protease inhibitors: 
0,1 mM PMSF 
2 μg/ml aprotinin 
10 μg/ml leupeptin 
Endo H reaction buffer 50 mM Sodium citrate, pH 5.5 
7% ?-mercaptoethanol 
0.01% SDS 
Hybridisation buffer 10% dextran sulphate in prehybridisation buffer 
Lysis buffer for 2D gel electrophoresis 7 M Urea 
2 M Thiourea 
4% CHAPS 
10 mM DTT 
2% Pharmalyte 3-10 
Nuclear extraction buffer 0.5 mM NaCl 
1% Triton X-100 
20 mM Tris (pH 8.0) 
PBS 137 mM NaCl 
2.7 mM KCl 
8.1 mM Disodium phosphate dihydrate 
1.5 mM Potassium dihydrogen phosphate 
Ponceau S staining solution 0.2% Ponceau S 
1% acetic acid 
Prehybridisation buffer 2x SSC buffer containing: 
20% formamide 
0.2% BSA 
1 mg/ml yeast transfer RNA 
Radioimmunoprecipitation assay (RIPA) buffer 
(Cell lysis buffer for immunoblotting) 
0.15 M NaCl 
50 mM Tris/HCl 
1% deoxycholic acid 
1% Triton X-100 
0.1% SDS 
Protease inhibitors: 
0.1 mM PMSF 
50 μg/ml aprotinin 
2 μg/ml leupeptin 
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buffer composition 
Resolving gel 375 mM Tris-HCl pH 8.8 
0.1% SDS 
0.05% APS 
0.05% TEMED 
5, 8, 10 or 12% acrylamide (depending on the 
size of proteins analysed) 
2x SDS-Urea sample buffer 4% SDS 
2.4 M urea 
20% glycerol 
125 mM Tris 
7% ?-mercaptoethanol 
some bromophenol blue crystals 
2x SSC buffer 30 mM sodium citrate 
300 mM sodium chloride  
Stacking gel 187.5 M Tris-HCL pH 6.8 
0.05% SDS 
0.025% APS 
0.1% TEMED 
2% acrylamide 
TCA solution 15% TCA 
22 mM DTT 
solved in acetone 
Transfer buffer for immunoblotting 
(according to Bjerrum & Schafer-Nielsen, 1986) 
48 mM Tris 
39 mM glycine 
20% methanol 
Washing solution for TCA/acetone precipitation 20 mM DTT 
solved in 90% acetone 
6.1.5 Nucleic acids 
AllStars Negative Control siRNA Qiagen, Hilden, Germany 
Cy3 labelled oligo(dT)50  Jena Bioscience, Jena, Germany 
Hs_INDO_10 FlexiTube siRNA (gene 
accession number: NM_002164) 
Qiagen, Hilden, Germany 
Hs_IFNB1_1 FlexiTube siRNA (gene accession 
number: NM_002176) 
Qiagen, Hilden, Germany 
Mycoplasma positive control DNA (16S rRNA 
fragment from Mycoplasma bovis) 
in-house generation 
Transfer ribonucleic acid from baker’s yeast Sigma-Aldrich Chemie, München, Germany 
 
All primers were synthesized by and purchased from Jena Bioscience, Jena, Germany. 
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Table 7: Primer for human genes 
 
target 
gene 
protein product sequence 5’ - 3’ 
 
product 
size 
annealing 
tempera-
ture 
primer 
efficien-
cy E 
GAPDH Glyceraldehyde-3-
phosphate 
dehydrogenase 
tcaagtggggcgatgctggc 
tgggggcatcagcagagggg 
135 bp 64 °C 1.99 
HLA-A, 
-B and –
C  
MHCI molecule en-
coded by major HLA 
genes A, B and C  
ctgaggtgctgggccctg 
cccacttctggaaggttc 
133 bp 54 °C 2.00 
IDO1 Indoleamine 2,3-
dioxygenase 
gtgatgctggcctgcgggaa 
ttggctgctggcttgcagga 
117 bp 63 °C 1.96 
LMP7 immunoproteasome ? 
type subunit 8  
gcgcctgctggccaaggaat 
gagaggcccatgccccggta 
120 bp 65 °C 1.98 
LMP2 immunoproteasome ? 
type subunit 9 
ggggaggtgggtgcttccct 
acgtgatcacctgtcatgtatagggc 
140 bp 64 °C 2.00 
MECL1 immunoproteasome ? 
type subunit 10 
gctccgggggcaatgtggac 
gcggccagacctcttcacgg 
101 bp 64 °C 1.99 
TAP 1 Transporter associated 
with antigen process-
sing subunit 1 
gcagctcatggagaaaaagg 
gaaaagggagggagatggag 
108 bp 58 °C 1.95 
TAP 2 Transporter associated 
with antigen process-
sing subunit 2 
caggcctgtgctcaaggggc 
ttctgcagcagggcagccac 
108 bp 63 °C 1.99 
 
 
 
Table 8: Primer for C. trachomatis D genes 
 
target 
gene 
protein product sequence 5’ - 3’ 
 
product 
size 
annealing 
tempera-
ture 
primer 
efficien-
cy E 
16S 
rRNA 
- cggtaatacggagggtgcta 
ctacgcatttcaccgctaca 
176 bp 60°C 2.00 
ct858 CPAF cggagggtcttttccgcgct 
tcccaaggaggcggtcctga 
139 bp 60°C 1.99 
dnaA Chromosomal 
replication initiation 
protein 
gcctttgaaaactggattgc 
gcgtttgatctctgcaacaa 
189 bp 56 °C 1.98 
ftsW Cell division protein ttgggacttggtatcgcttc 
tagccaacgcttagctccat 
153 bp 58 °C 2.00 
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target 
gene 
protein product sequence 5’ - 3’ 
 
product 
size 
annealing 
temperat
ure 
primer 
efficien
cy E 
groEL Hsp60 chaperone 
GroEL 
ccagcaaaactgctgacaaa 
tgctccagctgttacattgc 
101 bp 55 °C 1.82 
groEL_
2 
Hsp60 chaperone 
Ct604 
cggaaacaggaacggtagaa 
aatcacaagcggtgttttcc 
131 bp 54°C 1.88 
omcB 60 kDa cysteine-rich 
outer membrane 
protein 
agcacgaccacgtttaagcgga 
accaaggaacagcaacagctcgt 
167 bp 62°C 1.97 
ompA MOMP aatttcagatgggtgccaag 
ccactggtggctcctaatgt 
190 bp 57 °C 1.98 
pgsA_2 CDP-diacylglycerol-
glycerol-3-phosphate 
3-phosphatidyl-
transferase 
cctcacgttcacacaacctcccg 
cgcatagcgtacgcaaagtgct 
98 bp 62°C 1.90 
trpB Tryptophan synthase 
subunit ? 
tgagtcaggacgagcctttt 
atgtgcgagagcatgtgaag 
121 bp 56°C 1.89 
 
 
Table 9: Primer for detection of mycoplasma contamination 
 
target gene sequence 5’ - 3’ 
 
product size annealing 
temperature 
16S rRNA ccagactcctacgggaggca 
tgcgagcatactactcaggc 
560 bp 55°C 
 
6.1.6 Antibodies 
Table 10: Primary antibodies 
 
target name/clone origin company/source Application/dilution 
C. trachomatis 
CPAF 
CPAF 
antiserum 
mp Institute for Medical 
Microbiology and 
Hygiene, University 
Hospital Ulm, Germany 
Immunoprecipitation (5 μl 
per reaction),  
Immunoblot (1:2000) 
GAPDH FL-335 rp Santa Cruz 
Biotechnology, 
Heidelberg, Germany 
Immunoblot (1:1000) 
(loading control) 
GM130 EP892Y rm Abcam, Cambridge, UK Immunofluorescence 
(1:500),  
Immunoblot (1:2000) 
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target name/clone origin company/source Application/dilution 
Golgin-245 
(p230) 
15/p230 trans 
Golgi 
mm BD Biosciences, 
Heidelberg, Germany 
Immunofluorescence 
(1:250),  
Immunoblot (1:250) 
HLA-ABC LY5.1 mm Anogen, Mississauga, 
Canada 
Immunoblot (1:1000) 
C. trachomatis 
HSP60 
A57-B9 mm Acris Antibodies, 
Herford, Germany 
Immunoblot (1:1000) 
IFNAR MMHAR-2 mm Millipore, Schwalbach, 
Germany 
Neutralisation of type I 
IFN activity in cell 
culture (1 μg/ml) 
LMP2 H-200 rp Santa Cruz 
Biotechnology, 
Heidelberg, Germany 
Immunoblot (1:1000) 
LMP7 1B3 mm Abnova, Heidelberg, 
Germany 
Immunoblot (1:500) 
MECL1 H-70 rp Santa Cruz 
Biotechnology, 
Heidelberg, Germany 
Immunoblot (1:1000) 
C. trachomatis 
MOMP 
1297/142 mm Acris Antibodies, 
Herford, Germany 
Immunoblot (1:1000) 
C. trachomatis 
MOMP 
MikroTrak 
Chlamydia 
trachomatis 
Culture 
Confirmation 
Test (FITC 
conjugated) 
mm Trinity Biotech Plc, Bray, 
Ireland 
Immunofluorescence 
(1:20),  
Flow cytometry (1:100) 
MHCI (native) W6/32  
(PE/unconju-
gated) 
mm PE-conjugated: Santa 
Cruz Biotechnology, 
Heidelberg, Germany; 
unconjugated: Friedrich 
Loeffler Institute 
Tübingen, Germany 
Flow cytometry (1:50),  
Immunofluorescence 
(1:50) 
NXF1 (TAP) 53H8 mm Abcam, Cambridge, UK Immunoblot (1:2000) 
PARP-1 Anti-Poly-
(ADP-
Ribose)-
Polymerase 
rp Roche Applied Science, 
Mannheim, Germany 
Immunoblot (1:2000) 
RFX5 Anti-RFX5 rp BioMol, Hamburg, 
Germany 
Immunoblot (1:1000) 
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target name/clone origin company/source application 
TAP1 148.3 (van Endert 
et al., 1994) 
mm Friedrich  Loeffler Institute 
Tübingen, Germany 
Immunoblot (1:1000) 
TAP2 435.3 (van Endert 
et al., 1994) 
mm Friedrich  Loeffler Institute 
Tübingen, Germany 
Immunoblot (1:1000) 
unspecific normal mouse 
IgG 
mp Santa Cruz Biotechnology, 
Heidelberg, Germany 
Immunoprecipitation 
(irrelevant antibody 
control; 5 μl per reaction) 
unspecific FITC- and PE-
conjugated 
mouse IgG 
mp Dianova, Hamburg, 
Germany 
Flow cytometry (1:200) 
mm: mouse monoclonal, mp: mouse polyclonal, rm: rabbit monoclonal, rp: rabbit polyclonal 
 
Secondary antibodies 
Affinity Pure Goat anti-mouse IgG (H+L), 
alkaline phosphatase conjugated 
Dianova, Hamburg, Germany 
Affinity Pure Goat anti-rabbit IgG (H+L), 
alkaline phosphatase conjugated 
Dianova, Hamburg, Germany 
Alexa Fluor 633 goat anti-rabbit IgG (H+L) Invitrogen, Darmstadt, Germany 
Alexa Fluor 488 rabbit anti-mouse IgG (H+L) Invitrogen, Darmstadt, Germany 
Alexa Fluor 633 rabbit anti-mouse IgG (H+L) Invitrogen, Darmstadt, Germany 
6.1.7 Material 
25 cm2 and 75 cm2 cell culture flasks Greiner Bio-One, Frickenhausen, Germany 
6 well and 24 well cell culture plates Greiner Bio-One, Frickenhausen, Germany 
Cell scrapers Nunc, Langenselbold, Germany 
Chocolate agar in-house production 
Columbia Blood agar in-house production 
Extra Thick Blot Paper Bio-Rad Laboratories, München, Germany 
Immobiline DryStrip gels GE Healthcare Europe, München, Germany 
Nitrocellulose Membrane, 0.45 μm Bio-Rad Laboratories, München, Germany 
Smart Cycler 25 μl tubes Peqlab, Erlangen, Germany 
Ultracentrifuge Tubes, Quick-Seal, Polyallomer, 
33 ml 
Beckman Coulter, Krefeld, Germany 
Winkle agar in-house production 
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6.1.8 Devices 
Branson Sonifier 250  Branson Ultrasonics, Dietzenbach, Germany 
Centrifuge Rotanta 460 RS Hettich, Tuttlingen, Germany 
Confocal laser scanning microscope LSM 5 Exciter Zeiss, Jena, Germany 
Epifluorescence microscope Axioskop Zeiss, Jena, Germany 
Ettan DALT System GE Healthcare Europe, München, Germany 
FACSCalibur flow cytometer BD Biosciences, Heidelberg, Germany 
IPGphor II GE Healthcare Europe, München, Germany 
MALDI TOF/TOF mass spectrometer Ultraflex I Bruker Daltonics, Bremen 
Mini-PROTEAN Tetra Electrophoresis System Bio-Rad Laboratories, München, Germany 
MTP anchor chip 384 Bruker Daltonics, Bremen 
NanoDrop ND-1000 Spectrophotometer Peqlab, Erlangen, Germany 
OptimaTM L-80 XP Ultracentrifuge with SW 32 T 
rotor 
Beckman Coulter, Krefeld, Germany 
SmartCycler II Cepheid, Maurens-Scopont, France 
Spectrophotometer Ultraspec 2000 GE Healthcare Europe, München, Germany 
Tissue grinder, conical Bel-Art, Pequannock, New Jersey, USA 
Trans-Blot SD Semi-Dry Transfer Cell Bio-Rad Laboratories, München, Germany 
TRIO-Thermoblock Biometra, Göttingen, Germany 
6.1.9 Software 
CellQuest Pro Version 4.0.2 BD Biosciences, Heidelberg, Germany 
Delta 2D, version 3.4 Decodon, Greifswald, Germany 
ImageJ Open source software from 
http://rsbweb.nih.gov/ij/ 
Labscan software 5 GE Healthcare Europe, München, Germany 
MASCOT interface (MASCOT 2.1.0) Matrix Science, London, UK 
Protein Scape 1.3 Protagen, Dortmund, Germany 
Smart Cycler Dx Software Cepheid, Maurens-Scopont, France 
ZEN Software 2009 Zeiss, Jena, Germany 
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6.2 Comparative 2D gel electrophoresis of chlamydial RB proteins from 
infected HeLa cells and fibroblasts 
A comparative proteome analysis of RBs isolated from infected HeLa cells and fibroblasts 
at 24 h p.i. was done to identify proteins that are differentially regulated between both cell 
types. The RBs were isolated from the cells through density gradient ultracentrifugation 
and protein samples were generated as described in chapter 2.2.17. The RB proteins were 
separated by their isoelectric point (pI) and molecular weight through 2D gel electro-
phoresis. The gel of RB proteins from HeLa cells is depicted in Fig. 31 and the gel of RB 
proteins from fibroblasts in Fig. 32. Proteins identified by mass spectrometry (MS) are 
indicated. The most abundant protein was MOMP, and could be readily detected both on 
the HeLa and fibroblast gel. Due to co-purification of human proteins during the ultra-
centrifugation step and the low infectivity rate of fibroblasts the protein sample of RBs 
isolated from fibroblasts contained mainly human proteins (as identified by MS) which 
masked the detection of chlamydial proteins. Thus, it was not possible to compare the two 
samples with each other for detecting differential expression. However, the gel of RBs iso-
lated from HeLa cells and the plentiful detected proteins show that it is principally possible 
to generate a 2D gel from purified RBs, which are more fragile than the rigid EBs. Thus, in 
situations where the growth of Chlamydia should be compared under different conditions a 
comparative proteome analysis using isolated RBs could be a more exact tool in examining 
chlamydial protein expression than treating cells with cycloheximide and marking chlamy-
dial proteins with radioactive amino acids, because cycloheximide inhibits host cell protein 
synthesis and thus could influence the host cell condition. 
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Table 11: Proteins from HeLa gel identified with MS (*MS/MS) 
 
name protein 
description 
identified MS 
matches 
accession  
number 
theoret-
ical 
MW  
(kDa) 
Mascot  
Score 
se-
quence  
cover-
age 
(%) 
AhpC thioredoxin 
peroxidase 
CT D/UW-3/CX gi|15605333 21.70 77 54.87 
CdsD Phosphopeptide 
binding protein; 
predicted inner 
membrane ring 
protein of 
TTSS; 
homologue to 
YscD 
CT 70 
CT D(s)2923 
gi|255349053 
gi|255507271 
89.59 
89.58 
216 
216 
59.59 
59.59 
CT017 hypothetical 
protein 
Ctra70_00090 (CT 70) 
CT017 (CT D/UW-
3/CX) 
gi|255348379 
gi|15604735 
47.70 
47.76 
102 
117 
45.73 
46.65 
CT066 hypothetical 
protein 
CT D/UW-3/CX gi|15604785 17.94 32.8 52.23 
CT621 hypothetical 
protein; TTSS 
secreted into 
cytosol and 
nucleus 
(Hobolt-
Pedersen et al., 
2009) 
G9768_03260 (CT 
G/9768) 
CT621 (CT D/UW-
3/CX) 
CTL0885 (CT 
434/Bu) 
CTDEC_0621 (CT D-
EC) 
Ctra70_03315 (CT 70) 
CTB_6251 (CT 
B/TZ1A828/OT) 
gi|296436157 
 
gi|15605352 
 
gi|166154836 
 
gi|297748751 
 
gi|255349003 
gi|237804971 
92.57 
 
92.65 
 
92.57 
 
93.22 
 
92.68 
92.63 
97.2 
 
103 
 
98.2 
 
94.4 
 
147 
91.3 
47.24 
 
45.31 
 
42.31 
 
45.04 
 
51.32 
43.63 
CT623 hypothetical 
protein 
CHLPN 76 kD 
protein-like (CT 
A/HAR-13) 
CT D/UW-3/CX* 
gi|76789362 
 
 
gi|15605354 
49.99 
 
 
48.34 
41.8 
 
 
117.5 
26.91 
 
 
7.18 
DhnA fructose-
bisphosphate 
aldolase 
CT D/UW-3/CX* gi|15604935 37.96 102.3 5.75 
DnaK molecular 
chaperone 
DnaK, heat 
shock protein 70 
75 kD membrane 
protein (CT)* 
C. muridarum Nigg 
CT D/UW-3/CX 
gi|144555 
 
gi|270285464 
gi|15605121 
70.45 
 
70.53 
70.78 
181.48 
 
85.5 
104 
7.82 
 
41.37 
48.48 
Dut Deoxyuridine 
5’-triphosphate 
nucleotide-
hydrolase 
CT D/UW-3/CX 
C. muridarum Nigg 
CT D/UW-3/CX 
gi|15605013 
gi|7190605 
gi|15605013 
15.33 
16.22 
15.33 
63.78 
61.8 
78.1 
25.52 
54.19 
77.24 
EF-G Elongation 
factor G 
CT 70 gi|255348805 76.49 117 45.39 
EF-Ts Elongation 
factor Ts 
CT A/HAR-13 
CT D/UW-3/CX* 
CT D(s)2923 
gi|76789419 
gi|15605412 
gi|255507286 
30.78 
30.86 
30.76 
95 
27.59 
107 
63.12 
3.90 
67.73 
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CT gi|46370964 21.93 98.3 78.71 
EF-Tu elongation 
factor Tu 
CT D/UW-3/CX gi|15605043 43.27 91.2 51.52 
Eno phosphopyru-
vate hydratase, 
enolase 
CT 434/Bu 
CT D/UW-3/CX 
gi|166154802 
gi|15605316 
45.41 
45.41 
45.2 
45.2 
44.58 
37.50 
GatA aspartyl/ 
glutamyl-tRNA 
amidotrans-
ferase subunit A 
CT D/UW-3/CX gi|15604721 53.55 80.20 50.51 
GroEL Chaperonin 
GroEL, heat 
shock protein 60 
Heat shock protein (C. 
muridarum)* 
chaperonin GroEL 
(CT A/HAR-13) 
chaperonin homologue 
(C. psittaci)* 
chaperonin GroEL 
(CT 6276) 
groE (CT)* 
gi|402333 
 
gi|76788825 
 
gi|7240534 
 
gi|255310911 
 
gi|144505 
58.11 
 
58,08 
 
44.97 
 
58.10 
 
58.03 
94.63 
 
57.30 
 
106.95 
 
89.50 
 
43.98 
6.80 
 
23.7 
 
3.36 
 
36.03 
 
2.21 
GroES Co-Chaperonin 
10 
CT* gi|1589856 10.65 121.78 18.56 
MOMP major outer 
membrane 
protein 
CT 
CT 
CT 
CT 
CT 
CT 
CT 
CT 
CT D/UW-3/CX  
CT D(s)2923 
CT 
CT 
gi|209363151 
gi|209363125 
gi|209363119 
gi|61696984 
gi|11561792 
gi|209363153 
gi|209363119 
gi|11561792 
gi|15605414 
gi|255507288 
gi|209363119 
gi|209363153 
39.37 
39.42 
39.41 
33.51 
41.42 
39.37 
39.41 
41.42 
42.41 
42.48 
39.41 
39.37 
97 
108 
108 
83.60 
78.50 
95.30 
107 
75.5 
95.2 
94 
85.7 
99.6 
58.68 
62.53 
61.71 
66.34 
60.52 
66.67 
66.67 
49.61 
51.15 
51.15 
43.25 
49.86 
PdhC branched-chain 
alpha-keto acid 
dehydrogenase 
subunit E2 
CT D/UW-3/CX* 
CT 434/Bu 
gi|15604968 
gi|166154458 
46.29 
46.37 
69.99 
81.30 
3.50 
37.76 
Pnp polynucleotide 
phosphorylase/ 
polyadenylase 
CT D/UW-3/CX 
 
gi|15605577 75.45 70.4 32.66 
PorB outer membrane 
protein B 
CT D/UW-3/CX* 
CT D/UW-3/CX* 
gi|15605446 
gi|15605446 
37.37 
37.37 
28.65 
36.18 
4.41 
3.82 
RpoB DNA-directed 
RNA polymer-
ase subunit beta  
CT 434/Bu gi|166154525 139.97 205 29.87 
RpsA 30S ribosomal 
protein S1 
CT E/11023 gi|296438403 63.46 110 30.93 
Rs7 30S ribosomal 
protein S7 
C. muridarum Nigg gi|15835337 17.80 72 52.23 
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Table 12: Proteins from fibroblast gel identified with MS (*MS/MS) 
 
name protein 
description 
identified MS 
matches 
accession  
number 
theoreti
cal MW  
(kDa) 
Mascot  
Score 
se-
quence  
cover-
age 
(%) 
GroEL Chaperonin 
GroEL, heat 
shock protein 60 
CT 6276 gi|255310911 58.10 110 39.52 
MOMP major outer 
membrane 
protein 
CT* 
CT D(s)2923 
CT 
CT 
CT 
CT 
CT 
CT 
CT D/UW-3/CX  
CT 
CT 
CT 
CT D(s)2923 
CT 
CT D/UW-3/CX  
CT 
gi|40719 
gi|255507288 
gi|11561792 
gi|38683387 
gi|38683369 
gi|168478744 
gi|168478718 
gi|168478732 
gi|15605414 
gi|61696984 
gi|38683369 
gi|168478718 
gi|255507288 
gi|168478744 
gi|15605414 
gi|11561792 
42.51 
42.48 
41.42 
34.00 
38.70 
41.43 
41.43 
41.34 
42.41 
33.51 
38.70 
41.43 
42.48 
41.43 
42.41 
41.42 
137.6 
128 
92.2 
89.5 
95.6 
94.5 
105 
94.6 
117 
93.3 
105 
116 
143 
105 
132 
102 
8.91 
61.83 
60.52 
63.49 
63.33 
61.82 
61.98 
62.24 
61.83 
65.05 
63.33 
61.98 
61.83 
61.82 
61.83 
60.52 
PmpD polymorphic 
outer membrane 
protein D 
CT 70 
CT D-EC 
gi|255349213 
gi|297748940 
160.47 
161.63 
110 
72.4 
27.19 
21.59 
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